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Transcription, the first stage of gene expression, is performed by the multi-
subunit RNA polymerase (RNAP). The indispensable nature of transcription and 
sequence divergence from eukaryotic counterparts make bacterial RNAP an 
excellent target for antibiotics. Yet very few clinical antibiotics target RNAP. The 
growing prevalence of antibiotic resistance amongst pathogenic bacteria 
demands the identification of novel antibacterial compounds acting through novel 
molecular mechanisms. This work consists of four distinct projects in which we 
investigated the molecular mechanisms of several previously uncharacterised 
transcription inhibitors. 
(i) Most clinical antibiotics are derived from the natural products of 
actinomycete bacteria. Consequently, we screened a library of actinomycetes 
compiled by our industrial collaborators DemurisTM for producers of novel 
inhibitors of bacterial transcription. From this screen we identified Antibiotic 
A39079S-1, produced by Streptomyces strain DEM40380, as an inhibitor of 
bacterial RNAP. The compound is an ansamycin type antibiotic with a previously 
uncharacterised mechanism of action. Here, we show the compound inhibits 
bacterial RNAP through a steric occlusion mechanism typical of rifamycins.  
 
(ii) Recently, the antibiotic ureidothiophene (Urd) was identified within 
a commercial screen of synthetic compounds in which inhibition of S. aureus 
RNAP was analysed. Here, we characterised the molecular mechanism of action 
by which Urd inhibits bacterial RNAP. We show the inhibitor targets regulatory 
sub-region 1.2 of the sigma subunit to prevent melting of the -10 promoter 
element. Consequently, Urd inhibits formation of the open promoter complex, a 
key step in transcription initiation.   
 
(iii) A prior screening program conducted by DemurisTM had identified 
the rifamycin type natural product kanglemycin A (KglA) as an inhibitor of 
rifampicin resistant RNAPs. Here, we show the unique ansa-bridge substituents 




KglA inhibits transcription through a unique steric occlusion mechanism by 
preventing extension of the nascent transcript at an earlier stage than rifampicin. 
  
(iv) Finally, we investigated ADP-ribosylation as a mechanism of KglA 
inactivation by Mycobacterium smegmatis and Mycobacterium abscessus 
Rifampin ADP-ribosyltransferase (Arr) enzymes. We show KglA is not a substrate 
of the rifampicin inactivating Arr purified from Mycobacterium smegmatis, but 
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Chapter 1. Introduction 
 
The first step of gene expression involves the conversion of genetic information 
encoded in a DNA template into a molecule of RNA. This process is called 
transcription. In all cellular organisms, transcription is performed by the multi-
subunit enzyme DNA-dependent RNA polymerase (RNAP). RNAP catalyses the 
synthesis of RNA from a DNA template using ribonucleoside triphosphates. 
(NTPs) as substrates. 
The essential nature of RNAP makes it an excellent target for therapeutic 
intervention. Indeed, inhibition of RNAP is an established approach in broad 
spectrum antibacterial therapy and antitubercular therapy (Villain-Guillot et al., 
2007a, Darst, 2004, Chopra, 2007, Ma et al., 2016, Mosaei and Harbottle, 2019). 
Furthermore, understanding the mechanisms by which RNAP is targeted at a 
molecular level is of great value in the development of novel therapeutics. The 
expanding public health threat of antibiotic resistance demands the discovery of 
novel antibiotics with which to target resistant pathogenic bacteria. Additionally, 
understanding bacterial mechanisms of resistance is becoming increasingly 
important for effective drug development. 
This introduction aims to briefly highlight the nature of transcription in bacteria 
and how RNAP is targeted by antimicrobial inhibitors. Most inhibitors covered in 
this work target initiation of transcription. Thus, there will be particular emphasis 
on processes of transcription initiation. Mechanisms of antibiotic resistance will 
also be briefly highlighted. Additionally, individual results chapters will also 
contain a brief introduction and discussion section. 
1.1 The transcription cycle 
The process of transcription in bacteria occurs in 3 distinct phases of i) initiation 
ii) elongation and iii) termination.  
1.1.1 Initiation 
During initiation of transcription in bacteria, RNAP is required to identify and bind 




RNAP (α2β'βω) is unable to achieve this independently (Ruff et al., 2015, 
Burgess et al., 1969). The core enzyme requires an additional initiation factor for 
recruitment to promoter sequences and the melting of duplex DNA. In bacteria, 
this accessory factor is the σ factor which binds to the core enzyme to form the 
holoenzyme (Burgess and Anthony, 2001, Murakami and Darst, 2003, Borukhov 
and Nudler, 2003, Burgess et al., 1969). The primary σ factor (σ70 in Escherichia 
coli) directs transcription to the majority of promoters during exponential growth 
phase (Paget and Helmann, 2003). Alternative σ factors control transcription of 
genes in response to certain environmental conditions (Paget, 2015). 
Following binding of σ to core, σ directs the resultant holoenzyme to a set of 
promoters dictated by the sequence specificity of the given σ factor (Figure 1.1). 
The σ70 holoenzyme recognises cognate -10 (consensus: 5’-TATAAT-3’) and -35 
(consensus: 5’-TTGACA-3’) promoter hexamers upstream of the transcription 
start site (TSS, denoted as +1) (Paget and Helmann, 2003, Murakami, 2013, 
Burgess and Anthony, 2001). σ70 is comprised of five distinct modular domains 
(σR1.1, σR2, σR3, σR3.2 and σR4) of which σR2 and σR4 are responsible for 
the recognition of the cognate -10 and -35 promoter elements, respectively 
(Campbell et al., 2002a). Binding of duplex promoter DNA to RNAP constitutes 
the formation of the closed promoter complex (RPc) in which promoter DNA 
remains double stranded (Ruff et al., 2015, Mazumder and Kapanidis, 2019, 
Hawley and McClure, 1980, Li and McClure, 1998). Following formation of RPc, 
σ70 nucleates promoter melting by intercalating aromatic residues into DNA at the 
-12 position of duplex DNA (Feklistov and Darst, 2009). Conserved non-template 
DNA bases (NT) at the −11 and −7 positions are flipped out of the DNA duplex 
and stabilised in protein pockets on σR2 (Zhang et al., 2012, Murakami et al., 
2002b, Bae et al., 2015a). The template strand is loaded into the main cleft of 
RNAP to position the TSS within the active centre. The melted portion of DNA, 
known as the transcription bubble, extends from the -11 position to the +2 
position (Murakami, 2015, Bae et al., 2015a). RNAP complexed with melted 
promoter DNA is termed the open promoter complex (RPo). RNAP is then 
competent for binding of NTPs and the synthesis of RNA transcripts. 
Before transitioning into processive elongation, the open complex undergoes a 




contacts and reiteratively synthesises short RNAs, this species is termed the 
initially transcribing complex (RPitc) (Figure 1.1). This reiterative abortive 
synthesis is achieved by a DNA scrunching mechanism, in which DNA is pulled 
into the active centre whilst the trailing edge of the enzyme remains static on the 
DNA template (Kapanidis et al., 2006). Energy stored in this ‘scrunched complex’ 
is resolved either by the release of the short nascent RNA transcript as an 
abortive product and the return of the enzyme to the open promoter complex, or 
the energy of the scrunched complex causes RNAP to relinquish its contacts with 
the promoter, dissociate from the σ factor and transition to a highly stable 
elongation complex (EC) (Gralla et al., 1980, Carpousis and Gralla, 1980). (See 
section 1.2 for further detail regarding initiation of transcription)  
Figure 1.1 Schematic of the transcription cycle and σ:DNA interactions. Adapted from (Alhadid et 
al., 2017). The beginning of the transcription cycle is delineated by the binding of σ (orange) to 
core RNAP (grey) to form the RNAP holoenzyme. The secondary channel (dark grey) and RNA 
exit channel (light grey) are depicted on the right and left hand sides of RNAP, respectively. 
σR3.2 is depicted within the RNA exit channel. Holoenzyme binds double stranded promoter DNA 
to form the closed promoter complex (RPc) by recognition of the -10 and -35 promoter elements 
by σR2 and σR4 (purple dots), respectively. RPc undergoes spontaneous isomerisation to the 
transcription competent open promoter complex (RPo). RPo then undergoes a period of 
reiterative abortive synthesis in which short RNAs are synthesised and released (RPitc). 
Eventually, RNAP escapes the promoter by displacing σR3.2, relinquishing promoter specific 
contacts, and dissociating from sigma, before transition to a highly processive elongation 
complex. (The author directs the reader to section 1.2 for further details regarding the 





1.1.2 Elongation  
During elongation, the EC travels along the DNA template synthesising a 
complementary RNA transcript. Transcription elongation in prokaryotes is 
extraordinarily processive; the enzyme is capable of synthesising transcripts 
thousands of nucleotides in length without disassembly of the EC (Nudler et al., 
1996). Extension of RNA occurs through the nucleotide addition cycle (NAC) 
(Figure 1.2). NAC is marked by binding of the NTP substrate within the active 
centre followed by nucleotidyl transfer at the growing 3’ end of the nascent 
transcript. Thus, the RNAP active centre contains a binding site for the 3’ 
terminus of RNA (i site) and a binding site for the incoming NTP (i+1 site) 
(Vassylyev et al., 2007a, Korzheva et al., 2000). Following nucleotide addition, 
release of pyrophosphate generates an EC in which the 3’ end of RNA is bound 
in the i+1 site of the active centre. This is termed the pre-translocated state. To 
ensure further elongation of the transcript, the EC must translocate, positioning 
the 3’ end of the transcript into the i site and vacate the i+1 site for an incoming 
NTP substrate. This is termed the post-translocated state (Korzheva et al., 2000) 
Throughout elongation, the EC transiently maintains a transcription bubble of ~12 
bp containing a 9-10bp RNA-DNA hybrid (Nudler et al., 1997). Translocation is 
accompanied by 1bp melting of downstream duplex DNA and a corresponding 
1bp restoration of duplex DNA upstream. Additionally, translocation of RNAP 
causes the RNA-DNA hybrid to shorten by 1bp. This shortening of the RNA-DNA 
hybrid, combined with movement of the transcription bubble, makes passive 
translocation energetically unfavourable (Nudler, 2009, Bar-Nahum et al., 2005a). 
Therefore, it is thought NTP substrate plays a role in assisting RNAP 
translocation. Within this model, RNAP oscillates between pre- and post- 
translocated states with the 3’ end of RNA moving between the i and i+1 site. 
Binding of NTP stabilises the post translocated state by occupying the vacant site 
and locking the enzyme in a catalytically competent state (Bar-Nahum et al., 
2005b). The substrate acts as a stationary pawl in the ‘Brownian ratchet’ 
mechanism of RNAP translocation. Subsequent nucleotidyl transfer and 
pyrophosphate release act to reduce the thermodynamic stability of the EC owing 




binding. Consequently, upon pyrophosphate release, the EC can move laterally, 
adopt the post-translocated state and repeat the nucleotide addition process.  
 
 
Figure 1.2 The nucleotide addition cycle (NAC). Template DNA is shown in red, RNA is shown in 
blue, incoming nucleotides are shown in yellow, and catalytic Mg2+ shown in magenta. Non-
template is omitted for clarity. At the beginning of the NAC, RNAP is in the post-translocated state 
in which RNA 3’-OH is located in the active centre i site. NTPs diffuse into the active site with 
chelated Mg-II, and bind the i+1 site. RNAP then catalyses phosphodiester bond formation, 
following which a pyrophosphate molecule is released. Following catalysis, RNAP then 
translocates, vacating the i+1 site and manoeuvring the RNA 3’-OH into the i site in preparation 





Principally, polymerisation of RNA occurs through the nucleophilic attack of the 3’ 
hydroxyl group of the RNA strand on the α-phosphate of an incoming NTP. This 
SN2-type reaction results in the formation a new phosphodiester bond and 
displacement of pyrophosphate. The RNAP active centre, like all nucleic acid 
polymerases, catalyses this process through a two metal ion mechanism 
(Sosunov et al., 2003) (Figure 1.4). RNAP co-ordinates a catalytic Mg2+ ion (Mg-I) 
by an evolutionarily conserved invariant aspartate triad of β'. Principally, Mg-I is 
tasked with activation of the 3’ terminus hydroxyl group and correct positioning of 
the incoming NTP through coordination with the α-phosphate. A second Mg2+ 
(Mg-II) is bound by RNAP ~ 6Å away from Mg-I and with lower affinity. It is 
thought to be delivered to the active centre bound to incoming NTP, stabilised by 
the α-, β- and γ- phosphates. The role of Mg-II is to coordinate the negatively 
charged oxygens of the α-, β- and γ- phosphates, ensuring their correct 
orientation for the nucleophilic attack of the 3’ hydroxyl group (Nudler, 2009, 
Sosunov et al., 2003). The detailed structure of the active centre and its role in 
catalysis will be discussed further in 1.2.1.  
1.1.3 Termination  
Transcription termination in prokaryotes occurs through 2 distinct mechanisms; 
intrinsic termination (Rho-independent) and Rho-dependent termination. In 
intrinsic termination, RNAP transcribes a palindromic G-C rich region followed by 
a U-rich tract. Following transcription of the U-rich tract, RNAP pauses. This 
pause allows the G-C rich region of the transcript to form a hairpin structure 
within the RNA exit channel. The hairpin extends into the main channel causing a 
shortening of the RNA-DNA hybrid and displacing RNA from the exit channel. 
The destabilised EC then dissociates into its constituent parts for further rounds 
of transcription (Gusarov and Nudler, 1999). 
In Rho-dependent termination, the homohexameric Rec-A family helicase Rho 
binds preferentially to C-rich regions of transcribed RNA. RNA is threaded 
through Rho’s central pore, triggering 5’ to 3’ RNA translocase activity (Pallabi et 
al., 2017, Ananya et al., 2016). Rho translocates towards RNAP halted at Rho 
dependent termination sites. Rho then interacts with RNAP to inactivate and 




1.2 Structure & Mechanisms of RNAP 
1.2.1 Overall core RNAP structure  
The core RNAP is composed of 5 subunits (α2ββ’ω) with an overall molecular 
weight of ~ 400KDa (Murakami, 2015, Korzheva et al., 2000, Vassylyev et al., 
2002, Borukhov and Nudler, 2003, Zhang et al., 1999). The enzyme possesses a 
distinctive crab claw structure with the two largest subunits β and β’ constituting 
the opposing pincer-like structures (Figure 1.3, left panel). The β and β’ subunits 
delineate the main channel of RNAP with the active centre located towards the 
rear of the claw. The two α subunits are located at the back of the enzyme. They 
form a homodimer through interactions of their N-termini onto which the β and β’ 
subunits are loaded during RNAP assembly (Ishihama, 1992). The ω subunit also 
plays a role in assembly, it is thought to aid in recruitment of the β’ subunit during 
assembly and stabilise its conformation within the fully assembled RNAP 
(Mathew and Chatterji, 2006). 
Figure 1.3 Overall structure of E. coli core RNAP and the RNAP elongation complex (surface 
representations). (Left) The structure of the RNAP core enzyme. β is depicted in yellow, β’ is 
depicted in green, ω is depicted in purple, α-II is depicted in dark grey, and α-I depicted in light 
grey. (Right) The structure of the E. coli RNAP elongation complex. Individual subunits are 
depicted as in core RNAP, with DNA depicted in blue. (Images constructed from PDB file 6RH3) 
 
Duplex DNA enters RNAP through the main channel formed by the β and β’ 




into the transcription bubble and the template strand is passed through the active 
centre to direct complimentary RNA synthesis (Vassylyev et al., 2007a, Korzheva 
et al., 2000). During transcription, the main channel houses a transiently 
maintained 9-10bp RNA-DNA hybrid (Mustaev et al., 2017, Nudler et al., 1997). 
Once RNA extends beyond 10bp, the 5’ end is threaded through the RNA exit 
channel. Access of NTP substrate to the active centre is thought to be enabled 
through the secondary channel. Also termed the pore, the secondary channel is a 
~12Å wide channel that extends from the active centre to the surface of the 
enzyme. NTPs are thought to diffuse through the secondary channel to the active 
site where they are selected for incorporation at the 3’ end of RNA (Korzheva et 
al., 2000, Batada et al., 2004). Additionally, the secondary channel 
accommodates the 3’ end of RNA during backtracking of RNAP (Mustaev et al., 
2017, Korzheva et al., 1998). However, there is also some evidence to suggest 
that NTPs are able to access the active site through the main channel (Landick, 
2005, Burton et al., 2005). 
Within the overall structure, RNAP possesses a number of mobile elements vital 
to the enzyme function. The majority of the β’ subunit constitutes the larger of the 
two pincers, termed the ‘clamp’ (Chakraborty et al., 2012). It is a highly mobile 
domain able to hinge around a flexible region at its base termed the switch region 
comprised of five discrete elements (SW1–SW5) (Belogurov et al., 2009, 
Mukhopadhyay et al., 2008). The clamp is able to swing open to accommodate 
the DNA within the active centre cleft. Upon binding of DNA, the clamp reverts to 
a closed conformation to retain melted DNA within the active centre during 
initiation and elongation (Chakraborty et al., 2012, Duchi et al., 2018, Feklistov et 
al., 2017). Within the main channel there are a number of other structural motifs 
that influence the transcription process. The β flap domain, β’ lid, β’ zipper, and 
Zn2+ finger domain contribute to the structure of the RNA exit channel. These 
domains contribute to the stability and length of the RNA-DNA hybrid within the 
main channel and displace RNA from the DNA template during elongation 
(Korzheva and Mustaev, 2001, Vassylyev et al., 2007a). The β’ lid functions as 
an upstream zip lock serving to displace RNA and prevent overextended 
hybridisation with the template-strand. The β’ rudder domain further stabilises the 




structural element of the active centre termed the bridge helix (BH) acts along 
with the β fork loop-II to serve as the downstream zip lock (see section 1.2.2 for 
further details on BH function). Following de-hybridsation at the upstream edge, 
the RNA is channelled into a narrow cavity formed by the β’ lid, β’ Zn2+ finger and 
the β flap domain. The β lobes accommodate the non-template strand during 
elongation (Korzheva et al., 2000).  
1.2.2 Architecture of the active centre  
The active site of RNAP, denoted by catalytic Mg-I and Mg-II ions, is located 
within the main cleft at the rear of the crab claw (Vassylyev et al., 2002, 
Vassylyev et al., 2007b). As shown in Figure 1.4, Mg-I is tasked with activation of 
the 3’ RNA hydroxyl group and positioning the incoming NTP through 
coordination with the α-phosphate. Whereas Mg-II is charged with coordinating 
the α-, β- and γ- phosphates, ensuring their correct orientation for the nucleophilic 
attack of the 3’ hydroxyl group (Sosunov et al., 2003) . In doing so, Mg-I and Mg-
II stabilise the pentavalent transitions state that typifies such SN2-type reactions. 
Mg-I is bound permanently within the active centre, coordinated through the 
aspartate triad of the universally conserved NADFDGD motif present in the β’ 
subunit. Any substitution of these aspartate residues (β'D460, β'D462 and 
β'D464, E. coli numbering) abolishes all catalytic activity of RNAP (Sosunov et 
al., 2005, Zaychikov et al., 1996). Mg-II is thought to be brought to the active 
centre bound to the incoming NTP substrate and coordinated primarily by two of 
the catalytic aspartates (β'D460, β'D462). Consequently, Mg-II is bound to RNAP 




Figure 1.4 Catalytic mechanism of phosphodiester bond formation. Adapted from (Sosunov et al., 
2005) Two catalytic magnesium ions (green) are coordinated by three β’ aspartate residues (E. 
coli numbering). The incoming NTP substrate is in blue. Curly arrows depict the movement of 
electron pairs during the formation of the phosphodiester bond. Activated RNA 3’-hydroxyl group 
attacks the α- phosphate of the NTP bound in the i+1 site, forming a new phosphodiester bond, 
and displacing a pyrophosphate molecule. 
 
Two structural domains of the active centre, the trigger loop (TL) and BH, are 
known to play crucial roles in catalysis in all RNAPs. The TL is a highly flexible 
domain located in the vicinity of the active centre that moves between closed and 
open conformations during catalysis (Mejia et al., 2015, Temiakov et al., 2005a, 
Zhang et al., 1999) (Figure 1.5). It, along with the BH, contributes to binding and 
selection of cognate NTP substrates (Vassylyev et al., 2007a, Vassylyev et al., 
2007b, Wang et al., 2006). Firstly, the open TL conformation permits NTP entry 
into a ‘pre-insertion site’. If bound NTP matches the base of the i+1 site, the TL 
refolds to the closed conformation. This closed state is stabilised through 
interactions of the TL with the base of cognate NTP substrate (Vassylyev et al., 
2007b, Wang et al., 2006, Yuzenkova et al., 2010) . Incorrect hydrogen bonding 
of non-cognate substrates with the i+1 template base prevents complete TL 
refolding due to steric clash with the base of the incoming NTP (Wang et al., 
2006, Vassylyev et al., 2007b, Yuzenkova et al., 2010). As a fully closed TL is a 
prerequisite for catalysis, the TL contributes to transcription fidelity. Furthermore, 
the TL directly contributes to catalysis through β' residues R933 and H936 (E. coli 
numbering). In the closed conformation, these residues are brought into close 
proximity to the catalytic Mg2+ ions and coordinate the α-, β- and γ- phosphates of 
the incoming NTP substrate, further stabilising the transition state during 




Figure 1.5 Location of the bridge helix (BH) and trigger loop (TL). Adapted from (Hein and 
Landick, 2010) Structure of the T. thermophilus elongation complex. DNA is depicted in black, 
RNA is depicted in red. RNA polymerase subunits are shown as partially transparent surface 
representations (α, β, and β'; blue, gray and pink, respectively). The positions of the BH (cyan) 
and closed (folded) TL (orange) are shown. Conformational change to the open (unfolded) TL 
(yellow) is indicated by the black double ended arrow. The thick black arrow indicates proposed 
NTP access through the secondary channel. Active site Mg2+ is indicated in yellow and α,β-
methylene-ATP substrate indicated in green.  
 
Alongside the TL, the BH plays a concerted role in loading of cognate NTP and 
the translocation of RNAP following phosphodiester bond formation. The BH is a 
large metastable α-helix which spans the main cleft of RNAP, bisecting the main 
cleft into the primary and secondary channels (Vassylyev et al., 2007a, Zhang et 
al., 1999, Korzheva et al., 2000). During catalysis, the BH is thought to transition 
between straight and kinked conformations. The TL and BH are proposed to work 
in tandem to enable translocation by a two pawl ratchet mechanism (Bar-Nahum 
et al., 2005a). Transition of the TL to the folded conformation is thought to induce 
a kink of the BH which may push the 3’ nucleotide into the i site, vacating the i+1 
site for further nucleotide addition. Consequently, the RNAP moves from the pre-
translocated state to the post-translocated state. Additionally, the BH works 
alongside the TL to correctly position the incoming NTP for catalysis (Korzheva et 
al., 2000, Vassylyev et al., 2007a). 
1.2.3 σ70 and the holoenzyme 
For sequence-dependent transcription initiation, the core enzyme must bind the 
initiation factor, σ (Figure 1.6). In recent years, a number of high resolution 
structures have described the exquisite architecture of the σ factor and its 
organisation within the bacterial holoenzyme (Murakami et al., 2002a, Murakami 
et al., 2002b, Murakami, 2013). 
In the case of E. coli, σ70 possesses a number of distinct modular domains; 
σR1.1, σR2, σR3, σR3.2 and σR4. σR2, σR3 and σR4 are structured globular 
domains adjoined by flexible linkers (Figure 1.7). σR3.2 constitutes a 
functionalised linker between σR3 and σR4, whereas σR1.1 is a negatively 
charged disordered domain (Campbell et al., 2002b). σR2, σR3 and σR4 




domain both on the exterior and within the main channel, while σR3 and σR4 
interact with the β flap domain. σR3.2 serves as a flexible linker domain situated 
between the globular domains of σR3 and σR4. It extends into the main channel 
and interacts with template DNA upstream of the active centre in the open 
promoter complex (Murakami, 2013, Murakami et al., 2002a, Murakami et al., 
2002b). It is implicated in a number of aspects of transcription initiation (see 
below). σR1.1 is located within the main RNAP cleft within the holoenzyme, 
acting as a ‘gatekeeper’ by mimicking negatively charged DNA. Within the open 
promoter complex, promoter DNA displaces σR1.1 from the main channel. 
Figure 1.6 Overall structure of the E. coli holoenzyme (surface representation). β is depicted in 
yellow, β’ is depicted in green, ω is depicted in purple, α-II is depicted in dark grey, α-I depicted in 








1.2.4 Promoter architecture and the open complex (RPo) 
During σ70 -dependent initiation, within the context of the holoenzyme, σR2 and 
σR4 engage with the -10 (consensus: 5’-TATAAT-3’) and -35 (consensus: 5’-
TTGACA-3’) hexamers, respectively (Ruff et al., 2015, Zhang et al., 2012, Bae et 
al., 2015a, Feng et al., 2016, Dickson et al., 1975) (Figure 1.7). Although, note, in 
nature, almost all promoters diverge somewhat from these canonical sequences. 
A consensus spacer region of 17bps separates the -10 and 35 sequences, 
although this distance can vary from between 16-19bp, depending upon the 
promoter (Shimada et al., 2014, Hawley and McClure, 1983). Furthermore, the α-
C terminal domains (αCTD) interacts with DNA upstream of the -35, at positions -
40 to -60, termed the UP element (Ross et al., 1993, Gourse et al., 2000). This 
additional promoter element has been shown to influence rates of promoter 
complex formation and overall rates of transcription. Additionally, some 
promoters, such as the galP1 promoter, possess an additional motif (consensus: 
5’-TG-3’) 2 bps upstream of the -10 element which interacts with σR3 to further 
stabilise open promoter complexes (Barne et al., 1997, Haugen et al., 2006). 
Furthermore, the region between the TSS and -10, termed the discriminator 
region, is also thought to play a role in RPo lifetime (Haugen et al., 2006, 
Shimada et al., 2014).  
As shown in Figure 1.7, within RPo, σR2 binds to the -10 element, σR3 binds to 
the extended -10 motif and σR4 binds to the -35 promoter element. In particular, 
a helix-turn-helix substructure of σR4, σR4.2, binds to bases of the -35 element 
(Zhang et al., 2012, Murakami et al., 2002b, Murakami et al., 2002a).  A 
substructure of σR2, σR2.3, makes specific contacts with the conserved NT 
adenosine and thymine bases at the -11 position and -7 position, respectively 
(Zhang et al., 2012, Murakami et al., 2002b, Murakami et al., 2002a, Feng et al., 
2016). The bases are flipped out of the duplex into protein pockets, while σ70 
makes further non-specific contacts with other bases of the -10 elements to 








Figure 1.7 Domain architecture of σ70 and its interaction with promoter DNA within the open 
promoter complex. Adapted from (Paget, 2015). A) Schematic represents the overall globular 
domain structure of σ70 with respective subdomains noted and their interactions with promoter 
DNA in the context of the open promoter complex denoted by dashed arrows (RPo). σR4 (σ4) is 
denoted in red, σR3 (σ3) is denoted in dark blue, σR2 (σ2) is denoted in green, and σR1.2 is 
denoted in orange (NCR; non conserved region). In the schematic of promoter DNA below, 




transcription start site. The non-template (NT) strand is depicted in purple, and the template (T) 
strand is depicted in cyan. B) Structure of the E. coli transcription initiation complex. σ70 domains 
(surface representations) and DNA (sphere representations) are coloured as in A. For clarity the 
β, α-II and ω subunits are omitted.  
 
A further substructure of σR2, σR1.2, interacts with non-template promoter DNA 
downstream of the -10 element within the discriminator region (Zhang et al., 
2012, Haugen et al., 2006, Haugen et al., 2008a). The base at non-template 
strand position -6 is stabilised in a protein pocket on σR1.2 within the open 
complex, whilst interactions are also made with the -5 and -4 positions. 
Interestingly, σR1.2 facilitates the binding of single stranded -10 promoter DNA 
by σR2 through an allosteric signal within the context of the holoenzyme (Zenkin 
et al., 2007). Holoenzymes lacking σR1.2 are unable to recognise single stranded 
-10 promoter sequence DNA (Zenkin et al., 2007, Wilson and Dombroski, 1997). 
Furthermore, certain substitutions in σR1.2 make the holoenzyme incapable of 
forming stable open complexes and are highly defective in transcription initiation 
(Baldwin and Dombroski, 2001). It is hypothesised σR1.2 stabilises a particular σ 
factor conformation required for optimal -10 promoter element recognition (Zenkin 
et al., 2007). 
1.2.5 Mechanism of open complex formation 
Several promoter complex structures, inhibitor-promoter complex structures, 
single molecule experiments and footprinting data have allowed the elucidation of 
several intermediates that lie on the pathway towards RPo (Ruff et al., 2015, Roe 
et al., 1984, Buc and McClure, 1985, Mazumder and Kapanidis, 2019). Although 
individual promoters likely have varying intermediates and kinetics, there is a 
general consensus on how RPc transitions to RPo, and a simple sequence of 
events can generally be attributed to all promoters. Firstly, the holoenzyme must 
recognise promoter DNA to form an initial closed promoter complex intermediate, 
termed RPi1, in which promoter DNA is double stranded (Figure 1.8, A). 
Subsequently, a rate-limiting isomerisation to a heparin resistant intermediate, 
termed I2,occurs in which an unstable melted DNA bubble is formed, before a 
final transition to stable transcription competent RPo (Ruff et al., 2015, Bae et al., 





Figure 1.8 Formation of the open promoter complex (RPo). Adapted from (Feklistov et al., 2017) 
A) Kinetic scheme of promoter melting by RNAP (R, RNAP; P, promoter DNA; RPi1, promoter 
melting intermediate 1; RPi2, promoter melting intermediate 2, and RPo, open promoter complex. 
B) Modelled positions of downstream duplex DNA within intermediates of promoter melting. 
Respective intermediates and DNA trajectories are indicated with respect to the above kinetic 
equation. Promoter elements are indicated, σR2.3 is depicted in green. C) Schematic of 
spontaneous DNA unwinding during promoter melting. Blue symbols indicate positively charged 
interior surface of the active site cleft. σR2.3 is depicted in green, template DNA is depicted in 
yellow, non-template DNA is depicted in blue with -10 promoter element and conserved -11 
adenosine depicted in red, and catalytic Mg2+ depicted in magenta. Schematic model of RPi1 to 




The slow isomerisation of I1 > I2 is thought to be driven by both thermal dynamics 
and an active role of RNAP. It is widely accepted the first step of promoter 
melting involves flipping-out of the conserved non-template -11 adenosine base 
into protein pockets on σR2 (Feng et al., 2016, Zhang et al., 2012, Bae et al., 
2015a). This is thought to activate recognition of the remaining bases of the -10 
element and allow promoter melting to propagate to the TSS. Several conserved 
aromatic residues of σR2.3, namely F419, Y430, W433 and W434 stabilise the 
flipped out base and act to bend promoter DNA 90o towards the RNAP active site 
cleft during melting (Mazumder and Kapanidis, 2019a, Feklistov and Darst, 2009, 
Koo et al., 2009). Y430 and W433 are implicated in intercalation of double 
stranded promoter DNA at the -12 position to initiate nucleation and stabilise the 
flipped out conformation of the -11 base (Feklistov and Darst, 2011).  
Formation of RPo varies greatly depending upon both urea and salt 
concentration. This dependency suggests formation of stable RPo involves 
significant conformational changes of RNAP, namely the mobile β' clamp domain 
(Mekler et al., 2014, Drennan et al., 2012). Within RPo, the clamp adopts a 
‘closed’ conformation, in which the entry of single stranded DNA is prohibited due 
to the width of the cleft and the interactions of σR2 with promoter DNA above the 
cleft (Feklistov et al., 2017, Boyaci et al., 2019). This indicates RPo formation 
requires dynamic movement of the clamp during promoter melting. Single 
molecule FRET studies have shown that the clamp can adopt several 
conformations; a ‘closed’, ‘partly closed’ and ‘open’ conformation, with the ‘open’ 
conformation predominating in solution (Chakraborty et al., 2012). Indeed, 
several current models suggest promoter melting is intricately linked with 
dynamics of the clamp (Boyaci et al., 2019, Feklistov et al., 2017, Lin et al., 
2017a). It is now proposed, following recognition of upstream promoter elements, 
a transient, thermally driven closure of the clamp allows σR2 to engage with the -
10 promoter element, consequently nucleating promoter melting above the cleft 
(Feklistov et al., 2017). As melting propagates downstream of the -10 towards the 
TSS, opening of the clamp (oRNAP) allows negatively charged single stranded 
template DNA to be pulled towards the active centre by electrostatic interactions 
with positively charged residues within the cleft (Feklistov et al., 2017) (Figure 




remains open, likely represents the unstable open promoter intermediate I2. 
Subsequent closure of the clamp stabilises the complex to form transcription 
competent RPo in which template DNA is bound stably within the active site.   
1.2.6 Mechanism of initial transcription and promoter escape 
In the presence of NTPs, an open promoter complex undergoes reiterative RNA 
synthesis which can result in either short abortive RNA synthesis or productive 
RNA synthesis (Kapanidis et al., 2006). The productive pathway is characterised 
by synthesis of an RNA molecule of 9-11nt in length, at which point the RNAP 
relinquishes contacts with the promoter and enters processive elongation. In 
contrast, the abortive pathway involves RNAP retaining contacts with the 
promoter, synthesising and releasing short RNAs (termed abortive products), 
returning to RPo, and then reinitiating synthesis of RNA (Carpousis and Gralla, 
1980, Gralla et al., 1980). The balance between these two pathways is influenced 
by promoter sequence and the initially transcribed sequence (Hsu et al., 2003, 
Hsu, 2009). Indeed, it is thought to be an influential regulatory mechanism at 
certain promoters in vivo.  
Utilisation of single molecule methods enabled identification of the mechanism by 
which RNAP proceeds through abortive transcription. By measuring distances 
within promoter complexes engaged in abortive RNA synthesis, it was discovered 
downstream DNA is pulled into RNAP 1bp per nucleotide addition cycle causing 
an enlargement of the transcription bubble, whilst the enzyme remains stationary 
on the promoter fragment (Revyakin et al., 2006). This so-called ‘DNA 
scrunching’ mechanism is an essential step in promoter escape. It is believed, 
during abortive transcription, accumulated DNA unwinding and compaction 
create a high energy intermediate in which stress accumulation drives the 
breakage of specific interactions between RNAP, promoter DNA and σ70. 
Conversely, this high energy intermediate can be resolved by releasing the short 
RNA product and returning to RPo to reinitiate RNA synthesis.    
Structural studies of the RNAP holoenzyme and initially transcribing complexes 
show the σ70 substructure σR3.2 is located in the path of extending RNA during 
initiation (Basu et al., 2014, Murakami et al., 2002a, Murakami et al., 2002b). 




clash with σR3.2. This structural data was reaffirmed by biochemical assays in 
which it was shown RNAP lacking σR3.2 do not synthesise abortive transcripts 
(Murakami et al., 2002b). Consequently, following clash of the nascent transcript 
with σR3.2, it is thought the nascent transcript either dislodges σR3.2 from its 
position, or the short RNA is released as an abortive transcript. Along with DNA 
scrunching stress, this mechanism is thought integral to RNAP promoter escape 
and the transition to elongation. To escape the promoter, sequence specific 
interactions within the open promoter complex must be broken. This principle is 
supported by the observation that, somewhat paradoxically, promoter escape is 
negatively correlated with the strength of the promoter (Ko and Heyduk, 2014, 
Hsu et al., 2006, Vo et al., 2003), supporting the proposed idea energy created 
within the initiation complex determines the breaking of sequence specific 
contacts. By clashing with and displacing σR3.2 the growing transcript displaces 
σR4 from the initiation complex, enabling RNAP to escape the promoter, 
dissociate from σ70, and allow transition to processive elongation.   
1.3 RNA polymerase targeting antibacterials 
The essential nature of RNAP and its divergence from eukaryotic counterparts 
make it an excellent target for antimicrobial therapy. A highly complex molecular 
architecture means a large number of antibacterials, both natural and synthetic, 
bind RNAP and inhibit various stages of the transcription cycle. Additionally, 
conserved sequence homology amongst prokaryotic RNAPs often facilitates 
broad spectrum activity amongst RNAP targeting antibacterials. Furthermore, 
RNAP inhibitors are not just valuable antibiotics, they are often useful aids with 
which to dissect RNAP function. Known RNAP inhibitors can generally be 
grouped into a several main categories depending on the mechanism by which 
they inhibit RNAP; (i) inhibitors of nascent RNA extension (ii) inhibitors of 
holoenzyme assembly (iii) nucleoside analogues (iv) inhibitors of active centre 







1.3.1 Inhibitors of nascent RNA extension 
Ansamycins (Rifamycins) 
Ansamycins are a family of natural product antibiotics produced by several 
strains of Actinobacteria (Kim et al., 2006, Wang et al., 2012). They possess a 
distinctive structure, comprised of an aromatic nucleus, commonly a 
naphthoquinone moiety, bridged at its non-adjacent ends by an aliphatic chain 
(Figure 1.9). A subclass of the ansamycins, the rifamycins, were first isolated in 
1959 from the fermentation broth of Amycolotopsis mediterranei, and found to 
possess potent antibacterial activity on account of strong inhibition of prokaryotic 
RNAP (Sensi et al., 1959). The principal rifamycin, rifamycin B, was only 
moderately active, but could be further converted into two more potent species, 
rifamycin O and rifamycin S (Sensi et al., 1960) (Figure 1.9). Reduction of 
rifamycin S to rifamycin SV (Rif SV) yielded the first drug compound of the class 
to be introduced to the clinic (Figure 1.9). Rif SV was used intravenously and 
topically in the treatment of staphylococcal infections, hepatic infections, and 
tuberculosis infections. However, despite good antibacterial activity, Rif SV 
exhibited poor oral bioavailability and marked liver sequestration (Floss and Yu, 
2005). Subsequently, Rif SV became the basis of extensive structure activity 
relationship (SAR) experimentation with the aim of resolving pharmacokinetic 
problems.  
Early SAR studies indicated hydroxyl groups at C1 and C8 on the 
naphthoquinone core, and at C21 and C23 on the ansa- bridge were essential for 
rifamycin function. Modification of any of these functional groups rendered the 
compound inactive (Bacchi et al., 1998). Furthermore, these essential oxygen 
functionalities must remain in a specific spatial orientation for activity (Bacchi et 
al., 2008). Consequently, most alterations to the ansa-bridge, which generally 
effect the conformation of the aliphatic bridge, abolish or significantly reduce 
activity. The naphthalene moiety was identified as the most amenable to 
synthetic modification, particularly at positions C3 and C4. Early efforts focused 
primarily around modifications at C3 (Floss and Yu, 2005). Addition of a 4-methyl-
1-piperazinyl moiety at C3 yielded by far the most important and widely used 




the clinic in 1968 and remains the front-line treatment against Mycobacterium 
tuberculosis infections, the causative agent of tuberculosis (Aristoff et al., 2010). 
 
 
Figure 1.9 Chemical structures of natural and semi-synthetic rifamycins. Adapted from (Robertsen 
and Musiol-Kroll, 2019). Structures of the naturally derived rifamycins; rifamycin B and rifamycin 
SV, and the semi-synthetic derivatives rifampicin, rifabutin, rifapentin, and rifamixin. 
 
Fascinatingly, Rif is 1000 times more potent at mycobacterial RNAPs, when 
compared to E. coli RNAP. This difference is not thought to be due to differences 
in binding site, as this region of RNAP is highly conserved in RNAPs (Zenkin et 
al., 2005a). Indeed, the mechanistic details of this phenomenon remain elusive. 




synthesised by further modifications focused around the C3/C4 positions, and are 
approved for the treatment of a broad range of infections (Aristoff et al., 2010) 
(Figure 1.9). Rifamycins are generally broad spectrum antimicrobials and exhibit 
their highest activity against gram positive bacteria, with MICs commonly below 
0.1μg/ml (Aristoff et al., 2010).  
The antibacterial activity of rifamycin is due to potent inhibition of DNA-dependent 
RNA synthesis as a consequence of binding to prokaryotic RNAP (Campbell et 
al., 2001, McClure and Cech, 1978). Co-crystal structures of several rifamycins 
bound to RNAP show the inhibitors bind at a site within the main RNAP cleft, 
around 12 Å from the active centre (the ‘Rif pocket’) (Campbell et al., 2001, 
Artsimovitch et al., 2005). They bind in the pathway of nascent RNA and sterically 
block its propagation beyond 2-3nt in length (Figure 1.10). When the extending 
RNA collides with the bound rifamycin, it is released as a short abortive product. 
If RNA extends beyond 3-mer, rifamycins cannot bind to RNAP. Consequently, 
rifamycins are unable to inhibit the elongation complex (McClure and Cech, 1978, 
Campbell et al., 2001). 
This ‘steric occlusion’ mechanism, broadly speaking, is mutual to all rifamycins. 
However, slight mechanistic differences exist depending on the substituent 
present at C3/C4. For example, rifabutin inhibits the formation of the first 
phosphodiester bond (when transcription is initiated with a 5’ non-phosphorylated 
dinucleotide primer), whereas Rif and rifapentine inhibit synthesis of the second 
phosphodiester bond (Artsimovitch et al., 2005). It was proposed an additional 
‘allosteric mechanism’ may act in addition to the ‘steric occlusion’ mechanism, in 
which rifamycins allosterically modulate RNAPs affinity for catalytic Mg2+. 
However, this model was later invalidated (Feklistov et al., 2008). Indeed, most 
biochemical and structural data support ‘steric occlusion’ as the principle 







Figure 1.10 Mechanism of transcription inhibition by rifampicin. Adapted from (Artsimovitch and 
Vassylyev, 2006). An initially transcribing complex (upper panel) composed of core enzyme (light 
gray, with bridge helix (bridge) shown in dark gray), σ factor (magenta, with σR3.2 (σHL) shown 
extending into the primary channel toward the RNA:DNA hybrid), promoter DNA (template strand 
in red and non-template strand in dark blue), and nascent RNA (yellow) base paired with the 
template strand. Catalytic Mg2+ is depicted in magenta. Binding of Rif (black/blue) causes a steric 
clash with the 5’ triphosphate of nascent RNA causing it its dissociation through the RNAP 
secondary (lower panel) 
 
Resistance to Rif (RifR) is most commonly caused by amino acid substitutions of 
the Rif-pocket that alter residues involved in binding contacts, or alter the 
conformation of the binding pocket, thus preventing binding of the antibiotic 
(Campbell et al., 2001, Molodtsov et al., 2017a). As shown in Figure 1.11, the 




termed the Rif-resistance determining region (RRDR), which is further subdivided 
into four distinct clusters; cluster I (amino acid residues 507-534, E. coli 
numbering), cluster II (amino acid residues 563-572), cluster III (amino acid 
residues 684-690), and the N-terminal cluster (amino acid residues 143-146) 
(Goldstein, 2014, Tupin et al., 2010b) . Almost ~100 unique amino acid 
substitutions have been identified in clinical isolates of RifR Mycobacterium 
tuberculosis (Sandgren et al., 2009). Interestingly, however, only three of these 
mutations account for the vast majority of RifR clinical isolates, with βS531L, 
βH526 and βD516V mutations accounting for ~41%, 36% and 9%, respectively 
(Campbell et al., 2001) (Figure 1.11). The rapid selection rate for mutations (10-7-
10-8) of the Rif pocket observed with rifamycins remains a major drawback in their 




Figure 1.11 Sequence alignment of rifampicin resistance determining regions (RRDRs) with 
common mutations observed in E. coli and M. tuberculosis (MTB) conferring resistance to 
rifampicin. Adapted from (Molodtsov et al., 2017a). Individual RRDR regions are indicated above 
the sequence alignments. Positions that share the same amino acid are depicted with a gray 
background. Mutations that confer resistance in E. coli or MTB are indicated, with major mutation 
sites indicated. Mutations exclusive to E. coli RNAP are depicted in blue, mutations exclusive to 




In addition to alteration of RNAP, resistance to rifamycins is known to occur 
through a number of other mechanisms, including target duplication, antibiotic 
modification, and decreased cell permeability. Genome sequencing of the Rif 
resistant pathogen Nocardia farcinica IFM 10152 identified the presence of two 
genes encoding the RNAP β subunit, rpoB1 and rpoB2 (Ishikawa et al., 2004). 
Further analysis of the two genes revealed rpoB2 possesses amino acid 
substitutions in the RRDR that likely result in resistance to Rif. Indeed, generation 
of rpoB2 knockout strains confirmed the gene confers Rif resistance. This 
mechanism of gene duplication is apparently common among species of 
Nocardia and has also been described in a related Actinomadura strain (Vigliotta 
et al., 2005), suggesting Rif producing Actinomadura, such as A. mediterranei, 
may utilise this mechanism to resist the antibiotic. However, at present, this 
theory is unconfirmed.  
Inactivation of rifamycins by covalent modification is a strategy utilised by a 
number of different bacteria, and is thought to prevent binding of the antibiotic to 
RNAP. Bacteria can inactivate Rif in a number of different ways, including 
hydroxylation, glycosylation, phosphorylation, and ADP-ribosylation. In addition to 
duplication of the β subunit, N. farcinica encodes a Rif monooxygenase which 
catalyses 2’ N-hydroxylation of Rif, resulting in a compound with greatly reduced 
antibacterial activity (Abdelwahab et al., 2016). Additionally, 2’ N-hydroxylation of 
Rif is thought to prime the compound for degradation. A related monoxygenase 
has also been identified in the pathogen Rhodococcus equi (Andersen et al., 
1997). Certain Bacillus strains, Nocardia species and related actinomycetes are 
also able inactivate Rif by O-23 glycosylation and O-21 phosphorylation (Dabbs 
et al., 1995, Tanaka et al., 1996). Furthermore, a recent phosphotransferase 
isolated from Listeria monocytogenes phosphorylates Rif at the C21 position 
(Stogios et al., 2016). The opportunistic pathogen Mycobacterium smegmatis 
inactivates Rif by ADP-ribosylation at the C23 position, a reaction catalysed by 
rifampicin ADP-ribosyltransferase enzymes (Arr) (Morisaki et al., 2000). 
Rifamycin SV, and newer semi-synthetic Rif derivatives rifapentine, rifamixin and 
rifabutin, are also substrates for Arr (Baysarowich et al., 2008, Shin et al., 2018). 
Homologues are widely distributed in environmental bacteria and also present in 




Actinetobacter baumannii, and certain E. coli strains (Shin et al., 2018, Houang et 
al., 2003, Arlet et al., 2001, Naas et al., 2001, Tribuddharat and Fennewald, 
1999). Interestingly, Rif analogues with bulky carbamate substituents at the C25 
position are resistant to inactivation by M. smegmatis Arr (Combrink et al., 2007). 
Indeed, recently solved structures of Rif complexed with M. smegmatis Arr 
suggest the bulky substituents would prevent Rif binding to the enzyme, 
consequently evading ADP-ribosylation (Baysarowich et al., 2008).  
A further strategy of resistance to rifamycins (although not exclusive to 
rifamycins) is through altered membrane permeability. For antibiotics with 
cytoplasmic targets the compounds must enter the cell and accumulate at 
sufficiently high concentrations for activity. Bacteria can prevent this in two ways; 
(i) by an intrinsic or acquired decrease in membrane barrier permeability, and (ii) 
by overexpression of membrane associated efflux pumps. Mycobacteria possess 
an inherently impermeable cell envelope as a consequence of their waxy, mycolic 
acid rich cell wall. Early investigations of a Rif resistant Mycobacterium, 
Mycobacteria intracellulare, showed that the strain was intrinsically resistant to 
Rif, yet its RNAP was sensitive to the antibiotic (Hui et al., 1977). Further 
experimentation showed resistance was due to inability of the compound to cross 
the cell envelope. Several efflux pumps are implicated in Mycobacterial 
resistance to Rif and several other antibiotics. The putative efflux pump Tap is 
upregulated by certain Rif resistant Mycobacteria when grown in the presence of 
Rif (Szumowski et al., 2013), suggesting expression of efflux pumps can be 
induced by Mycobacteria in response to treatment with Rif. 
Sorangicin 
Sorangicin (Sor) is a macrolide polyether antibiotic isolated from the fermentation 
broth of Myxobacterium cellulosum. It is a complex of two active structural 
variants, A and B (Irschik et al., 1987). Sor exhibits broad spectrum antibiotic 
activity but is predominantly effective against Gram positives, particularly 
Mycobacteria (Irschik et al., 1987). Sor was shown to effectively inhibit both E. 
coli and T. aquaticus RNAP at IC50’s below 1 μM (Campbell et al., 2005).  The 
crystal structure of Sor complexed with T. aquaticus RNAP showed the inhibitor 




B). Indeed, the mechanism of Sor is essentially the same as Rif; the compound 
sterically blocks formation of the second phosphodiester bond, causing the 
nascent transcript to be released as a short abortive RNA (Campbell et al., 2005). 
Due to the mutual binding site with Rif, there is considerable, but not 
comprehensive, cross resistance (Xu et al., 2005, Campbell et al., 2005). 
Molecular dynamics simulations indicate Sor possesses greater conformational 
flexibility within the Rif binding pocket, and consequently is less susceptible to 
alterations in binding pocket structure. This flexibility is thought to allow Sor to 
retain activity at some RifR RNAPs. For example Sor retains activity at the 
prevalent RifR mutation βS531L (E. coli numbering) (Campbell et al., 2005). 
However, it is worthy to note, selection of spontaneous mutations conferring 
resistance to Sor are selected for at a rate almost identical to Rif (Rommele et al., 
1990). 
 
Figure 1.12 Binding site of rifampicin, sorangicin, and GE23077 on RNAP. Adapted from (Ma et 
al., 2016) (A) T. thermophillus holoenzyme with core subunits (α, β, and β') depicted in gray, and 




red asterisk and arrow. The Rif/Sor binding site is depicted in green. The boxed region is depicted 
in B and C. (B) The overlapping binding site of Sor and Rif. Initiating RNA dinucleotide is depicted 
in orange. Rifampicin is depicted in red and sorangicin is depicted in yellow. Other structures in 
view are depicted as in A. (C) The binding site of GE23077 (orange). The compound binds in the i 
and i+1 sites (pale green). ATP entering the active centre through the secondary channel is 
depicted in red. Other structures in view are depicted as in A. Proximity to the Rif binding site 
(green) is illustrated by bound Rif SV (orange). A hybrid molecule of Rif SV covalently GE23077 
remains active against WT and RifR RNAPs.  
 
GE23077 
GE23077 (GE) is a macrocyclic heptapeptide antibiotic isolated from the culture 
of Actinomadura species in 2004 (Ciciliato et al., 2004). The compound is a 
specific inhibitor of both WT and RifR bacterial RNAP (Sarubbi et al., 2004, Zhang 
et al., 2014a). However, it exhibits limited antibacterial activity due to limited 
membrane permeability (Sarubbi et al., 2004, Zhang et al., 2014a, Ciciliato et al., 
2004). Activity is improved against ΔtolC strains, and when GE is combined with 
a membrane perturbing agent. GE inhibits transcription initiation by preventing 
the synthesis of 2nt nascent transcripts. The crystal structure of GE complexed 
with Thermus thermophilus RNAP holoenzyme showed the compound binds the i 
and i+1 sites within the RNAP active centre, adjacent to the catalytic Mg2+ (Figure 
1.12, C). Numerous binding contacts are formed with residues of the β and β’ 
subunits, including the three aspartate residues responsible for coordination of 
catalytic Mg2+ (Zhang et al., 2014a). By binding within the i and i+1 sites, GE acts 
to sterically hinder the binding of initiating NTP substrates required to start 
transcription. Interestingly, despite establishing extensive binding contacts, only 
four residues of the β subunit (βE565, βG566, βM681 and βN684) have been 
identified that confer viable resistance to GE, suggesting the i and i+1 sites offer 
a promising target for antibiotics. Furthermore, the proximity of the GE binding 
site to the Rif pocket has enabled the synthesis of a bipartite molecule combining 
Rif SV and GE that remains active against WT and RifR RNAPs (Zhang et al., 
2014a) (Figure 1.12, C). By producing such hybrid antibiotics it is hoped the rate 






1.3.2 Disrupting holoenzyme assembly 
SB-2 series 
Transcription initiation requires the binding of a σ initiation factor to RNAP core to 
facilitate formation of the initiation competent holoenzyme (Ruff et al., 2015). A 
high throughput screen of the ChemBridgeTM library, in which binding affinity 
between E. coli RNAP core and the housekeeping σ70 was measured, identified a 
series of synthetic compounds termed the SB-2 series (André et al., 2006, Andre 
et al., 2004). Two initial hit compounds, SB11 and SB15, were identified for their 
specific inhibition of core : σ70 association. Subsequently, both compounds were 
found to inhibit in vitro transcription performed by E. coli RNAP holoenzyme. A 
series of furanyl rhodanine derivatives of the SB series were shown to possess 
antibiotic activity against a number of Gram positive bacteria, specifically from the 
Bacillus, Streptococcus and Staphylococcus genera (Villain-Guillot et al., 2007b, 
André et al., 2006).  
Fascinatingly, SB series compounds are capable of inhibiting σ-independent 
transcription at poly (dA-dT) DNA template, suggesting the binding site of SB 
compounds is situated on RNAP core (André et al., 2006). Furthermore, this 
observation complicates the apparent mechanism of action by which SB 
compounds function. It is likely the compound inhibits transcription by RNAP 
holoenzyme by hindering interactions between σ and RNAP core. The 
compounds inhibit transcription following the formation the holoenzyme 
suggesting their hindrance of σ: core interactions is mediated allosterically (André 
et al., 2006).  However, it is also possible the compound targets a structural 
element of catalytic core required for function. However, as of yet, no structure of 
bacterial RNAP complexed with SB compounds has been solved. Mutations 
conferring resistance to SB series compounds also remain elusive. 








1.3.3 Nucleoside analogues  
Pseudoridmycin 
Nucleoside analogues are compounds structurally related to NTP substrates. 
They can often compete with NTPs for their respective binding sites and 
consequently inhibit nucleic acid binding enzymes, including nucleic acid 
polymerases (Périgaud et al., 1992). Pseudoridmycin (PUM) was the first 
nucleoside analogue identified capable of specific inhibition of bacterial RNAP 
(Maffioli et al., 2017). It is produced by several bacteria from the Streptomyces 
genus (Rosenqvist et al., 2019, Maffioli et al., 2017). Initially, the compound was 
identified from a large screen of microbial extracts for its ability to inhibit E. coli 
RNAP, but not the structurally unrelated RNAP of the SP6 bacteriophage. The 
compound displayed antibacterial activity against a wide range of bacteria, 
including an array of drug-resistant pathogens (Maffioli et al., 2017).  
Inhibition of bacterial transcription by PUM in vitro indicated the compound 
inhibits RNAP by competing with UTP for the i+1 site. Incorporation of UTP, but 
not ATP, CTP, or GTP, was inhibited by PUM in both single and multiple 
nucleotide addition experiments. Furthermore, PUM lost activity at DNA 
templates that do not direct incorporation of UTP. Spontaneous mutations 
conferring resistance to PUM in E. coli mapped to a region within the RNAP 
active centre, overlapping the i+1 site (Maffioli et al., 2017).  Indeed, the crystal 
structure of T. thermophilus RNAP complexed with PUM confirmed PUM targets 
the i+1 site (Figure 1.13, A,B). The compound forms Watson-Crick base pair 
interactions with residues of the template strand and forms polar interactions with 
several residues of the i+1 site in a manner analogous to NTP substrates (Maffioli 
et al., 2017) (Figure 1.13, B, C). The formation of Watson Crick interactions 
between the PUM base moiety and template strand are only possible at template 
positions directing incorporation of UTP, offering an explanation for PUMs 










Figure 1.13 Inhibition of RNAP by Pseudoridmycin (PUM). Adapted from (Mosaei and Harbottle, 
2019). (A) Orthogonal views of PUM binding position within the active centre of T. thermophilus 
RNAP. RNAP is depicted in gray, PUM is depicted in yellow, and the active centre Mg2+ is 
depicted as magenta sphere. (B) The active centre of T. thermophillus RNAP with PUM (yellow) 
(left) and CMPcPP (purple) (right); a non-hydrolysable nucleoside, bound within the active centre 
i+1 site. The RNAP bridge helix (BH) is depicted in gray, RNAP active centre Mg2+ depicted as 
magenta spheres, and template DNA is depicted in blue. (C) Vital interactions of PUM (left) and 
CMPcPP (right) within the i+1 site of T. thermophilus RNAP (E. coli numbering in brackets). Note 




1.3.4 Inhibitors of mobile elements of the active site 
Salinamides 
The salinamides are a group of structurally related compounds belonging to a 
rare class of depsipeptides isolated from several marine Streptomyces species 
(Trischman et al., 1994, Moore et al., 1999). Salinamide A (Sal), B and F are 
effective antibiotics as a consequence of potent inhibition of bacterial RNAP 
(Hassan et al., 2015, Degen et al., 2014). Biochemical experiments showed Sal 
inhibits both transcription initiation and elongation, as well as the reverse reaction 
of phosphodiester bond formation - pyrophosphorolysis. Sal does not compete 
with binding of NTP substrates, nor does the compound inhibit the formation of 
the promoter complex (Degen et al., 2014). By identifying spontaneous and 
induced Sal resistance mutations, Degan et al identified a putative binding site 
adjacent to the RNAP active centre, overlapping the N-terminal hinge of the BH 
(BH-HN), plus two other structural components implicated in the conformational 
changes of the BH during  nucleotide addition, the ‘F-loop’ and ‘link region’. 
Indeed, Cocrystalisation of Sal and E. coli RNAP showed the inhibitor binds in a 
region between the secondary channel and BH, making direct interactions with 
the BH-HN, link region and F-loop (Figure 1.14 A, B). The compound interacts 
with the BH-HN in an unbent (straight) conformation (Degen et al., 2014). A bent 
conformation of BH-HN has been identified in several molecular dynamics 
simulations, and is thought to be an important intermediate during catalysis of 
both phosphodiester bond formation and pyrophosphorolysis (Kireeva et al., 
2012, Weinzierl, 2010). Thus, it is thought Sal inhibits RNAP by stabilising BH-HN 
in an unbent conformation and consequently prevents conformational cycling of 
the BH-HN between the bent and straight conformations important for catalysis. 
Additionally, the crystal structure of RNAP complexed with Sal possessed a 
disordered TL (Degen et al., 2014). Structural modelling of Sal binding within the 
crystal structure of a T. thermophilus RNAP elongation complex bound to NTP 
substrate suggests Sal may sterically hinder correct folding of the TL. Thus, Sal 
inhibition of TL conformational changes may contribute to the mechanism by 
which Sal inhibits transcription. Although, biochemical data presented by Degen 
et al suggested Sal inhibition was not dependent on TL, a recent smFRET 




indicated Sal inhibits TL folding in solution, suggesting TL is indeed a target for 
Sal (Mazumder et al., 2019, Degen et al., 2014). 
Streptolydigin 
Streptolydigin (Stl) was first isolated from Streptomyces lydicus in 1955 (Lewis et 
al., 1955, Crum et al., 1955, Deboer et al., 1955). It possessed a distinctive 
structure containing an acylated tetramic acid, a ‘streptolol’ side chain, and a 
monosaccharide moiety. Stl exhibited potent antibacterial activity against a broad 
spectrum of bacteria by inhibiting bacterial RNAP. The compound was able to 
inhibit initiation, elongation, and pyrophosphorolysis activities (Temiakov et al., 
2005b). Additionally, early biochemical studies showed Stl inhibits both 
translocation and nucleotide binding (McClure, 1980). Interestingly, spontaneous 
Stl resistant mutations had been reported in two distinct clusters adjacent the 
RNAP active centre, β543–546 and β‘792–793 (Tuske et al., 2005, Yang and 
Price, 1995, Severinov et al., 1995). The two clusters occupied distinct non 
adjacent regions, approximately 15Å apart, located close to the active centre.  
Saturation mutagenesis experiments delineated 72 individual mutations from 26 
distinct residues, defining a determinant that overlapped three distinct structural 
features; the BH, TL, and a region of the β subunit termed the ‘Stl pocket’ 
(comprised of residues β543–545 and β570–571) (Tuske et al., 2005, Vassylyev 
et al., 2007b, Temiakov et al., 2005a). Interestingly, some of the determinant 
slightly overlapped the proposed binding determinant of the transcription 
inhibiting lasso peptide Microcin J25 (see 1.3.5) (Braffman et al., 2019). 
Indeed, several crystal structures of T. thermophilus RNAP complexed with Stl 
show the inhibitor binds a site adjacent to, but not overlapping, the RNAP active 
site (Temiakov et al., 2005a, Tuske et al., 2005, Vassylyev et al., 2007b) (Figure 
1.14, A, B). The monosaccharide moiety of Stl occupies a space proximal to the 
TL and central region of BH, making polar interactions with downstream DNA and 
hydrophobic interactions with the TL. The streptolol moiety interacts with the ‘Stl 
pocket’ and the N terminal end of the BH, whilst the tetramic acid moiety interacts 
directly with the TL, resulting in its displacement. Interestingly, deletion of the TL 
increases Stl binding affinity at T. thermophilus RNAP (Temiakov et al., 2005a).  




straight conformation, whilst concurrently trapping the TL in an unfolded 
conformation. In doing so, Stl stabilises the RNAP active site in an inactive 
substrate bound conformation in which accurate substrate loading is disfavoured. 
Consequently, the inhibitor blocks the dynamic conformational changes essential 
for effectual catalysis (Temiakov et al., 2005a). 
CBR Series 
The original CBR series compound, CBR703, was identified in a high throughput 
screen of synthetic compounds in which activity against E. coli RNAP was 
assessed, and activity against E.coli ΔtolC determined (Zhu et al., 2014, 
Artsimovitch et al., 2003). The CBR series possess a distinctive structure 
comprised of two linked aromatic rings. In vitro analysis showed CBRs inhibited 
all catalytic activities of RNAP, but had minimal effect on translocation of RNAP 
(Artsimovitch et al., 2003). Interestingly, CBR703 was active against RNAPs from 
a number of Gram-positive and Gram-negative species, but failed to inhibit 
Mycobacterium tuberculosis RNAP (Feng et al., 2015). Recent crystal structure of 
RNAP complexed with CBR703 show the compound binds at a hydrophobic two-
pocket site adjacent to the β’ fork loop and N-terminal region of the bridge helix, 
in addition to the β subunit link domain, DII loop, and F-loop 2 (Figure 1.14).  
The binding mode is supported by identification of several spontaneous and 
induced mutations conferring resistance to CBR703. Interestingly, the selection 
rate of CBR703 resistance mutations in certain E. coli strains is as low as 1x10-12, 
indicating the CBR binding site may be a desirable target for future therapeutic 
antibiotics (Feng et al., 2015).  
Inhibition of RNAP by CBR703 is thought to be caused by allosteric inhibition of 
TL folding, as consequence of interaction with the β’ fork loop, and through 
inhibition of conformation cycling of the BH-HN (Bae et al., 2015b) (Figure 1.14, 
C). It has also been proposed CBR compounds weaken BH-TL interactions, 
consequently destabilising TL folding required for catalysis (Malinen et al., 2014).  
Interestingly, however, inhibition of nucleotide addition by CBR703 is only 
partially dependent upon the TL, whilst inhibition of pyrophosphorolysis occurs 
entirely independent of the TL. Only inhibition of intrinsic hydrolysis by CBR703 is 




unidentified conformational change of the active centre during catalysis of 
catalytic processes involving NTPs (i.e. nucleotide addition and 
pyrophosphorolysis).  Such conformational changes may be regulated by BH-HN 




Figure 1.14. Inhibitors of mobile elements of the active centre. Adapted from (Mosaei and 
Harbottle, 2019) (A)  Orthoganal views of binding positions of Sal (Red), Stl (green), and CBR703, 
(blue) represented in sphere models, mapped onto the structure of T. thermophilus RNAP 
holoenzyme (gray ribbon model). The active centre Mg2+ is depicted as a pale pink sphere (B) 




shown in a grey semi-transparent surface model and different structural elements of the active 
centre displayed in ribbon models. The bridge helix (BH) is depicted in yellow, the trigger loop 
(TL) is depicted in cyan, the ‘link’ domain is depicted in brown, the DII loop is depicted in 
magenta, the F-loop is depicted in black, and the F-loop 2 is depicted in orange. Template and 
non-template DNA is depicted in pale blue and RNA is depicted violet. (C) Structures of different 
conformations of the BH and TL; closed TL and straight BH associated with closed active site 
(Left panel); and open TL and bent BH associated with an open active site (right panel). The N-
terminal and C-terminal hinges are highlighted in magenta 
D-AAP1 
A novel class of synthetic compounds was recently identified from the high 
throughput screen of a synthetic compound library. D-AAP1, the progenitor 
molecule of the class, was found to possess potent activity against M. 
tuberculosis RNAP in vitro, but exhibited poor activity against other bacterial 
RNAPs and human RNAPs (Lin et al., 2017b). The compound exhibits potent, 
selective activity against several Mycobacteria including M. tuberculosis, M. 
avium, and M. smegmatis, but poor activity against other bacterial and 
mammalian cells. The crystal structure of M. tuberculosis RNAP in complex with 
D-AAP1 and isolation of resistance determinants demonstrated the inhibitor binds 
a pocket adjacent to the BH-HN (Lin et al., 2017b). The binding site overlaps 
directly with that of CBR series compounds. Consequently, the two compounds 
are thought to inhibit RNAP through the same mechanism. However, the 
specificity of D-AAP1 for Mycobacteria is drawn from subtle structural differences 
seen in Mycobacterial RNAP. The binding site of D-AAP1 is comprised of three 
individual protein pockets on the surface of M. tuberculosis RNAP which interact 
with the three ringed structure of the compound. On the other hand, the 
respective binding site of CBR series compounds on E. coli RNAP is comprised 
of two protein pockets on the enzyme surface which interact with the two ringed 
structure of CBRs (Lin et al., 2017b).  
1.3.5 Inhibitors of NTP uptake 
Microcin J25  
Microcin J25 (MccJ25) is a cyclic 21 residue antibiotic peptide synthesised by E. 
coli strains containing the pTUC plasmid encoding the gene cluster mcjABCD 
(Bayro et al., 2003, Wilson et al., 2003). It was first identified in 1992 from E. coli 




threaded lasso structure with 2 distinct elements; a ‘lariat ring’ formed through a 
covalent linkage between the N-terminus and glutamic acid at position 8, through 
which a ‘tail’ structure, comprised of residues 9-21, is sterically trapped (Bayro et 
al., 2003, Wilson et al., 2003) (Figure 1.15, A). MccJ25 inhibits both transcription 
initiation and elongation of E. coli RNAP in vitro (Adelman et al., 2004). Mutations 
conferring resistance to MccJ25, generated through saturation mutagenesis, 
mapped almost entirely to the secondary channel, indicating a putative binding 
site (Mukhopadhyay et al., 2004, Yuzenkova et al., 2002). It was proposed 
MccJ25 acts to plug the RNAP secondary channel through a so called ‘cork-in-a-
bottle’ mechanism, consequently stopping uptake of NTP substrates into the 
active centre. Certainly, MccJ25 increases Km of NTP binding, supporting the 
proposed mechanism (Mukhopadhyay et al., 2004). However, many MccJ25 
resistance determinants overlap the binding site of the active site inhibitor 
Streptolydigin on the β subunit, indicating certain elements of their mechanisms 
of action may be shared (Yuzenkova et al., 2002). Indeed, binding of MccJ25 and 
streptolydigin occurs competitively, further substantiating this proposal. 
The recently published crystal structure of MccJ25 complexed with E. coli RNAP 
confirmed the peptide binds deep within the secondary channel (Braffman et al., 
2019) (Figure 1.15, B). The tail structure is oriented towards the active centre, 
with the lariat ring located roughly 6.5 Å from the catalytic Mg2+. Modelling of 
MccJ25 binding within T. thermophilus de novo initiation complex suggests the 
peptide would afford both an electronic and steric clash with the triphosphate 
moiety of the 3’-NTP substrate. Furthermore, MccJ25 reduces the solvent 
accessible gap of the secondary channel from 11 Å to below 5 Å, decreasing the 
accessibility of NTP substrates to the active centre (Braffman et al., 2019). These 
observations offer an explanation for the increased Km for NTP binding seen with 
MccJ25. In addition to obstruction of NTP substrate binding, MccJ25 forms 
binding interactions with the BH and unfolded TL. When bound to RNAP the 
peptide introduces a severe steric clash to correct TL folding (Braffman et al., 
2019) (Figure 1.15, C, D). As a result, TL folding is highly disfavoured in the 
presence of MccJ25. Correct folding of the TL is essential for closure of the active 
site during nucleotide addition. Consequently, it appears MccJ25 inhibits RNAP 




the TL vital for efficient catalysis, ii) obstructing access of NTP substrates through 






Figure 1.15 Inhibition of RNAP by lasso peptide microcin J25 (MccJ25) and capistruin (Cap). 
Adapted from (Braffman et al., 2019). (A) Schematic of MccJ25 (left) and Cap (right). (B) Overall 
structure of E. coli RNAP holoenzyme complexed with MccJ25 (left panel) (molecular model 
coloured as in A) and Cap (molecular model coloured as in A) RNAP is shown as a surface model 
with subunits coloured as in their respective labels. (C) View into the secondary channel with 
varying trigger loop conformations of E. coli RNAP. RNAP is depicted as a ribbon representation 
(β, cyan; β’, light pink) The Active centre Mg2+ is depicted as a yellow sphere, the two alpha 
helices or the TL are depicted TLH1 and TLH2. The F-loop and BH structures are indicated.       . 
(Left panel) Structure of E. coli RNAP with an open (unfolded) TL. (Right panel) Structure of the 
E. coli RNAP transcription initiation complex with a closed (folded) TL. Nucleic acids are shown as 
molecular sphere models (DNA, light gray; post translocated RNA transcript, red). (D) Both panels 
are as right panel of C, with binding site of MccJ25 (left) and Cap (right) superimposed. Note the 
steric clash with the closed TL induced by both lasso peptides. 
 
Capistruin 
Capistruin (Cap) is a 19 amino-acid lasso peptide produced by Burkholderia 
thailandesis E264 (Knappe et al., 2008). It was identified from a genome mining 
experiment aimed at identifying putative lasso peptide precursors, and homologs 
of Mcc25 processing enzymes. Cap is structurally comparable to MccJ25; its N-
terminus is covalently fused to an aspartate residue a position 9, producing a 9 
amino-acid ring, through which the C-terminal tail threads, sterically locked in 
position by an arginine residue at position 15 (Knappe et al., 2008) (Figure 1.15, 
A). Cap was shown to inhibit in vitro transcription by WT E. coli RNAP, but failed 
to inhibit an MccJ25 resistant RNAP containing a β’T931I mutation (Kuznedelov 
et al., 2011). This indicated Cap may bind at the same site on RNAP. Indeed, the 
crystal structure of E. coli RNAP complexed with Cap shows the peptide also 
binds within the secondary channel (Braffman et al., 2019). However, despite 
Cap sharing several binding interactions with residues involved in Mcc25 
interactions, Cap binding determinants are distinct. The peptide binds RNAP with 
a similar orientation to MccJ25; ring and tail proximal to the active site, and loop 
distal (Figure 1.15, B). Yet, Cap binds at a site further from the active centre, 
within a region of the secondary channel that is wider than that occupied by 
MccJ25. Consequently, Cap does not obstruct the channel to the same degree 
as MccJ25, and would seemingly not preclude access of NTP substrates. 
Furthermore, Cap resides almost 12 Å away from the active site Mg2+. Modelling 
within T. thermophilus de novo initiation complex indicates Cap and NTP 




is not caused by preventing access and binding of NTPs to the active site. 
Indeed, biochemical analysis showed transcription inhibition by Cap is principally 
not dependent on NTP concentration (Braffman et al., 2019). However, like 
MccJ25, Cap interacts with both the BH and an unfolded TL. When bound to 
RNAP the peptide introduces a severe steric clash to correct TL folding in a 
manner analogous to Mcc25 (Figure 1.15, C, D). Therefore, in the presence of 
Cap, folding of the TL is highly disfavoured. Hence, despite a similar binding 
mode to MccJ25, it seems the principal mode of action of Cap is through 
inhibition of correct TL folding, a process essential for efficient catalysis of 
nucleotide addition by RNAP.  
1.5.6 Inhibitors of promoter open complex formation 
Fidaxomicin (Lipiarmycin) 
Fidaxomicin (Fdx), also known as lipiarmycin, is a first in class macrocyclic 
antibiotic first identified from culture of the actinomycete bacteria 
Dactylosporangium aurantiacum (Johnson, 2007). It has recently been approved 
for clinical treatment of clostridium difficile-associated diarrhoea. Initial 
biochemical experiments indicated Fdx targets the RNAP switch region, inhibiting 
promoter melting and σ-dependent transcription initiation (Tupin et al., 2010a, Lin 
et al., 2017a). The compound doesn’t inhibit the formation of the promoter 
complex, but was shown to inhibit the binding of template DNA within the RNAP 
active centre (Tupin et al., 2010a). Two recent studies utilising cryo-electron 
microscopy (cryo-EM) elucidated the structure of Fdx complexed with M. 
tuberculosis RNAP (Lin et al., 2017a, Boyaci et al., 2018). The compound 
interacts with SW2, SW3 and SW4, in addition to several clamp alpha helices. Of 
the 5 discrete switch elements, SW1 and SW2 are the principal mediators of 
conformational changes of the clamp. The inhibitor makes 5 essential polar 
interactions with several residues of β and β’ (β’Q94, β’R99, β’248, β’337 and 
βK1303; E. coli numbering). Substitutions at any of these positions confer 
resistance to Fdx (Lin et al., 2017a).  
Structural data indicated the binding of Fdx to RNAP locks the clamp domain in 
an open conformation (Lin et al., 2017a, Boyaci et al., 2018) (Figure 1.16). 




clamp required for simultaneous engagement of both the -10 and -35 promoter 
elements by σR2 and σR4, respectively. This observation is reaffirmed by 
biochemical observations indicating Fdx-RNAP complexes can bind to upstream 
promoter elements, but fail to engage the -10 promoter element, and therefore 
fail to nucleate promote melting (Lin et al., 2017a, Morichaud et al., 2016, Tupin 
et al., 2010a). Specifically, it is proposed the ‘tryptophan wedge’ (Trp wedge), 
responsible for intercalation into the NT strand at the -12 position to nucleate 
promoter melting, cannot engage DNA when the clamp is in an open 
conformation (Figure 1.16, B). Additionally, the protein pocket on σR2 
responsible for binding and stabilising the flipped out non template base at the -
11 position, cannot interact with DNA with the clamp locked open (Lin et al., 
2017a). Therefore, Fdx is thought to inhibit σ-dependent transcription initiation by 
preventing recognition of the -10 promoter element by σR2, and consequently 






Fig 1.16 Mechanism of action of Fidaxomicin (Fdx). Adapted from (Lin et al., 2017a). (A) Structure 
of M. tuberculosis RNAP holoenzyme with a closed clamp conformation in the absence of Fdx 
(left), RPc (centre) and RPo (right. σ is depicted in green ribbon model, σR2 is depicted in green 
surface model, non-template -11 pocket is depicted as yellow surface model, σR2 ‘Trp wedge’ 
depicted as a blue surface model, σR4 is depicted as a yellow surface, and DNA is depicted as a 
blue cartoon model. Note the ability of σR2 and σR4 to simultaneously engage promoter −10 and 
−35 elements, respectively, in both RPc and RPo. (B) Same as A, except Fdx (cyan) is bound to 
RNAP with clamp locked in an open conformation. Colours are as in A, except σ is depicted as a 
brown ribbon model, σR2 NT-11 pocket is depicted as a brown surface model, σR2 Trp wedge 
and σR4 recognition helix are depicted as a pink surface model. Note in the presence of Fdx, σR2 
and σR4 cannot simultaneously engage promoter −10 and −35 elements in RPc and RPo. 
 
Squaramides, myxopyronin, corallopyronin and ripostatin  
Myxopyronin (Myx), corallopyronin (Cor) and ripostatin (Rip) are switch region 
targeting natural products isolated from several species of Myxobacteria 
(Schäberle et al., 2014). The inhibitors bind within a pocket adjacent to the Fdx 
binding site and inhibit RNAP through a slightly different mechanism (Boyaci et 
al., 2019, Mukhopadhyay et al., 2008, Belogurov et al., 2008, Srivastava et al., 
2011). Structural analysis of T. thermophilus RNAP complexed with Myx 
indicates the compound interacts predominantly with SW1 and SW2 to lock the 
RNAP clamp domain in a closed conformation (Belogurov et al., 2009, 
Mukhopadhyay et al., 2008). Introduction of mutations to RNAP elucidated 
several binding determinants essential for Myx activity, all of which exhibit 
extensive cross resistance with Cor and Rip, indicating the compounds bind 
within a mutual pocket (Srivastava et al., 2011, Mukhopadhyay et al., 2008). 
Indeed, a recent cryo-EM structure of Cor complexed with M. tuberculosis 
promoter complexes showed the compound indeed binds within the same pocket 
as Myx on RNAP (Boyaci et al., 2019). The structure of RNAP-Cor promoter 
complexes elucidated a putative intermediate enroute to RPo, in which the 
promoter is partially melted upstream of the transcription start site (Figure 1.17). 
Indeed, biochemical analysis of Myx and Cor show the compounds do not 
entirely prevent promoter melting, but instead prevent the propagation of 
promoter melting reaching the TSS (Srivastava et al., 2011, Mukhopadhyay et al., 
2008). The Cor-RNAP structure indicates late promoter melting might occur 
within the RNAP active centre cleft, and the inhibitors likely act to trap a late 




indicates a transient opening of the clamp is essential for propagation of melting 
to the TSS, owing to restricted access to the active site cleft due to confined 
space between fork loop-2 and SW2 when the clamp is in a closed conformation 
(Boyaci et al., 2019). Furthermore, binding of both Cor and Myx cause a refolding 
of SW2 that is thought to induce a large steric clash with the position of template 
DNA in RPo. This observation is reaffirmed by inhibition of transcription by Myx 
and Cor at artificially melted promoters (Srivastava et al., 2011). Therefore, it 
appears Myx, Cor and Rip inhibit transcription by preventing essential opening of 
the RNAP clamp during promoter melting, and also act to prevent correct 
positioning of template DNA within the active site. 
 
 
Figure 1.17 Inhibition of RNAP by Corallopyronin (Cor). Adapted from (Boyaci et al., 2019) (Left 
panel) Structure of M. tuberculosis RNAP promoter complex in the presence of Cor. Colouring of 
structures is as indicated by the figure legend. Cor traps a putative promoter melting intermediate 
with the promoter partially melted upstream of the TSS. Note template DNA is not loaded within 
the active site. (Right panel) Structure of M. tuberculosis RNAP promoter complex in the absence 






Squaramides (SQ) are a class of synthetic compounds that also target the RNAP 
switch region (Molodtsov et al., 2015). The compounds are active against efflux 
negative strains of E. coli and Haemophilus influenzae (Buurman et al., 2012). 
Crystal structures of SQ complexed with E. coli RNAP show the inhibitors bind 
within the same pocket as Myx and Cor. SQ acts to displace SW2 in a similar 
manner to Myx and Cor, likely effecting clamp conformation, and leading to a 
steric clash with template DNA at positions +3 and +4 (Molodtsov et al., 2015). 
Therefore, it is likely SQ inhibit RNAP is a similar manner to Myx, Cor and Rip, by 
sterically occluding binding of melted promoter DNA within the active site, whilst 







   
  
     











Chapter 2. Materials & Methods 
2.1 Reagents and Antibiotics 
All chemicals, antibiotics and reagents were purchased from Sigma unless 
otherwise stated. All enzymes and their respective buffers were purchased from 
New England Biolabs. NTPs, chromatography columns, and phosphorimaging 
screens were purchased from GE Healthcare. Ureidothiophene was purchased 
from ChemBridgeTM. All promoter DNA fragments were produced by PCR using 
Phusion DNA polymerase from their respective primers (IDT) and purified by 
agarose gel electrophoresis (Qiagen). All radiochemicals were purchased from 
Hartmann Analytic. 
2.2 PCR 
PCR was performed in 50 μL reactions containing the following; 200 μM dNTPs, 
1 unit of Phusion DNA polymerase, ~ 1 ng of template DNA, 10 μM forward 
primer and 10 μM reverse primer and 10 μl 5X Phusion High Fidelity Buffer. All 
primers used can be found in the appendix. The cycling parameters of each 
individual reaction were as recommended by the manufacturer (New England 
Biolabs). Annealing temperature was varied depending upon primer Tm and 
extension time set at 30 seconds per 1000 amplified base pairs.  
2.3 Growth Media and Strains  
All bacterial strains used in this work are described in the Appendix. Unless 
otherwise stated, all strains were grown in liquid Luria – Bertani (LB) medium (1 
% tryptone, 0.5 % yeast extract, 1 % NaCl) or plated on to LB agar (1% tryptone, 
0.5% yeast extract, 1% NaCl, 2% agar) and supplemented with the relevant 
antibiotic when required. Ampicillin was added to a final concentration of 100 
μg/ml. Kanamycin was added to a final concentration of 50 μg/ml.  
2.4 Actinomycete Extract Preparation 
All actinomycete bacteria, provided by DemurisTM, were grown on GYM agar (0.4 
% glucose, 0.4 % yeast extract, 1 % malt extract and 1 % agar) for roughly 7 
days at 30 oC. Growth medium was then extracted with methanol (MeOH) and 




were then cleaned up on a C18 HyperSepTM solid phase extraction (SPE) 
cartridge (ThermoFisher Scientific) and eluted with MeOH.  
2.5 Tandem Liquid Chromatography – Mass Spectrometry    
All analytical separations were performed on an Agilent 1260 HPLC by injection 
of 1-5 μl of sample onto a Raptor ARC-18 LC-2.7 μm - 150×2.1 mm column 
(Restek) or an Ultra C4 5 μm 150 x 2.1 mm operated at 0.2 μl/min and eluted 
using a 30 min linear gradient from 5 % to 100 % acetonitrile. Mobile phases 
were supplemented with 0.1 % formic acid. Mass spectra were recorded in 
positive-ion mode on a Bruker MicrOTOF II time-of-flight mass spectrometer. 
2.6 Disk diffusion assay 
Standard disk diffusion assay (Kirby-Bauer) was performed with respective strain 
as described (Bauer et al., 1966). Briefly, paper disks were loaded with up to 10 
μg of compound, air-dried and placed on LB plates with an embedded lawn of 
respective strain. Reporter strains disk assays were performed with X-gal infused 
agar (100 μg/ml). Plates were incubated overnight at 37oC and scanned. 
2.7 Molecular Cloning 
DNA inserts for cloning were generated by PCR from genomic DNA of respective 
strain. Genomic DNA was purified using the GenElute™ Bacterial Genomic DNA 
Kit (Sigma) by the manufacturer’s protocol. Primers used can be found in the 
appendix. Amplified insert DNA was purified using the Qiagen Gel Extraction kit, 
following the protocol provided. Plasmid and insert DNA were restricted using the 
appropriate restriction enzymes for 1 hour at 37 ⁰C before being gel purified. 1 
unit of Thermosensitive Alkaline Phosphatase (Promega) was added to the 
digested plasmid and incubated for a further 30 mins. For ligation, 3 times molar 
excess of insert DNA to plasmid DNA was incubated at rt using T4 DNA ligase 
(New England Biolabs) for 1-2 h. 5 μl of ligation mix was transformed into 50 μl of 
DH5α competent E. coli cells (New England Biolabs). Cells were transformed 
according to the supplied protocol. Cells were plated on LB containing the 
respective selection antibiotic, either 100 μg/ml ampicillin or 50 μg/ml kanamycin. 
Roughly 5 colonies were picked and grown overnight in LB supplemented with 




using the Qiagen Mini Prep Kit. Presence of insert was then assessed by PCR 
amplification. Individual PCR reactions were loaded onto a 1% agarose gel to 
resolve the amplified insert. Positive clones were then sequenced to verify insert 
presence. All sequencing was carried out by Eurofins Genomics using their 
standard primers. Resultant sequences were visualised using SnapGene 
software. 
2.8 Site-directed mutagenesis  
Amino acid substitutions were introduced using the QuikChange XL Site-Directed 
Mutagenesis Kit (Agilent Technologies). PCR was performed in 50 μL reactions 
containing the following; 125 ng forward primer, 125 ng reverse primer, ~ 10 ng of 
template DNA, 200 μM dNTPs, 5 μl of 10X reaction buffer, 3 μl of QuikSolution, 
2.5 units PfuTurbo DNA Polymerase. All primers used can be found in the 
Appendix. The cycling parameters of each individual reaction were as 
recommended by the manufacturer’s instructions. Annealing temperature was 
varied depending upon primer Tm. 
Following PCR, 10 units of DpnI (Agilent Technologies) was added to each 
reaction for 1 hour at 37 °C to digest parental DNA. 2 μl of the DpnI treated 
reaction were transformed into DH5α competent E. coli cells (New England 
Biolabs) according to the manufacturer’s guidelines.  
2.9 Buffers 
All Buffer compositions can be found in respective methods text. All 
chromatography buffers were filtered through bottle top 0.45 μm PVDF filters 
(Sarstedt) prior to use. 
2.10 Protein expression and purification 
2.10.1 Purification of E. coli core RNAP 
Core E. coli RNAP subunits were expressed in T7 express cells (New England 
Biolabs) transformed with pGEMABC (encoding rpoA, rpoB, and rpoC) and 
pACYCDuet-1_Ec_rpoZ (encoding rpoZ) (Murakami, 2013). Expression was 
induced by addition of 0.4 mM final IPTG to exponentially growing cells and 




were then harvested by centrifugation and resuspended in grinding buffer (50 mm 
Tris-HCl (pH 7.9), 10% glycerol, 200mM NaCl and 1× protease inhibitor mixture). 
Cells were then lysed by sonication and debris cleared by centrifugation. RNAP 
was precipitated from the lysate by addition of polyethyleneimine solution to a 
final concentration of 0.6% and the pellet recovered by centrifugation. The pellet 
was first washed with TGED buffer (10 mM Tris-HCl (pH 7.0), 10% glycerol, 0.1 
mM EDTA, and 2 mM DTT) + 0.5 M NaCl. RNAP was then eluted from the pellet 
by suspension in TGED buffer 1 M NaCl and then precipitated by ammonium 
sulphate to a final concentration of 60 % saturation. RNAP was resuspended in 
TGED buffer + 50 mM NaCl. Lysate was filtered through 0.45 μM PVDF filter 
(Merck) and injected at 1 ml/min onto a 5 ml HiTrap Heparin Affinity column (GE 
healthcare) equilibrated with heparin buffer A (TGED buffer + 50 mM NaCl). 
RNAP was eluted by linear gradient to 100 % heparin buffer B (TGED buffer + 
1M NaCl) at a flow rate of 1 ml/min, and fractions collected. Individual fractions 
were assessed for the presence of RNAP by SDS-PAGE electrophoresis. RNAP-
containing eluates were pooled and injected at 1 ml/min onto a 5 ml Resource Q 
ion-exchange column (GE Healthcare) equilibrated with ResourceQ buffer A 
(TGED buffer + 50 mM NaCl). RNAP was eluted by linear gradient to 100% 
ResourceQ buffer B (TGED buffer + 1M NaCl) at a flow rate of 1 ml/min, and 
fractions collected. Individual fractions were assessed for the presence of RNAP 
by SDS-PAGE electrophoresis. RNAP-containing fractions were pooled and 
concentrated by centrifugation by Ultra-15 Centrifugal Filter Units (Amicon) at 4oC 
according the manufacturers guidelines. RNAP was then dialysed into storage 
buffer (10 mM Tris-HCl (pH 7.5), 50% glycerol, 100 mM NaCl, 0.1 mM EDTA, 1 
mM DTT) at 4°C. 
2.10.2 Purification of S. epidermidis RNAP 
Cellular Staphylococcus epidermidis WT RNAP holoenzyme and E105Q σA 
RNAP holoenzyme were purified from respective strains of WT Staphylococcus 
epidermidis ATCC 12228 and Staphylococcus epidermidis ATCC 12228 
harbouring an E105Q mutation in rpoD (see Isolation of ureidothiophene resistant 
staphylococcus epidermidis). Cells were grown to late exponential phase and 
then harvested by centrifugation and resuspended in grinding buffer (50 mm Tris-




Cells were then lysed by sonication and debris cleared by centrifugation. RNAP 
holoenzymes were purified by HiTrap Heparin Affinity and Resource Q (GE 
Healthcare) column chromatography essentially as described in 2.10.1. 
2.10.3 Purification of mutant E. coli RNAPs 
RIF-resistant & KglA-resistant mutations were introduced in pIA581 plasmid 
(Svetlov and Artsimovitch, 2015) (encoding E. coli rpoA, rpoB, and rpoC, with 
6xHis-tag on N terminus of β subunit) by site-directed mutagenesis. Mutant 
plasmids were co-transformed with pACYCDuet-1_Ec_rpoZ (encoding rpoZ) 
(Murakami, 2013) in T7 Express strain (New England Biolabs). Expression was 
induced by addition of 0.4 mM final IPTG to exponentially growing cells and 
incubated on an orbital shaker (150 rpm) at room temperature overnight. Cells 
were then harvested by centrifugation and resuspended in grinding buffer (50 mm 
Tris-HCl (pH 7.9), 10% glycerol, 200mM NaCl and 1× protease inhibitor mixture). 
Cells were then lysed by sonication and debris cleared by centrifugation. Lysate 
was filtered through 0.45 μM PVDF filter (Merck) and injected onto a 5ml His-trap 
Ni 2+-NTA column (GE Healthcare) equilibrated with Ni 2+ buffer A (50 mm Tris-
HCl (pH 7.9), 10% glycerol, 600mM NaCl). Mutant RNAPs was eluted by 
stepwise increase of Ni 2+ buffer B (50 mm Tris-HCl (pH 7.9), 10% glycerol, 
600mM NaCl, 200mM imidazole) to increase imidazole concentration of eluent 
(0mM, 25mM, 50mM, 100mM and 200mM). Eluates were assessed for the 
presence of RNAP by SDS-PAGE electrophoresis.  
2.10.4 Purification of E. coli σ70 subunit 
E. coli σ70 subunit was expressed in T7 express cells (New England Biolabs) 
transformed with pET28 expression vector encoding N-terminal 6x His-tagged E. 
coli σ70 subunit. Expression was induced by addition of 0.4 mM final IPTG to 
exponentially growing cells and incubated on an orbital shaker (150 rpm) at room 
temperature overnight. Cells were then harvested by centrifugation and 
resuspended in grinding buffer (50 mm Tris-HCl (pH 7.9), 10% glycerol, 200mM 
NaCl and 1× protease inhibitor mixture). Cells were then lysed by sonication and 
debris cleared by centrifugation. E. coli σ70 was then purified by HisTrap HP (GE 
Healthcare) nickel affinity chromatography essentially as described in 2.10.3. 




encoding N-terminus 6x His-tag E. coli σ70 by site-directed mutagenesis (Agilent 
technologies) and purified as above. 
 
2.10.5 Purification of M. smegmatis and M. abscessus Arr 
M. smegmatis and M. abscessus Arr was expressed in T7 express cells (New 
England Biolabs) transformed with pET28 expression vector encoding N-terminal 
6x His-tagged M. smegmatis Arr or M. abscessus Arr. Expression was induced 
by addition of 0.4 mM final IPTG to exponentially growing cells and incubated on 
an orbital shaker (150rpm) at room temperature overnight. Cells were then 
harvested by centrifugation and resuspended in grinding buffer (50 mm Tris-HCl 
(pH 7.9), 10% glycerol, 200mM NaCl and 1× protease inhibitor mixture). Cells 
were then lysed by sonication and debris cleared by centrifugation. E. coli σ70 was 
then purified by HisTrap HP (GE Healthcare) nickel affinity chromatography 
essentially as described in 2.10.3.  
2.10.6 Purification of S. aureus, M. smegmatis and T. aquaticus RNAP 
M. smegmatis and T. aquaticus RNAPs were purified and provided by Dr Amber 
Riaz-Bradley and Dr Christina Julius (Newcastle University) as described 
(Kuznedelov et al., 2003, Mukherjee and Chatterji, 2008). S. aureus RNAP was 
provided by Dr Caitlin Griffiths (Newcastle University). 
2.11 5’ radiolabelling of RNA and DNA primers 
5’-radiolablled DNA primers were used to synthesise 5’-labelled template DNA by 
PCR (as described in 2.2). Where applicable, 5’ radiolabelled RNA primers were 
used in the assembly of artificially assembled elongation complexes. For 5’ 
labelling, 25 μL reactions containing the following; 2.5 μl Primer (10 μm final), 1 
unit T4 Polynucleotide Kinase, 5 μl γ-[32P]-ATP (10 mCi/ml) and 2.5 μl. 10x PNK 
A Buffer incubated at 37 °C for 1 hour. The reaction was inactivated by heating to 
75oC for 10 mins and cleaned up on a bio-spin 6 column (Bio-Rad). 
2.12 In vitro transcription assays 




Transcription from promoter DNA fragments was performed essentially as 
described (Mosaei et al., 2018). Briefly, reactions were performed in 10 μL of 
transcription buffer TB (20 mM Tris HCl pH 7.9, 40 mM KCl, 10 mM MgCl2). 1 
pmol of E. coli RNAP core with 3 pmols of σ70 or 1 pmol of T. aquaticus RNAP 
core with 3 pmols of T. aquaticus σA or 1 pmol of M. smegmatis or S. aureus or S. 
epidermidis RNAP holoenzymes were incubated in TB with 1 μL of DMSO (or 
50% MeOH in the case of bacterial extracts) containing or not containing inhibitor 
at 37°C (or 60°C in case of T. aquaticus RNAP) for 5 mins. Transcription was 
initiated by the addition of 2 μL mixture of nucleotides and promoter DNA in TB, 
containing (final concentrations): 10 nM promoter DNA, 25 μM CpA (for T7A1 and 
GalP1 promoters) or 100 μM ApA (for lacUV5 promoter), 0.2 μl α-[32P]UTP 
(10mCi/ml) (Hartmann Analytic), 10 μM UTP with (run off transcription) or without 
(abortive transcription) 100 μM ATP, CTP and GTP. Reactions were stopped 
after 10 min incubation at 37°C (or 60°C in case of T. aquaticus RNAP) for run off 
transcription or 5 minutes for abortive transcription by the addition of equal 
volume of formamide-containing loading buffer. Products were resolved in 
denaturing polyacrylamide gels, revealed by PhosphorImaging (GE Healthcare), 
and analyzed using ImageQuant software (GE Healthcare) 
2.12.2 In vitro transcription on M13ori hairpins 
In vitro transcription on M13ori hairpin template was performed as described in 
(Zenkin and Severinov, 2004). Briefly, reactions were performed in 20 μL final 
volumes. 3 pmols of wild-type RNAP core with 15 pmols of σ70 and 3 pmols of 
single-stranded M13ori promoter (IDT) were incubated at 37 °C for 10 min in TB. 
Transcription was initiated by the addition of 1 mM ATP, CTP and UTP, 100 µM 
GTP and 0.2 μl α-[32P] GTP (10 mCi/ml) (Hartmann Analytic). Reactions were 
stopped after 30-min incubation at 37°C by the addition of formamide-containing 
loading buffer. Products were separated on denaturing polyacrylamide gels, 
revealed by phosphorimaging (GE Healthcare), and analysed using ImageQuant 
software (GE Healthcare). All quantifications were made in triplicate. 





Elongation complexes were assembled as previously described (Yuzenkova et 
al., 2013). Sequences of assembled elongation complexes used here are 
illustrated in their corresponding figures. Reactions were carried out in 15 μL final 
volume. Briefly, RNA was 5’-radiolabelled by T4 polynucleotide kinase and γ-
[32P]-ATP prior to complex assembly. The reaction was inactivated by heating to 
75oC for 10 mins and cleaned up on a bio-spin 6 column (Bio-Rad). 
Subsequently, 0.5 pmol of 5’-labelled RNA and 1 pmol template DNA were 
incubated in TB at 45°C for 5 mins and then cooled slowly to 4°C to anneal the 
hybrid. The RNA: DNA hybrid was then incubated with 5pmol core RNAP for 5 
mins at 37 oC. The complexes were then incubated with 10 pmol non-template 
DNA bearing a 5’-biotin tag for 5 mins at 37°C .The complexes were then 
immobilised on 5 μL streptavidin beads and then washed first with high salt (1 M 
KCl) and then low salt (40 mM KCl) TB. Reactions were then started with one or 
a combination of 1 μM GTP, CTP, UTP and ATP and incubated at 37 °C for the 
times indicated in the respective figures. Reactions were stopped by the addition 
of formamide-containing loading buffer. Products were separated on denaturing 
polyacrylamide gels, revealed by phosphorimaging (GE Healthcare), and 
analysed using ImageQuant software (GE Healthcare). All quantifications were 
made in triplicate. Rate constants were derived from kinetic data curves fitted to a 
single exponent equation using non-linear regression in SigmaPlot software. 
2.13 KMnO4 and DNAse I footprinting 
Reactions were performed in 20 μL final volume of TB (20 mM Tris HCl pH 7.9, 
40 mM KCl, 10 mM MgCl2). 5 pmol RNAP core and 10 pmols of σ70 were 
incubated in TB. For DNAse I footprinting, 1/10 reaction volume of Urd solution in 
DMSO was added and incubated at 37°C for 5 mins. An identical volume of 
DMSO was added to control samples. For KMnO4 footprinting, 1/10 reaction 
volume of Urd solution in 75% ethanol was added and incubated at 37°C for 5 
mins. An identical volume of 75% ethanol was added to control samples.  
Reactions were supplemented with 0.25 pmol promoter DNA labelled at the 5’ 
end of the non-template strand and incubated for a further 2 minutes at 37°C. 
Samples were then treated with 0.25 units DNAse I (Roche) or 5mM KMnO4 and 
incubated at 37 °C for 30 seconds. For DNAse I footprinting, reactions were 




footprinting, the reactions were stopped with an equal volume of 2-
mercaptoethanol. The KMnO4 treated samples were then subject to phenol-
chloroform extraction, ethanol precipitated and dried before resuspension in 
formamide-containing loading buffer. Products were resolved on polyacrylamide 
gels, revealed by phosphorimaging (GE Healthcare), and analysed using 
ImageQuant software (GE Healthcare) 
2.14 EMSA 
Reactions were performed in 20 μL final volume of EMSA Buffer (20 mM Tris HCl 
pH 7.9, 40 mM KCl, 10 mM MgCl2, 5% glycerol) 2 pmol of RNAP core and 6 
pmols of σ70 was incubated in EMSA buffer. Next, 1/10 reaction volume of Urd 
solution in DMSO was added and incubated at 37°C for 5 mins. An identical 
volume of DMSO was added to control samples. Reactions were supplemented 
with 0.2 pmol promoter DNA labelled at the 5’ end of the non-template strand and 
incubated for a further 5 minutes at 37 °C. Samples were then treated with 2 μL 
H2O or H2O with heparin (50μg/ml final) and incubated for a further 2 minutes at 
37°C. Samples were then supplemented with 2 μL dye solution (0.25% 
bromophenol blue and xylene cyanol) and loaded onto 4.5% non-denaturing 
polyacrylamide gel, revealed by phosphorimaging (GE Healthcare), and analysed 
using ImageQuant software (GE Healthcare). 
2.15 Isolation of ureidothiophene resistant staphylococcus 
epidermidis 
Firstly, MIC of S. epidermidis ATCC12228 was assessed by serial dilution on a 
24 well agar plate (2-fold dilutions from 100μg/ml). Individual wells contained 1 ml 
solid LB agar supplemented with 2.5% pluronic F68 (Thermofisher). Prior to agar 
setting, DMSO with or without ureidothiophene was added to the individual well to 
a final concertation of 5%. S. epidermidis ATCC12228 was streaked onto LB agar 
and grown at 37oC overnight. A single colony was picked and grown in liquid LB 
to 1 x106 CFU/ml. 10 μL of 106 CFU/ml S. epidermidis inoculant were dotted onto 
each well and the plate incubated at 37°C overnight. MIC was deduced as the 
concentration in which no visible cell growth was observed (3.125 μg/ml). 
Secondly, S. epidermidis ATCC12228 was streaked onto standard LB agar and 




~ 1x109 CFU/ml. 100 μL of 109 CFU/ml S. epidermidis ATCC12228 was streaked 
onto an LB agar plate containing 4x MIC ureidothiophene (12.5 μg/ml). 
Ureidothiophene resistant mutants were identified by their growth on this media, 
and confirmed by re-streaking on the same media. A single resistant strain was 
identified and sent for full illumina genome sequencing (MicrobesNG). Genome 
was assembled and SNPs identified by CLC Genomics Workbench software 
(Qiagen) 
2.16 Isolation of Kanglemycin A 
Kanglemycin A was purified by Dr Hamed Mosai-Sejzi (Newcastle University) as 
described (Mosaei et al., 2018)  
2.17 X-ray Crystallography   
X-ray crystallography data was gathered by Dr Vadim Molodstov (Pennsylvania 
State) and Professor Katsu Murakami (Pennsylvania State) as described (Mosaei 
et al., 2018) 
2.18 Determination of minimum inhibitory concentrations (MICs) 
for M. tuberculosis  
MIC determination data were gathered by Dr Joanna Bacon (Public Health 
England) as described (Mosaei et al., 2018). 
2.19 Rifampicin ADP-ribosyl transferase disk assay 
Reactions were performed in 10 μL final volume of Arr Buffer (20 mM Tris-HCl pH 
7.9, 40 mM KCl, 0.5 mM MgCl2). M. smegmatis or M. abscessus Arr at 
concentration indicated (0μM, 20 μM or 200 μM) was mixed with antibiotic (1 
mg/ml final) in 8 μL Arr buffer at 37oC for 5 minutes. 2 μL NAD+ in water was 
added (10mM final) and incubated for 1h at 37oC. Reaction was quenched with 
an equal volume of MeOH and spotted onto paper disks and a disk assay 
performed as described in 2.6 with an embedded lawn of S. aureus RM4220. 
2.20 In vitro Rifampicin ADP-ribosyl transferase activity assay 
Reactions were performed in 100 μL final volume of Arr Buffer (20 mM Tris-HCl 




was mixed with RIF or KglA at 100 μM in 80 μL Arr buffer at 37oC for 10 minutes. 
20 μL NAD+ in water was added (250 μM final) and incubated for 1 h at 37 oC. 
Reaction was quenched with 500 μL of Methanol. Methanol was then evaporated 
under negative pressure and the reaction analysed by LC-MS as described in 
2.5. 
 
2.21 Purification of ADP-ribosyl Rifampicin 
Reaction was performed in 2000 μL volume of Arr buffer (20 mM Tris-HCl pH 7.9, 
40 mM KCl, 0.5 mM MgCl2) containing the following; 25 μM M. smegmatis Arr, 5 
mg Rifampicin and 20 mM NAD+. Reaction was incubated at 37 oC for 24 hours 
and cleaned up on a 25 ml HyperSep™ C8 SPE cartridge. ADP-ribosyl RIF was 
eluted with 30% MeOH and dried under negative pressure by a HT-6 series 3 
evaporator (Genevac) to yield 4.8 mg of ADP-ribosyl RIF. Sample homogeneity 
was confirmed by tandem LC-MS as described in 2.5.  
2.22 Microscale thermophoresis 
Binding affinity experiments were carried out on a Monolith NT.115 Series 
instrument (Nano Temper Technologies GMBH). M. smegmatis and M. 
abscessus Arr were labelled with Monolith Protein Labelling Kit RED-NHS 2nd 
Generation Amine (Nano Temper Technologies GMBH) according to the 
manufacturers guidelines. Roughly 5 μl of sample in MST buffer (20 mM HEPES 
(pH 7.9), 40 mM KCl, 10 mM MgCl2) were loaded into Monolith NT.115 premium 
capillaries and thermophoresis measured for 30 s. Analysis was performed with 
Monolith software. Kd was quantified by analysing the change in normalized 
fluorescence (Fnorm = fluorescence after thermophoresis/initial fluorescence) as 
a function of inhibitor concentration. Curves for Kd data were fitted to a four-








Chapter 3. Aims 
Bacterial RNAP is an excellent target for antibiotics. However, very few clinical 
antibiotics target RNAP. The growing prevalence of antibiotic resistance amongst 
pathogenic bacteria demands the identification of novel antibacterial compounds, 
acting through novel molecular mechanisms. Here, we conduct several distinct 
projects in which we investigate previously uncharacterised molecular 
mechanisms underlying inhibition and resistance of transcription targeting 
antibiotics.  
(i) Most clinical antibiotics are derived from the natural products of 
actinomycete bacteria. Our industrial collaborators DemurisTM previously 
compiled a library of actinomycete bacteria that activate an RNAP reporter 
strain and therefore may produce novel inhibitors of bacterial transcription. 
Consequently, we aimed to identify and characterise novel inhibitors of 
bacterial transcription produced by strains from this particular strain 
library. 
(ii) The synthetic antibiotic ureidothiophene (Urd) was identified within a 
commercial screen of synthetic compounds in which inhibition of S. 
aureus RNAP was analysed. However, how the compound targets RNAP 
is unknown. Here, we aimed to characterise the molecular mechanism of 
action by which Urd inhibits bacterial RNAP. 
(iii) A prior screening program conducted by DemurisTM, and a subsequent 
collaboration with the lab of Professor Nikolay Zenkin identified the 
rifamycin type natural product kanglemycin A (KglA) as an inhibitor of 
rifampicin resistant RNAPs. Here, we aimed elucidate the molecular 
mechanism of action by which KglA inhibits RNAP  
(iv) Finally, we aimed to characterise ADP-ribosylation of Rif and KglA by 
Mycobacterium smegmatis and Mycobacterium abscessus Rifampicin 
ADP-ribosyltransferase (Arr) enzymes. 
 
By investigating these unique mechanistic processes we aim to further our 




understand the exact mechanisms utilised by pathogenic bacteria to facilitate 























Chapter 4. Streptomyces strain DEM40380 produces Antibiotic 
A39079S-1, a rifamycin type inhibitor of bacterial RNAP 
4.1 Introduction 
Actinomycete bacteria are prolific producers of bioactive secondary metabolites, 
many of which are efficacious therapeutics. Roughly two thirds of antibiotics used 
clinically, including β-lactams, tetracyclines, aminoglycosides, macrolides, 
rifamycins, and macrocyclic antibiotics are all derived from compounds produced 
by Actinomycetes. However, very few novel classes of antibiotics have been 
discovered in the last 40 years (Wohlleben et al., 2016). Research efforts in 
natural product drug discovery have declined since the 1970s, whilst ‘modern 
methods’ of drug discovery, such as rational design, have had limited success in 
identifying effective antibiotics (Jackson et al., 2018). The emergence of 
resistance to antibiotics is a growing public health concern, and demands the 
identification of novel antibacterials with which to treat drug resistant infections 
(Davies and Davies, 2010). Consequently, research efforts are revisiting 
actinomycete bacteria with the aim of identifying novel classes of antimicrobials.  
RNAP is a validated target for antibiotic therapy, exemplified by the successful 
use of rifampicin as a front line treatment against Mycobacterium tuberculosis 
infections. However, rapid selection of Rif resistant mutations in the Rif binding 
pocket remains a major issue, frequently leading to Rif resistant strains of M. 
tuberculosis (Goldstein, 2014). Indeed, there is a pressing need for novel 
transcription targeting compounds, acting through novel mechanisms, with which 
to treat resistant pathogens.  
Our industrial collaborators DemurisTM possess a unique collection of over 10,000 
diverse, highly dereplicated isolates of Actinomycete bacteria, sourced from a 
variety of terrestrial and marine environments. In an attempt to identify producers 
of transcription targeting antibiotics, Demuris performed a preliminary screen of 
their collection in which strains were screened against a Bacillus subtilus reporter 
strain (yvgS) that has lacZ fused to the promoter of the bacterial helicase HelD 
(Hutter et al., 2004a). This promoter is upregulated in response to sub-inhibitory 
concentrations of the transcription inhibitor Rif. Consequently, in a disk assay, it 




blue halo at the frontier of the zone of inhibition upon X-gal infused agar plates. 
By using this reporter strain, Demuris compiled a shortlisted library of 17 
actinomycete strains that activated reporter activity of yvgS, and consequently 
may produce novel inhibitors of RNAP (Figure 4.1).  
Here, we analysed this shortlisted library for novel inhibitors of transcription 
through a two-pronged approach. Individual strain extracts were subjected to in 
vitro transcription assays to identify the presence of selective inhibitors of 
bacterial RNAP. In parallel, extracts were subjected to tandem liquid 
chromatography-mass spectrometry (LC-MS), alongside a comprehensive 
literature search to identify previously characterised RNAP inhibitors. From this 
approach we aimed to identify producers of novel selective inhibitors of bacterial 
transcription.  
 
Figure 4.1 Table of actinomycete bacterial strains and their respective genus identified by 
DemurisTM for a screening program aimed at identifying novel inhibitors of bacterial RNAP. Strains 
were compiled as a result of activation of the B. subtilus yvgS reporter strain. The yvgS reporter 
has lacZ fused to the promoter of the bacterial helicase HelD; a promoter upregulated in response 
to sub-inhibitory concentrations of Rif (Hutter et al., 2004b). Consequently, in a disk assay, it is 
presumed strain extracts containing specific RNAP inhibitors produce a blue halo at the frontier of 





4.2.1 Identification of producers of transcription targeting compounds by in 
vitro transcription analysis and tandem liquid chromatography-mass 
spectrometry   
Firstly, our industrial collaborators at DemurisTM performed a preliminary screen 
of their extensive actinomycete collection in which strains were screened against 
the yvgS reporter strain. From this preliminary screen, DemurisTM technicians 
identified 17 actinomycete strains that activated reporter activity of yvgS, and 
consequently may produce novel inhibitors of RNAP (Figure 4.1). These strains 
were subsequently provided to us to pursue the further characterisation 
described herein. 
To identify producers of secondary metabolites targeting transcription, we 
cultivated individual isolates from the shortlisted library on GYM agar plates for 
approximately 7 days. Growth mediums were extracted with methanol and 
evaporated to dryness, from which aqueous extracts were prepared. These crude 
extracts were subsequently ‘cleaned-up’ on C18 solid phase extraction (SPE) 
cartridges and then eluted with methanol in preparation for in vitro analysis. 
Production of active compound(s) by individual strains was confirmed by a disk 
assay of the respective extract against the yvgS reporter strain prior to further in 
vitro analysis.   
Following extract preparation, we assessed the effect of extracts on in vitro 
transcription by WT E. coli RNAP on a linear DNA template containing the T7A1 
promoter. Extracts were added to in vitro transcription reactions before template 
DNA. Expectedly, all extracts were able to inhibit WT E. coli RNAP, confirming 
the presence of transcription inhibiting compounds in the respective extracts 
(Figure 4.2, A). Next, we investigated if this inhibition could be replicated at RifR 
RNAPs. We analysed the effect of extracts in a second in vitro transcription 
assay in which transcription was performed by a mutant RNAP bearing the 
rifampicin resistant mutation βH526Y. This particular mutation is frequently seen 
in clinical isolates of rifampicin resistant Mycobacterium tuberculosis, and confers 
high level resistance to Rif (Goldstein, 2014, Mosaei et al., 2018). In this 




extracts lost inhibitory activity, suggesting prior inhibition at WT RNAP is likely 
due to compounds targeting the Rif binding pocket (Figure 4.2, A). Moreover, all 
extracts that lost inhibitory activity at the mutant RNAP induced a marked 
increase in transcription levels relative to the control. It is possible these extracts 
are contaminated with NTP substrates and/or transcription activating compounds 
that can positively influence transcription rates when rifamycin type inhibitors are 






Figure 4.2 Inhibition of WT and RifR E. coli RNAP by strain extracts. (A) Quantification of inhibition 
of in vitro transcription by respective strain extracts. Transcription performed by WT E. coli RNAP 
and RifR βH526Y RNAP on a linear DNA template containing the T7A1 promoter. Reactions were 
initiated with dinucleotide primer CpA. Quantification is derived from average of [32P]-labelled run-
off and terminated transcription products. Values were normalised to quantity of [32P] RNA 
synthesised in the absence of inhibitor. Error bars are ± SD from at least 3 independent 
experiments. (B) Table of exact atomic masses corresponding to known natural product RNAP 
inhibitors. Masses were identified by tandem liquid chromatography-positive ion mass 
spectrometry (LC-MS) of respective strain extracts. Subsequently, exact masses [-H] were 
searched ± 0.05 Da within the dictionary of natural products (http://dnp.chemnetbase.com), and 
results analysed for respective natural product transcription inhibitors. 
 
To assess the presence of characterised RNAP inhibitors, extracts were 
subjected to tandem reverse phase liquid chromatography - mass spectrometry 
(LC-MS). Distinct peaks from total ion chromatograms were identified and 
corresponding molecular masses searched in the dictionary of natural products, a 
comprehensive archive of chemical data on natural products. Mass spectrometric 
analysis confirmed the vast majority of strains produced well characterised 
rifamycin type inhibitors. Excluding DEM1086, DEM10817, DEM10826, 
DEM10846, and DEM40380, all strain extracts contained masses corresponding 
to either rifamycin B, rifamycin S, or rifamycin SV. Of the strains in which no 
masses corresponding to RNAP inhibitors were identified, DEM1086, DEM10817, 
DEM10826, and DEM10846, all lost inhibitory activity at rifampicin resistant 
RNAP. This loss of activity at mutant RNAP suggests rifamycin type inhibitors 
may be present in these extracts that are hitherto unidentified, or are not yet 
registered in the dictionary of natural products. Nonetheless, identification and 
characterisation of novel rifamycins that fail to inhibit rifampicin resistant RNAPs 
falls outside the scope of this project. Consequently, all strain extracts which 
contained known rifamycin type inhibitors, and/or failed to inhibit transcription by 
rifampicin resistant RNAP, were dropped from further analysis. Thus, the strain 
extract of DEM40380 was selected for further investigation.  
4.2.2 DEM40380 extract inhibits both transcription initiation and elongation 
Specific inhibitors of RNAP often target a distinct stage of the transcription cycle. 
To investigate how the active compound(s) present in the crude extract of 
DEM40380 (DEM40380-CE) inhibit transcription, we first assessed if DEM40380-




DNA template containing the T7A1 promoter. Specifically, we investigated 
inhibition of CpApU synthesis. In this instance, transcription was initiated with the 
dinucleotide primer CpA. It is well described Rif fails to inhibit synthesis of the first 
phosphodiester bond under such conditions, i.e. when transcription is initiated 
with a 5’ non-phosphorylated dinucleotide. The principal mode of action of 
rifamycins is through steric occlusion of the translocating nascent transcript 
following formation of the first or second phosphodiester bond (Campbell et al., 
2001, McClure and Cech, 1978). Interestingly, however, as shown in Figure 4.3, 
DEM40380-CE exhibited dose dependent inhibition of CpApU synthesis. This 
suggests DEM40380-CE targets a step of transcription initiation preceding 
formation of the first phosphodiester bond, or inhibits an element of the 
nucleotide addition cycle. 
To establish if DEM40380-CE inhibits catalytic events, we assembled elongation 
complexes in vitro with fully complementary template and non-template strands, 
and 5′- radiolabelled RNA (Figure 4.3, B). By artificially assembling elongation 
complexes we circumvent transcription initiation events and can assess the effect 
of DEM40380-CE on transcription elongation. Indeed, as can be seen from figure 
4.3, high resolution gel analysis of run-off RNA products synthesised by RNAP 
showed DEM40380-CE moderately inhibits transcription elongation. Thus, these 
data suggest the compound(s) present in DEM40380-CE can inhibit both 








Figure 4.3 Extract of DEM40380 inhibits both transcription initiation and transcription elongation. 
(A) The reaction scheme of an in vitro transcription reaction from promoter DNA (B) The promoter 
DNA sequence of the T7A1 promoter used in C (C) Abortive synthesis of [32P]-labelled CpApU by 
WT E. coli RNAP on linear DNA template containing the T7A1 promoter in the absence and 
presence of a serial dilution of Rif or a serial dilution of DEM40380 extract. Reactions were 
initiated with the 5’-non-phosphorylated dinucleotide primer CpA. (D) The elongation complex 
(EC) used in C. Template DNA, non-template DNA, and 5’-[32P]-labelled RNA are as indicated. 
(E) 5’-[32P]-labelled RNA products synthesised from the EC scaffold shown in B, in the absence 
and presence of Rif (100μg/ml) (negative control) or DEM40380 extract (crude). 5’-[32P]-RNA13 





4.2.3 DEM40380-CE contains a selective and a non-selective transcription 
inhibitor 
To retain a high throughput nature to our initial screen, purification of bacterial 
extracts was kept minimal, comprising only a methanol extraction and single C18 
solid phase extraction. However, to identify the exact compound(s) responsible 
for transcription inhibition, a more thorough purification was warranted. We 
therefore performed a second C18 Solid Phase Extraction in which the cartridge 
was eluted with incremental methanol (MeOH) elutions to fractionate DEM40380-
CE. Fractions were evaporated to dryness and suspended in 50% MeOH. We 
subsequently analysed individual fractions in an in vitro transcription assay with 
WT E. coli RNAP on a linear DNA template containing the T7A1 promoter. 
Interestingly, as can be seen in figure 4.4, two distinct fraction groups inhibited 
transcription by WT E. coli RNAP; the 20% elution and 70%-90% elutions, 
suggesting 2 inhibitory compounds may be produced by DEM40380. Moreover, 
the 70%-90% elutions inhibited transcription of full length RNA products with 
concurrent accumulation of short abortive products. This mechanism is typical of 
rifamycin inhibitors which inhibit transcription through steric hindrance of the 
translocating nascent transcript following synthesis of the first or second 
phosphodiester bond (McClure and Cech, 1978, Campbell et al., 2001). 
To establish the selectivity of inhibitory fractions for bacterial RNAP, we assessed 
the effect of both the 20% elution fraction (DEM40380-F20) and the 80% elution 
fraction (DEM40380-F80) on in vitro transcription by RNA polymerase of the T7 
bacteriophage (T7 RNAP) on a linear DNA template containing the T7 promoter 
sequence. T7 RNAP is a single subunit polymerase, structurally unrelated to 
multi-subunit RNAPs (Cheetham et al., 1999). Consequently, T7 RNAP can be 
used as a tool with which to identify non-specific inhibitors of transcription, such 
as the DNA binding compound echinomycin. Disappointingly, DEM40380-F20 
inhibited transcription by T7 RNAP, suggesting the compound is a non-specific 
inhibitor of transcription. However, DEM40380-F80 doesn’t inhibit T7 RNAP 
indicating the inhibitory compound(s) present in this particular fraction are 







Figure 4.4 DEM40380 produces a specific and non-specific transcription inhibitor. (A) in vitro 
transcription by WT E. coli RNAP on a linear DNA template containing the T7A1 promoter, 
performed in the absence or presence of DEM40380 methanolic elution fractions. Fractions were 
obtained from incremental aqueous methanol elutions of DEM40380 crude extract loaded onto a 
C18 solid phase extraction cartridge. Fractions were subsequently dried and resuspended in 50% 
MeOH before in vitro transcription analysis. [32P]-RNA products (Run-off and terminated) are 
indicated. Reactions were initiated with the 5’-non-phosphorylated dinucleotide primer CpA. (B) in 
vitro transcription by RNAP of the T7 bacteriophage on a linear DNA template containing the T7 
promoter, performed in the absence or presence of 80% and 20% DEM40380 methanolic elution 
fractions (attained as in A), or in the presence of DNA binding compound echinomycin (100μg/ml). 
5’-[32P]-RNA run-off product is shown. (C)   Disk diffusion assay with echinomycin, rifampicin, and 
80% and 20% DEM40380 methanolic elution fractions (attained as in A). Paper disks soaked with 
antibiotic or respective fraction and were placed on LB agar plates infused with X-gal and lawn of 
yvgS B. subtilis reporter strain carrying the lacZ gene under the HelD promoter. This promoter is 
induced during partial inhibition of transcription (Hutter et al., 2004b). Note the blue halo at the 
frontier of the zone of growth inhibition in the case of transcription inhibitors.    
 
To provide further clarification on the selectivity of our inhibitory fractions, we 
subjected DEM40380-F20 and DEM40380-F80 to a disk assay against the yvgS 
reporter strain. In such a disk assay, it is presumed specific inhibitors of RNAP 




agar plates.  Like echinomycin, DEM40380-F20 fails to produce a blue halo at the 
frontier of the zone of growth inhibition, further substantiating the putative non-
specific mechanism of transcription inhibition (Figure 4.4, C). However, 
DEM40380-F80, like rifampicin produces a visible blue halo at the frontier of the 
zone of growth inhibition, further corroborating the presence of an antibiotic 
targeting RNAP. Consequently, we selected DEM40380-F80 for further analysis. 
 4.2.4 DEM40380 produces the RNAP targeting compound Antibiotic 
A39079S-1 
DEM40380-F80 inhibited transcription of full-length RNA transcripts (both 
terminated and run off) whilst concurrently causing an accumulation of short 
abortive products (Figure 4.4, A). This mechanism is typical of rifamycins, 
suggesting DEM40380-F80 may contain a ‘rifamycin-like’ compound. 
Consequently, we reanalysed DEM40380-F80 by LC-MS and performed a 
corresponding literature search in the dictionary of natural products. The HPLC 
chromatogram indicated a single prominent peak at 220nm absorbance, 
indicating sample homogeneity (Figure 4.5, A). Mass spectroscopic analysis of 
this peak showed 100% relative abundance of a species with m/z of 704.2779 
Da. Moreover, a further species was identified with m/z of 1385.5495 Da 
corresponding to [2M+Na], where [M+Na] = 704.27. An additional species with 
m/z of 682.288 Da was identified and presumed to correspond to [M+H] (Figure 
4.5, B). We therefore deduced DEM40380-F80 contains a compound with the 
exact mass of 681.288 Da. A search within the dictionary of natural products of 
681.288 ± 0.01 Da yielded a single hit; ‘Antibiotic A39079S-1’, suggesting 
DEM40380-F80 contains this particular compound.  Mass spectroscopic analysis 
of DEM40380 70 and 90% elution fractions showed they also contained Antibiotic 
A39079S-1. The structure of Antibiotic A39079S-1 is highly similar to the RNAP 
targeting ansamycin, rifamycin S (Rif-S), albeit with several subtle structural 
differences (Figure 4.5, C). The C27 methoxy group present in Rif-S is 
substituted by a hydroxyl group in Antibiotic A39079S-1. The methyl group at C16 
present in Rif-S is absent in Antibiotic A39079S-1, and an additional methyl group 




Antibiotic A39079S-1 was first isolated from Streptomyces spheroides NRRL 
15600 in Vancouver, Canada (Boeck, 1985). It is a broad spectrum antibiotic with 
a previously uncharacterised mechanism of action. Our results thus far and 
structural similarity to Rif-S indicate Antibiotic A39079S-1 targets RNAP through 
a mechanism of steric occlusion in which the compound binds within the Rif 
pocket and sterically blocks translocation of the nascent transcript. To further 
assess if Antibiotic A39079S-1 targets the Rif pocket on RNAP, we reassessed 
DEM40380-F80 in an in vitro transcription assay with RifR E. coli RNAP bearing 
βH526Y on a linear DNA template containing the T7A1 promoter. DEM40380-
F80 was unable to inhibit transcription performed by the mutant RNAP, 
suggesting Antibiotic A39079S-1 targets RNAP at the Rif binding pocket (Figure 
4.5, D). Previous inhibition of βH526Y RNAP by DEM40380-CE was presumably 






Figure 4.5 DEM40380 produces the rifamycin class compound ‘Antibiotic A39079S-1’ (A) A 
representative reverse phase HPLC trace of DEM40380 80% MeOH fraction (DEM40380-F80) at 
256nm absorbance. (B) Positive ion mass spectrum corresponding to peak ‘1’ identified in A. 
Probable Ion adducts of ‘Antibiotic A39079S-1’ are indicated. (C) Structural formulae of Antibiotic 
A39079S-1 (left) and Rifamycin S (right). Structural differences are indicated in red. (D) in vitro 
transcription by RifR βH526Y RNAP on a linear DNA template containing the T7A1 promoter, 
performed in the absence or presence of rifampicin or antibiotic A39079S-1. [32P]-RNA products 
(Run-off and terminated) are indicated. Reactions were initiated with the 5’-non-phosphorylated 





The growing prevalence of infections resistant to antibiotics demands compounds 
with novel modes of action and novel binding interactions. In this chapter, we 
aimed to identify novel RNAP inhibitors produced by actinomycete bacteria from 
a shortlisted library of actinomycetes compiled by our industrial collaborators at 
Demuris. Actinomycetes form a rich reservoir of active natural products, from 
which many of our current antibiotics are derived directly, or synthesised from. 
Demuris possess an extensive collection of actinomycete bacteria from a variety 
of marine and terrestrial sources. In an effort to identify novel transcription 
targeting antibiotics, Demuris performed a screen of their collection in which 
strains were screened against the Bacillus subtilus yvgS reporter strain which has 
lacZ fused to the promoter of the bacterial helicase HelD. This particular promoter 
is upregulated in response to sub-inhibitory concentrations of the transcription 
inhibitor Rif. Consequently, it was assumed this particular strain reports on 
producers of specific transcription inhibitors. However, our work here has shown 
most, if not all, strains forwarded for investigation produce rifamycin class 
antibiotics. This indicates producers of rifamycins may be far more prevalent than 
producers of other transcription inhibitors, or the yvgS reporter strain fails to 
report transcription inhibitors other than rifamycins. Indeed, work at Demuris 
following the course of this project showed certain actinomycete derived 
transcription inhibitors, such as streptolydigin, fail to activate yvgS (unpublished), 
illustrating the limited suitability of the yvgS reporter in drug discovery. 
Consequently, a reporter strain with broader scope for activation is required if 
actinomycete bacteria are to be comprehensively examined for novel RNAP 
inhibitors. 
Nevertheless, Streptomyces DEM40380, isolated from the Atacama Desert in 
Chile, was identified as a likely producer of a previously unknown RNAP inhibitor. 
In vitro transcription assays combined with mass spectroscopic analysis identified 
DEM40380 as a producer of Antibiotic A39079S-1, a broad spectrum ansamycin 
antibiotic with a previously undefined mechanism of action. Here, we have shown 
Antibiotic A39079S-1 exhibited a mechanism of action typical of rifamycin 
inhibitors, in which the compound inhibits transcription of full length RNA products 




compound acts through steric occlusion of the extending nascent transcript 
following initial phosphodiester bond synthesis (McClure and Cech, 1978, 
Campbell et al., 2001). Furthermore, the antibiotic lost activity at RNAP bearing 
the RifR mutation βH526Y, indicating the compound targets the Rif binding pocket 
on RNAP (Campbell et al., 2001). Indeed, Antibiotic A39079S-1 has a highly 
similar structure to the natural product rifamycin S, a potent inhibitor of RNAP 
(Sensi et al., 1960). The compound possesses the distinctive naphthelenic, 17-
mer ansa chain structure characteristic of rifamycin antibiotics. Yet, the activity of 
antibiotic A39079S-1 sheds new light on the structure-activity relationship of 
rifamycins. Indeed, in the context of antibiotic A39079S-1, the methoxy group at 
C27, common to most rifamycins, can seemingly be cleaved to a hydroxyl without 
abolishing activity. Furthermore, the absence of a C16 methyl group in Antibiotic 
A39079S-1 suggests this substituent is not required for the correct conformation 
of essential oxygen functionalities at C1, C8, C21 and C23. This observation may 
point to a site on the ansa- bridge where small substituents can be introduced 
successfully to the compound.  
To summarise, we have shown the previously uncharacterised compound 
Antibiotic A39079S-1 mediates antibiotic activity through selective inhibition of 
bacterial RNAP. The compound likely binds within the Rif binding pocket on 
RNAP to block the extension of the nascent transcript following initial 
phosphodiester bond formation. We have also shown actinomycetes remain an 
abundant source of active natural products. However, the methods by which we 
screen for producers of these compounds requires further work if we are to 
prevent re-discovery of non-novel compound classes. Indeed, our identification of 
strain DEM4038 as a producer of Antibiotic A39079S-1 provides an example of 









Chapter 5. Ureidothiophene inhibits recognition of -10 promotor 
element by targeting regulatory region 1.2 of sigma subunit 
 
5.1 Introduction  
The synthetic antibiotic ureidothiophene (Urd) (Figure 5.1, A) was discovered in a 
high-throughput screen of some 250,000 commercially available compounds in 
which activity against S. aureus RNAP holoenzyme was assessed in vitro (Arhin 
et al., 2006). The compound was shown to be highly active against S. aureus 
RNAP in vitro, with an IC50 of ~1μM. Urd possessed a narrow spectrum of activity 
against S. aureus ATCC 13709 and S. epidermidis with a ~MIC of 1μg/ml and 
0.25μg/ml, respectively (Arhin et al., 2006). An isopropyl derivative of Urd was 
shown to inhibit RNA and protein synthesis, but not DNA synthesis by S. aureus 
strain RN4220; an effect typical of selective RNAP inhibition. Additionally, the 
compound retained activity against Rif resistant strains of S. aureus suggesting 
the binding site of Urd is different to that of Rif (Arhin et al., 2006). However, the 
exact binding site and mechanism of inhibition by Urd at RNAP remained 
unknown. This study aimed to elucidate the molecular mechanism by which Urd 
inhibits bacterial RNAP. 
5.2 Results 
5.2.1 Ureidothiophene inhibits RNA polymerases in vitro 
Firstly, we assessed the effects of Urd on in vitro transcription by the wild-type E. 
coli RNAP, the most extensively characterised bacterial RNAP. Urd inhibited 
transcription on a linear DNA template containing lacUV5 promoter (IC50   ~15.1 ± 
8.1μg/ml) (Figure 5.1, B). A decrease in full length transcript synthesis coincided 
with a corresponding decrease in the synthesis of short abortive products. This 
mechanism is seemingly different to that of Rif which typically causes an 
accumulation of short abortive products whilst inhibiting full length transcript 
synthesis (McClure and Cech, 1978, Campbell et al., 2001). Indeed, Urd inhibits 
synthesis of both the tri- and tetra- nucleotide abortive products ApApU and 






Figure 5.1 Ureidothiophene (Urd) inhibits bacterial RNA polymerases. (A)  Structural formula of 
Urd. (B) Urd inhibition of in vitro transcription performed by WT E. coli RNAP on a linear DNA 
template containing the lacUV5 promoter.  [32P]-RNA products (Run-off and terminated) are 
indicated. Reactions were initiated with the 5’-non-phosphorylated dinucleotide primer ApA. (C) 
Urd inhibition of abortive synthesis of [32P]-labelled ApApU and ApApUpU by WT E. coli RNAP 
holoenzyme on linear DNA template containing the lacUV5 promoter. Reactions were initiated 
with the 5’-non-phosphorylated dinucleotide primer ApA. (D) Sequence of promoters used in E. 
Promoter elements and TSS are indicated. (E) Urd inhibition of in vitro transcription by E. coli 
RNAP holoenzyme on linear DNA templates containing different promoter sequences as indicated 
in D. Error bars are ± SD from 3 independent experiments. (F) Urd inhibition of in vitro 
transcription by bacterial RNAP holoenzymes from different bacteria on linear DNA templates 




To ensure the transcription inhibition by Urd wasn’t specific to the lacUV5 
promoter, we assessed Urd inhibition of abortive transcription by wild-type E. coli 
RNAP on linear DNA templates containing the T7A1, T7A2 promoter and the 
extended -10 galP1 promoter (Figure 5.1, D). These promoters represent 
differing deviations from consensus -10 and -35 promoter element sequences. 
For example, the galP1 promoter sequence possesses a 5’-TG-3’ motif 2 bps 
upstream of the -10 element but does not possess a recognisable -35 element. 
On the other hand, T7A1 and T7A2 possess distinct -10 and -35 promoter 
element sequences whilst also possessing differing lengths within the spacer 
region (see section 1.2.4 for further details on promoter architecture). Urd 
inhibited abortive transcription on T7A1, T7A2 and the extended -10 galP1 
promoters with comparable potency (Figure 5.1, E). This suggests Urd inhibition 
is not sequence specific per se, and possesses a general mechanism of 
inhibition. We also assessed the ability of Urd to inhibit transcription by different 
bacterial RNAPs (Figure 5.1, F). In this experiment we used the T7A1 promoter 
as template. Consistent with previous observations, S. aureus RNAP was highly 
susceptible to Urd with an IC50 ~ 0.3 (± 0.3) μg/ml (Arhin et al., 2006). In contrast, 
T. thermophilus and M. smegmatis RNAPs were much less sensitive to Urd.  
5.2.2 Ureidothiophene is an inhibitor of transcription initiation 
Concurrent inhibition of both abortive and run-off transcription suggests Urd may 
inhibit nucleotide binding or catalysis. Therefore, we analysed the ability of Urd to 
inhibit single and multiple nucleotide addition by elongation complexes formed by 
E. coli RNAP core. Elongation complexes were assembled with synthetic 
oligonucleotides wherein the elongation complex contained fully complementary 
template and non-template strands and 5′- radiolabelled RNA (Figure 5.2, A). As 
seen from Figure 5.2, even a high concentration (100 μg/mL) of Urd had no effect 
on single nucleotide and multiple nucleotide RNA extension, indicating that the 
inhibitor doesn’t effect NTP binding or catalysis. This suggests Urd targets an 







Figure 5.2. Ureidothiophene does not inhibit transcription elongation. (A) The elongation complex 
scaffold (EC) used in (B) and (C). Template DNA, non-template DNA, and 5’-[32P]-labelled RNA 
are as indicated. (B) 5’-[32P]-labelled RNA products synthesised from single nucleotide addition of 
the EC scaffold shown in A, in the absence and presence of Urd (100μg/ml). 5’-[32P]-RNA13 
primer and 5’-[32P]-RNA14 product are indicated. Rate constants are shown below the gels 
(numbers that follow the ± sign are standard errors). (C) 5’-[32P]-labelled RNA products 
synthesised from multiple nucleotide addition of the EC scaffold shown in A, in the absence and 
presence of Urd (100μg/ml). 5’-[32P]-RNA13 primer indicated, and quantified 5’-[32P]-RNA product 
is marked by asterisk. Rate constants are shown below the gels (numbers that follow the ± sign 







Figure 5.3 Urd inhibits formation of the RNAP open promoter complex. (A) Effect of order of 
addition of Urd, prior to, or following addition of promoter DNA, on inhibition of in vitro transcription 
by E. coli RNAP holoenzyme. (B) KMnO4 probing of RNAP-lacUV5 promoter complexes 
assembled in the absence and presence of Urd (100μg/ml) Non-template strand was 5’-[32P]-
labelled. The lacUV5 promoter sequence is shown above the gel with sensitive thymines 
indicated by black arrows. Profiles to the right of the gel are representative scans for free DNA 
(blue), RPo (red) and RPo + Urd (black). Position of thymine’s susceptible to modification by 
KMnO4 in RPo are indicated.  Sanger sequencing of the promoter fragment is shown on the left 
hand portion of the gel. (C) Electrophoretic mobility shift assay (EMSA) of RNAP-lacUV5 promoter 
complexes assembled in the absence and presence of Urd (100μg/ml). Complexes were further 
challenged with heparin as indicated. Non-template strand was 5’-[32P]-labelled. Complexes were 
resolved in native 4.5% PAGE. The position of the RNAP-lacUV5 promoter complexes (RP) and 






Figure 5.4 Urd prevents recognition of downstream promoter DNA. (A) DNAase I probing of 
RNAP-lacUV5 promoter complexes assembled in the absence and presence of Urd (100μg/ml) 
Non-template strand was 5’-[32P]-labelled. Profiles to the right of the gel are representative scans 
for free DNA (blue), RPo (red) and RPo + Urd (black). Sanger sequencing of the promoter 




DNase I footprinting data shown in A. Chart indicates peak area values for indicated bands within 
promoter DNA fragment in RPo in the presence and absence of Urd, normalised to peak area 
values for corresponding position in free DNA. Error bars are ± SD. 
 
5.2.3 Ureidothiophene prevents RNAP interaction with downstream 
promoter DNA 
We found Urd inhibition possesses a marked order-of-addition dependency. The 
compound inhibits initiation of transcription at a stage prior to formation of 
promoter open complex as it does not have any effect on transcription when 
added after formation of RPo (Figure 5.3, A). We therefore, analysed if Urd 
targets formation of the RPo by KMnO4 footprinting, which probes unpaired 
thymidine residues in the melted region of the RPo. Linear DNA fragment 
containing the lacUV5 promoter was radiolabelled at the 5’ end of the non-
template strand. As can be seen from Figure 5.3, B, Urd (100μg/ml) added before 
mixing RNAP and promoter DNA completely inhibited formation of RPo; 
thymidines in positions -10, -7, -5 and -3 that were melted in RPo, remained 
double-stranded in the presence of Urd.  
Urd may block interactions of RNAP with DNA or prevent crucial interactions of 
RNAP with promoter DNA that precede the melting and/or loading of promoter 
DNA in to the RNAP active-site cleft. In order to distinguish between these 
possibilities, we analysed RNAP-promoter formation by electrophoretic mobility 
shift assay (EMSA) (Straney and Crothers, 1985). E. coli RNAP was treated with 
Urd (100 μg/ml) and then incubated with radiolabelled lacUV5 promoter DNA. As 
can be seen from Figure 5.3, C, Urd did not abolish interaction of RNAP with 
promoter DNA. However, a challenge with polyanion heparin leads to destruction 
of the complexes formed in the presence of Urd. Heparin sequesters free RNAP 
and is also thought destabilise RPc, however has less effect on stable RPo 
(Walter et al., 1967). We therefore conclude that Urd blocks a stage of 
isomerisation into RPo, but does not abolish recognition of promoter DNA by 
RNAP. 
To understand the nature of Urd/RNAP/promoter complexes, we performed 
DNase I footprinting of promoter complexes in the absence or presence of Urd 




radiolabelled non-template strand). DNase I is a non-specific endonuclease that 
can be used to identify DNA regions protected by DNA binding proteins such as 
RNAP. Our results indicate Urd doesn’t cause a significant change in protection 
in the upstream promoter regions from positions -39 to -25 (Figure 5.4), 
suggesting that σR4.2 is engaged with the -35 promoter element in the presence 
of Urd. However, a large difference in protection pattern is observed downstream 
of the -35 promoter region. Hypersensitive sites at positions -23 and -24 on the 
non-template strand, that arise from distortion of the 18 base pair spacer region 
between the -10 and -35 promoter elements (Carpousis and Gralla, 1985), have 
diminished sensitivity to DNAse I digestion in the presence of Urd (Figure 5.2, A), 
suggesting the -10 may be disengaged by σR2 . Indeed, Urd causes a strong 
deprotection of nearly all bases downstream of position -20 up to +18. Notably, -
11 adenosine residue, essential for recognition of -10 element (Bae et al., 2015a, 
Roberts and Roberts, 1996), is deprotected in the presence of Urd indicating the -
10 element is unable to form stable contacts with σR2 (Figure 5.4, A, B). We 
therefore conclude that Urd doesn’t inhibit binding of the -35 promoter element, 
however the inhibitor prevents melting of -10 element and/or prevents correct 
loading of DNA within the active site cleft and DNA binding to the β/ β’ channel.  
5.2.4 Ureidothiophene doesn’t inhibit binding of DNA to downstream DNA-
binding channel or loading of template DNA into the active cleft 
Urd may occlude the access of single stranded template DNA into the active site 
cleft and/or occlude the binding of duplex DNA into the β and β’ downstream DNA 
binding channel and/or affect the recognition of downstream promoter elements 
essential for formation of RPo. Two previously described inhibitors of RNAP, 
fidaxomicin (Fdx) and ripostatin (Rip), were shown to inhibit isomerisation into 
RPo. Fdx blocks RPo formation by locking the RNAP clamp in an open 
conformation by binding to the switch region, the molecular hinge that facilitates 
clamp movement, and by blocking binding of template DNA within the active 
centre (Boyaci et al., 2018, Lin et al., 2017a, Tupin et al., 2010a). Like Urd, Fdx 
doesn’t affect the binding of upstream promoter elements whilst destabilising 
binding of downstream promoter DNA (Tupin et al., 2010a, Morichaud et al., 
2016). Rip also binds to the switch region but inhibits isomerisation to RPo at a 




transcription bubble that fails to propagate to the transcription start site. 
(Mukhopadhyay et al., 2008). 
We analysed if the mechanism of action of Urd has similarities with that of Fdx 
and Rip by using single-stranded promoter of the origin of replication of M13 
bacteriophage (M13ori; Figure 5.5, A) (Bochkareva and Zenkin, 2013, Zenkin and 
Severinov, 2004, Zenkin et al., 2006). M13ori forms a hairpin which is recognised 
by the downstream DNA-binding channel of RNAP but does not require -10 or -
35 elements for its function. Neither DNA upstream of the +4 position of the ‘non-
template’ strand, nor upstream of -3 position of the ‘template’ stand, are required 
for binding of the M13 hairpin by RNAP. Although, σ70 is required for the initiation 
 
Figure 5.5 Ureidothiophene doesn’t inhibit binding of DNA to downstream DNA-binding channel or 
loading of template DNA into the active cleft (A) Structure of the single-stranded M13 minimal 
promoter recognized by downstream-DNA-binding channel of RNAP, and which binding does not 
depend on -10/-35 elements or on the σ70 subunit. 18nt RNA product (pRNA) synthesized on 
M13ori promoter is shown with an arrow. (B) in vitro transcription of an 18nt pRNA primer 
performed by WT E. coli RNAP holoenzyme, on single stranded M13 minimal promoter template 
shown in A. Experiment was performed in the absence and presence of ureidothiophene, and 
switch region targeting inhibitors ripostatin and fidaxomicin.  [32P]-pRNA and [32P]-abortive 





of transcription at M13ori, σ70 is not required for the binding of M13ori to RNAP 
(Zenkin et al., 2006, Bochkareva and Zenkin, 2013, Zenkin and Severinov, 2004). 
Thus, M13ori can be used to assess if a compound inhibits downstream DNA-
binding and/or loading of the single-stranded DNA into the active cleft (Zenkin et 
al., 2006, Zenkin and Severinov, 2004). Therefore, we tested transcription by E. 
coli holoenzyme on minimal M13ori that leads to the formation of an 18nt primer 
RNA (pRNA; Figure 5.5, A, B), in the presence of the inhibitors Urd, Fdx and Rip. 
As expected, Fdx and Rip strongly inhibit transcription on M13ori (Fig 5B) 
(Srivastava et al., 2011, Tupin et al., 2010a). However, Urd has no effect of 
formation of pRNA. Results indicate that, unlike Fdx and Rip (Tupin et al., 2010a, 
Mukhopadhyay et al., 2008), Urd does not occlude the binding of single stranded 
template DNA into the active site and does not prevent binding of downstream 
DNA duplex to the downstream DNA channel. Taken together, the above data 
suggest that Urd inhibits isomerisation from RPc to RPo by precluding melting of 
the -10 promoter element, potentially through a previously unseen mode of 
action. 
5.2.5 Ureidothiophene targets σR1.2  
To delineate the putative binding site of Urd, we isolated an S. epidermidis 
spontaneous Urd resistant mutant conferring resistance to Urd termed Urd-Mut1 
(Figure 5.6, A). Urd-Mut1 was isolated from LB agar plates containing 12.5 μg/ml 
Urd (4 x MIC) and 2.5% Pluronic F68. The Pluronic F68 copolymer was used in 
this instance to improve solubility of Urd, and is further known to improve 
penetration of small molecules across cellular membranes. Ureidothiophene 
resistant mutants were identified by their growth on this media and confirmed by 
re-streaking on the same media, leading to the identification of a single mutant - 
Urd-Mut1. Note that the low number of mutants identified may perhaps be due to 
a low resistance frequency in the S. epidermidis strain used here and/or insufficient 
plating of cells onto the growth media (see section 2.15). Genome sequencing 
revealed a sole amino-acid substitution in the genome of the Urd-Mut1; an E105Q 
mutation in the rpoD gene encoding the primary sigma factor, SigA. The mutation 









Figure 5.6 Urd inhibits RNAP by targeting σR1.2. (A) Table indicating the MIC values of S. 
epidermidis ATCC12228 and Urd-Mut1, a spontaneous Urd resistant S. epidermidis ATCC12228 
with an σA E105Q mutation. MIC was gathered by solid agar dilution method (Wiegand et al., 2008). 
(B) Orthogonal views of the location of S. epidermidis σA E105 residue (E104; E. coli numbering) 
mapped onto the structure of E. coli holoenzyme. Core RNAP is depicted in grey ribbon model. σ70 
is depicted in orange with residue E104 indicated depicted as blue sphere model. (C) Abortive 
synthesis of [32P]-labelled CpApU by cellular WT S. epidermidis RNAP and cellular σA E105 S. 
epidermidis RNAP on linear DNA template containing the T7A1 promoter in the absence and 
presence of Urd. Reactions were initiated with the 5’-non-phosphorylated dinucleotide primer CpA. 
% inhibition by Urd normalised. (E) Urd inhibition of in vitro transcription by WT E. coli RNAP 
holoenzyme and σ70 E104Q E. coli RNAP holoenzyme. Error bars are ± SD from 3 independent 
experiments. (F) Structural recognition of the promoter -10 element by σR2, and proposed allosteric 
switch of σR1.2 within WT E. coli holoenzyme. Promoter DNA is depicted in black, with the -10 
element depicted with atomic colouring, non-template base at -7 position is indicated. σ70 is depicted 
in gray, and the RNAP β’ coiled-coil domain depicted in yellow. Residues within the proposed σR1.2 
allosteric switch are indicated in sphere model. σR1.2 (residues 96-126) is depicted in pink, σR2.3 
(residues 416 to 434) is depicted cyan, and 2.4 (residues 435-452) is coloured green (Feklistov and 
Darst, 2011).  
 
the resistance phenotype, we purified cellular RNAP holoenzyme from wild-type S. 
epidermidis and Urd-Mut1, and analysed sensitivity to Urd on the T7A1 promoter. 
Unlike the wild-type S. epidermidis RNAP, holoenzyme bearing the E105Q 
mutation is highly resistant to inhibition by Urd (Figure 5.6, C). This result confirms 
RNAP is a cellular target of Urd and also indicates the E105Q mutation underlies 
the observed resistance phenotype. To further corroborate this finding, we 
introduced the corresponding mutation into the E. coli σ70 subunit (E104Q; E. coli) 
and assessed the effect of the mutation on E.coli holoenzyme sensitivity to Urd. 
Indeed, the mutant holoenzyme was almost 6-fold more resistant to Urd than the 
WT RNAP (Figure 5.6, E). σR1.2 is implicated in the formation of RPo (Haugen et 
al., 2006, Zenkin et al., 2007, Wilson and Dombroski, 1997, Baldwin and 
Dombroski, 2001). Our results therefore suggest that inhibition of RPo formation 
by Urd may involve σR1.2. 
5.4 Discussion 
In this study, we have shown the transcription inhibitor Urd inhibits initiation of 
transcription by preventing the formation of a transcription competent open 
promoter complex. Our data indicate Urd inhibition of RPo formation may involve 
σR1.2. This particular σ sub-region is implicated in the formation of open 




(Baldwin and Dombroski, 2001, Zenkin et al., 2007).  Indeed, here, we identify a 
mechanism of transcription inhibition involving σR1.2 wherein Urd prevents 
melting of the -10 promoter element to prevent formation of an open promoter 
complex. 
Our data show Urd, like other inhibitors of open complex formation, acts at the 
promoter melting stage of transcription initiation. However, we have shown Urd 
acts through a different mechanism to previously described inhibitors of RPo 
formation, as the compound fails to inhibit loading of template DNA within the 
active centre. Fdx prevents recognition of the promoter -10 element and directly 
targets loading of single stranded template DNA into the active centre cleft, a 
detail supported by our own findings at M13ori DNA template (Tupin et al., 
2010a). Urd, however, despite also preventing simultaneous recognition of the -
10 and -35 elements, appears not to impede the interaction of single stranded 
template DNA at the active site, showing that Urd doesn’t inhibit RPo formation 
by targeting template loading. This is highly indicative Urd acts through a 
mechanism different to that of other inhibitors of RPo formation.  
A series of 2nd generation ureidothiophene-2-carboxylic acids (2G-Urds) 
structurally related to Urd were shown to possess mutually exclusive binding with 
Myx, Rip and Cor; switch region targeting ligands that bind to and lock the RNAP 
cleft in a closed conformation (Mukhopadhyay et al., 2008, Belogurov et al., 
2008, Fruth et al., 2014). Fruth et al used saturation transfer difference NMR to 
show 2G-Urds competitively bind with these closed cleft locking ligands (Fruth et 
al., 2014). In this case, the authors concluded that 2G-Urds competitively bind at 
the same site on RNAP - the switch region. However, these aforementioned 
inhibitors target a later promoter melting step in which the promoter DNA is 
partially melted but propagation to the transcription start site is obstructed due to 
clamp conformation (Boyaci et al., 2019). This is dissimilar to the earlier stage of 
promoter complex formation targeted by Urd in which complexes possess an 
entirely closed transcription bubble. If Urd binds at the same site as 2nd 
generation analogues, we propose an alternative explanation. It is tempting to 
speculate this competitive binding does not arise from direct competition at the 
switch region binding site but instead arises from altered clamp conformation 




required for Myx, Cor and Rip binding. Note that Myx, Cor and Rip are closed 
cleft locking ligands and therefore most probably require a closed clamp 
conformation in order for the compound to bind RNAP. Indeed, biochemical data 
from the same study suggests 2G-Urd compounds do not interact with RNAP 
residues crucial for Myx binding. We therefore suggest that Urd may affect 
conformation of the RNAP clamp, in addition to targeting σR1.2, predisposing an 
open or partly closed clamp conformation that may influence recognition of the -
10 and -35 elements, but not through a means identical to Fdx in which binding of 
template DNA within the active centre is affected.  
We have shown that Urd transcription inhibition is dependent on σ factor sub-
region 1.2, in particular residue E104. σR1.2 has previously been shown to play a 
role in formation of stable open promoter complexes, in particular it is implicated 
in allosteric control of -10 promoter element recognition by σR2.3 (Baldwin and 
Dombroski, 2001, Zenkin et al., 2007). Furthermore, σR1.2 interacts with the 
‘discriminator’ region of the non-template strand of promoter DNA to further 
stabilise RNAP promoter complexes (Haugen et al., 2006, Haugen et al., 2008b). 
The dependence of Urd inhibition on σR1.2 integrity suggests the compound 
mediates inhibition of transcription by interacting with or influencing this particular 
σ factor sub-region. The preclusion of recognition of the -10 promoter element by 
Urd suggests the inhibitor may target a crucial allosteric signal from σR1.2 to 
σR2.3.  
Mapping of the Urd resistance mutation E104Q onto the structure of E. coli 
holoenzyme shows the residue is located in the centre of the σR1.2 α-helix 
(Figure 5.6, B, F). It has been shown previously that holoenzymes with an E104V 
mutation are unable to form stable open promoter complexes and are highly 
defective in both abortive and run-off transcription, suggesting this residue is 
fundamental to the σR1.2 ‘allosteric signal’ (Baldwin and Dombroski, 2001) . 
Indeed, structural data of the E. coli holoenzyme shows this particular residue 
interacts with residue I290 of the β’ coiled-coil domain both within RPo and apo 
form of RNAP (Figure 5.6, F). Concurrently, residue E381 of σR2.1 also makes 
contacts with the same I290 residue, creating a mechanical linkage between 
σR1.2 and σR2.1 (Figure 5.6, F). This network of structural contacts is ideally 




reasonable to suggest this region must adopt a strict conformation for successful 
DNA binding. Interestingly, it has been previously shown that certain mutation of 
σR1.2 can augment the activity of Fdx at RNAP (Morichaud et al, 2016). 
However, here, we have shown an effect to the contrary for inhibition by Urd, 
wherein mutation of σR1.2 decreases activity of the compound at RNAP 
Nonetheless, although these observations serve to obfuscate interpretation of the 
data, they serve to reaffirm the role of σR1.2 in inhibition of RPo formation. 
Indeed, if the Urd resistance mutation E104Q delineates a residue targeted by 
Urd, it is plausible to propose Urd may effect the structural elements of the σR1.2 
allosteric signal and consequently prevent the conformation required for promoter 
recognition by σR2.3. However, it is possible the compound binds at a site away 
from these structural elements, and the mutation at residue E104 disrupts a 
separate allosteric signal linked to σR2. 
In summary, Urd is the first transcription inhibitor that blocks the formation of the 
open promoter complex by targeting σ factor sub-region 1.2, and provides an 
exciting new compound for future drug development. Additionally, the 
identification of a novel putative binding site affords a new target for rational drug 
design.  Urd also provides and interesting tool with which to dissect the process 
of transcription initiation. However, further structural analysis is required to 



















The natural product antibiotic Kanglemycin A (KglA) was first isolated from the 
fermentation broth of the actinomycete bacteria Nocardia mediterranei var. 
kanglensis 1741-64 (Wang et al., 1988). The compound was shown to possess 
activity against certain Gram positive bacteria. However, no mechanism of action 
had been previously described. The compound is an ansamycin antibiotic 
structurally related to the rifamycins (Figure 6.1, A). However, KglA possesses 
structural elements not seen in other naturally occurring or semisynthetic 
rifamycins. In particular, KglA contrasts from other rifamycins through two large 
substituents present on the ansa bridge; a 2,2-dimethylsuccinic acid chain at C20 
and a β-O-3,4-O,O’ methylene digitoxose moiety at C27. These variations are 
particularly unusual as synthetic ansa-bridge modifications of bioactive rifamycins 
frequently lead to inactivation of the compound. Consequently, synthetic 
modifications have focused primarily on the naphthoquinone moiety.  
More recently, our industrial collaborators at DemurisTM identified Amycolotopsis 
DEM30355 as a producer of KglA. In an attempt to identify new transcription 
targeting antibiotics, the strain extract was screened against the yvgS  
Bacillus subtilus reporter strain that has lacZ fused to the promoter of the 
bacterial helicase HelD (Figure 6.1, B). This particular promoter was chosen 
because it is known to be upregulated in response to sub-inhibitory 
concentrations of the transcription inhibitor rifampicin (Hutter et al., 2004b). 
Consequently, in a disk assay, rifamycin type transcription inhibitors produce a 
blue halo at the frontier of the zone of inhibition upon X-gal infused agar plates. 
DEM30355 produced a compound (later identified as KglA) that activated this 
reporter strain. Interestingly, KglA was also active against the Rif resistant B. 
subtilus reporter strain possessing a βH482R (βH526R in E. coli numbering) 
RNAP mutation. Accordingly, DEM30355 was cultivated at 500L scale and KglA 
extracted and purified by multi-step chromatography. Initial investigative work 





Figure 6.1 Preliminary identification of KglA as an inhibitor of RNAP. Adapted from (Mosaei et al., 
2018) (A) Chemical structures of Rifampicin (left), with the synthetic 4-methyl-1-piperazinyl moiety 
at C3 indicated in purple, and Kanglemycin A (right) with 2,2-dimethylsuccinic acid chain at C20 
and a β-O-3,4-O,O’ methylene digitoxose moiety at C27, indicated in pink and red, respectively. 
(B)  Disk diffusion assay with Kanglemycin A, Rifampicin, and Carbenicillin (negative control). 
Paper disks soaked with antibiotic were placed on LB agar plates infused with X-gal and lawn of 
yvgS B. subtilis reporter strain carrying the lacZ gene under the HelD promoter (left) and an 
identical Rif resistant yvgS B. subtilus possessing βH482R RNAP mutation (βH526R in E. coli 
numbering) (Mosaei et al., 2018). The HelD promoter is induced during partial inhibition of 
transcription (Hutter et al., 2004b). Note, the blue halo at the frontier of the zone of growth 
inhibition in the case of transcription inhibitors. (C) Quantification of inhibition of in vitro 




containing the T7A1 promoter. Quantification is derived from average of [32P]-labelled run-off and 
terminated transcription products. Values were normalised to quantity of [32P] RNA synthesised in 
the absence of inhibitor. Numbers in brackets are ± SD (Mosaei et al., 2018). 
 
inhibits WT E. coli RNAP in vitro. Furthermore, the compound retained activity 
against a suite of Rif-resistant RNAPs including βS531L, βD516V, βD516Y, 
βH526Y, βH526P,βH526R and βI572F (Figure 6.1, C). These mutants 
correspond to frequently observed Rif resistant clinical isolates of M. tuberculosis 
(Gill and Garcia, 2011).  
These initial results suggest that KglA binds to and inhibits bacterial RNAP. 
However, the exact mode of action of KglA at RNAP remained unknown. In this 
study we aimed to elucidate the molecular mechanism of transcription inhibition 
by KglA. 
6.2 Results 
6.2.1 Kanglemycin A inhibits transcription at an earlier stage than 
Rifampicin 
Activation of the helD promoter by KglA and the compounds structural similarities 
to rifamycins suggests it may inhibit transcription via a similar mechanism to that 
of rifampicin. Consequently, we compared the effects of Rif and KglA on 
transcription by WT E. coli RNAP on a linear DNA template containing the T7A1 
promoter. In this instance, the dinucleotide primer CpA was used to initiate 
transcription. Interestingly, KglA inhibited transcription of full length RNA 
transcripts (both terminated and run off) whilst concurrently causing an 
accumulation of short tri- and tetra- nucleotide abortive products (Figure 6.2, A). 
This mechanism is typical of rifamycins (McClure and Cech, 1978, Campbell et 
al., 2005), as illustrated by transcription inhibition of rifampicin. The principal 
mode of action of rifamycins is through steric occlusion of the translocating 
nascent transcript following initial phosphodiester bond synthesis (Campbell et 
al., 2001).  
This results in inhibition of synthesis of full length transcripts but accumulation of 
short abortive products. Interestingly, however, it was noted that the ratio of tri- 







Figure 6.2 Comparable mechanisms of rifampicin (Rif) and kanglemycin A (KglA). (A) In vitro 
transcription by E. coli RNAP on a linear DNA template containing the T7A1 promoter, performed 
in the absence or presence of rifampicin (left) or Kanglemycin A (right). [32P]-RNA products (Run-
off and terminated) are indicated. Reactions were initiated with the 5’-non-phosphorylated 
dinucleotide primer CpA. [32P]-CpApU and [32P]-CpApUpC are indicated. Note, tetra-nucleotides 
migrate faster than tri-nucleotides under the electrophoretic conditions used here (Borukhov et al., 
1993). (B) Bar chart showing quantification of the ratio of [32P]-CpApU and [32P]-CpApUpC in the 




respective abortive product in respect of the overall quantity of tri- and tetra- nucleotide abortive 
products synthesised in the respective reaction. (C) In vitro transcription by E. coli RNAP on a 
linear DNA template containing the T7A1 promoter, performed in the absence or presence of 
rifampicin or Kanglemycin. Indicated are different ratios of the di-nucleotide (pppApU) and the tri-
nucleotide (pppApUpC) abortive products in the presence of Rif and KglA. Transcription was 
performed in the presence of the nucleotides depicted (in the absence of the CpA primer). Note 
that, in the 33% gel, runoff and termination products remain in the gel well. 
 
than for Rif (Figure 6.2, B). In the presence of KglA, there is greater inhibition of 
tetra-nucleotide synthesis compared to Rif. This suggests that KglA acts at a 
stage preceding that of Rif, perhaps by increased steric hindrance to the 
translocating nascent transcript. 
Interestingly, KglA completely prevents synthesis of triphosphorylated tri-
nucleotide and even inhibited the production of triphosphorylated di-nucleotide 
(~70-fold inhibition), as compared to Rif (~3-fold inhibition) (Figure 6.2, C). This 
result further indicates that KglA affords additional hindrance to the translocating 
nascent transcript and may even effect binding of the initiating NTP substrate. 
6.2.2 Structural basis of Kanglemycin A – RNAP binding interaction  
To reveal the structural basis for RNAP inhibition by KglA, we established a 
collaboration with Prof Katsuhiko Murakami of the Department of Biochemistry & 
Molecular Biology at Pennsylvania State University (Penn State). All 
crystallographic data shown here were gathered by Dr Vadim Molodstov (Penn 
State) & Prof Katsuhiko Murakami (Penn State). 
To analyse binding interactions of the RNAP-KglA complex we determined the X-
ray crystal structure of T. thermophilus holoenzyme in complex with the pyrG 
promoter template and KglA at 3.0Å resolution (Mosaei et al., 2018) (Figure 6.3, 
A, B). Electron density maps showed unambiguous density within the Rif binding 
pocket of the RNAP β subunit. The binding mode of KglA within the binding 
pocket is highly similar to that of RIF. KglA forms polar contacts with several 
residues involved in RIF binding; including βQ513, βF514, βS531 and βR540 (E. 









Figure 6.3 Structural basis of kanglemyicn A (KglA) inhibition. (A) Overall view of T. thermophilus 
RNAP with KglA (left, PDB: 6CUU) and Rif (right, PDB: 1YNN) bound within the RIF-binding 
pocket. RNAP (gray core and orange σA) and DNA (red) are depicted as ribbon models, and KglA 
(blue) and Rif (green) stick model. (B)  A close-up view of the RIF-binding pocket of the T. 
thermophilus RNAP containing KglA (in blue, with the side chains in yellow) and Rif (green). 
RNAP is shown as a semi-transparent surface model (pale gray), KglA is shown as a stick model 
with the ansa bridge side chains labelled. (C) β subunit residues forming the RIF-binding pocket 
shown as stick models. The hydrogen bonds between KglA and β amino acid residues are 
depicted by yellow dotted lines. (D) Critical oxygen functionalities present in rifampicin (left) and 
kanglemycin (right) involved in binding to RNAP are circled in red. Relevant carbon atom 
numbering is indicated in the left panel (E) Quantification of inhibition of in vitro transcription by 
rifampicin (left panel) kanglemycin (right panel). Transcription was performed by WT E. coli RNAP 
and mutant RNAPs on a linear DNA template containing the T7A1 promoter. Reactions were 
initiated with 5’- non-phosphorylated dinucleotide primer CpA. Quantification is derived from 
average of [32P]-labelled run-off and terminated transcription products. Values were normalised to 
quantity of [32P] RNA synthesised in the absence of inhibitor. Error bars are ± SD from at least 3 
independent experiments.    
 
However, interestingly, KglA conformation within the Rif pocket is subtly different 
to that of Rif. The ansa-bridge adopts a slightly tilted conformation away from the 
molecular surface of the β subunit preventing the polar interaction of C23 with 
βF514 seen in RNAP-Rif complexes, an interaction thought essential to Rif 
binding. However, the β-O-3,4-O,O’ methylene digitoxose moiety at C27 creates 
a new hydrogen bond with the side chain of βR143; this interaction does not 
occur with Rif (Figure 6.3, C, D). Furthermore, the acid side chain establishes 
further non-polar interactions with surrounding residues dramatically increasing 
the overall binding surface of KglA compared to Rif. 
To validate this novel interaction by the novel C27 β-O-3,4-O,O’ methylene 
digitoxose moiety with βR143, we created E. coli RNAP with βR143A mutation. 
The mutation had no effect on sensitivity to Rif. However, the mutant RNAP was 
over 10-fold less sensitive to KglA, reaffirming the importance of this residue in 
KglA binding. Nevertheless, the IC50 of KglA for the mutant RNAP is still lower 
than for any Rif resistant mutant RNAP, suggesting other interactions within the 
binding pocket are still important. Indeed, only the introduction of a βR143A 
concurrently with the common clinical Rif resistant mutation βS531L induced 
resistance to KglA (Figure 6.3, E). (Note, in vitro transcription data for Rif shown 





6.2.3 Structural basis of Kanglemycin A mode of action 
Rifamycin inhibitors act through steric hindrance of translocating nascent 
transcript following the synthesis of the first or second phosphodiester bond 
formation (McClure and Cech, 1978). Consequently, this leads to a reduction in 
full length transcripts and increase in short abortive products. However, during de 
novo transcription, KglA inhibits transcription of both full length transcripts and 
abortive products, indicating that KglA acts at an earlier stage than Rif. 
To further investigate the effects of KglA on substrate binding and 
phosphodiester bond formation, the structure of a T. thermophilus RNAP de novo 
initiation complex (4Q4Z) was overlaid onto the T. thermophilus RNAP-KglA and 
RNAP-Rif complex structures. Modelling of Rif shows no substantial steric clash 
with initiating substrate nor DNA. Additionally, the piperazine N4 is positively 
charged and thus will not disfavour NTP binding in the i site through electrostatic 
repulsion with the negatively charged oxygens of the γ-phosphate (Figure 6.4, A). 
This is consistent with previous data suggesting Rif has a minor effect on Km of 
initiating substrate (McClure and Cech, 1978). Furthermore, there is sufficient 
flexibility in the Rif C3 sidechain and also sufficient space to accommodate 
extension of the nascent transcript to 3-mer before a significant clash with the γ-
phosphate of the initiating nucleotide.  
Structural modelling of KglA, however, within T. thermophilus RNAP de novo 
initiation complex indicates that the orientation of the unique C20 2,2-
dimethylsuccinic acid moiety would generate a moderate steric clash with the γ-
phosphate of the initiating NTP (Figure 6.4, B). This moderate clash explains how 
KglA can inhibit dinucleotide synthesis. Additionally, the modelled structure 
shows the negatively charged carboxylic acid group of the 2,2-dimethylsuccinic 
acid would further disfavour initiating NTP binding through electrostatic repulsion 
of the negatively charged oxygens of the 5’-triphosphate group (Figure 6.4, B). 
To test this hypothesis, we assessed KglA inhibition of transcription initiated with 
nucleotide monophosphate (NMP). Structural data suggest there would be no 
steric clash between the C20 2,2-dimethylsuccinic acid moiety and the α- 
phosphate of an initiating NMP. However, electrostatic repulsion between 2,2-




and transcript translocation and consequently inhibit di- and tri-nucleotide 
synthesis. As can be seen from Figure 6.4, C, as compared to Rif, KglA 
moderately inhibits synthesis of pApU suggesting this electrostatic repulsion 
plays an influential role in KglA inhibition. Furthermore, synthesis of pApUpC 
(which is not inhibited by Rif) is strongly inhibited by KglA. This data reaffirms 
both steric and electrostatic effects of KglA hinder both formation of the first 
phosphodiester bond and translocation of the 5’-phosphorylated dinucleotide. 
 
Figure 6.4 Structural basis for mechanism of action of kanglemycin A. View of the RNAP active 
site from T. thermophilus de novo initiation complex (PDB: 4Q4Z) with bound Rif (green) (PDB: 
1YNN) superimposed. Depicted  is the t-strand DNA from +1 to −7 (light gray), the initiating NTP 
substrates (i site NTP, ATP; i+1 NTP, CMPcPP; (orange/purple)) ,and two Mg2+ ions , Mg-I and 
Mg-II (green spheres; Mg-I is the bound in the active site, Mg-II is bound to the i+1 NTP). Rif and 
the NTPs are depicted as transparent surface models. Positive charge (+) of the Rif piperazine 
moiety (blue), and negative charge (-) of the i NTP γ-phosphate are indicated. (B) Identical to (A) 
but depicting Kanglemycin A (coloured as in Fig. 5.3). Note the proximity of electrostatic charge in 
each case. (C) ) In vitro transcription by E. coli RNAP on a linear DNA template containing the 
T7A1 promoter, performed in the absence or presence of rifampicin or Kanglemycin. Indicated are 
different ratios of the mono-phosphorylated di-nucleotide (pApU) and mono-phosphorylated tri-
nucleotide (pApUpC) abortive products in the presence of RIF and KglA. Transcription was 
performed in the presence of the nucleotides depicted (in the absence of the CpA and ATP 








Figure 6.5 Kanglemycin inhibits Mycobacterial RNAP and retain activity against RifR M. 
tuberculosis. (A) Table indicating the MIC values of Rif-susceptible M. tuberculosis strains H37Rv 
and 1192/015, and RIF-resistant M. tuberculosis 08/00483E by KglA and RIF. Data presented are 
the mean of four independent experiments ± SD (Mosaei et al., 2018). (B) Sequence alignment of 
the Rif resistance determining regions (RRDRs) of the β subunit of RNAPs from M. tuberculosis, 
M. smegmatis, E. coli and T. thermophilus. (C) in vitro transcription performed by WT M. 
smegmatis RNAP on a linear DNA template containing the T7A1 promoter in the presence and 
absence of rifampicin and kanglemycin A.  [32P]-RNA products (Run-off and terminated) are 
indicated. Reactions were initiated with the 5’-non-phosphorylated dinucleotide primer CpA. (D) In 
vitro transcription by M. smegmatis RNAP on a linear DNA template containing the T7A1 
promoter, performed in the absence or presence of rifampicin or Kanglemycin. Indicated are 
different ratios of the di-nucleotide (pppApU) and the tri-nucleotide (pppApUpC) abortive products 
in the presence of Rif and KglA. Transcription was performed in the presence of the nucleotides 
depicted (in the absence of the CpA primer) (E) Quantification of inhibition of in vitro transcription 
by rifampicin (left panel) kanglemycin (right panel). Transcription was performed by WT M. 
smegmatis RNAP on a linear DNA template containing the T7A1 promoter. Reactions were 
initiated with 5’- non-phosphorylated dinucleotide primer CpA. Quantification is derived from 
average of [32P]-labelled run-off and terminated transcription products. Values were normalised to 
quantity of [32P] RNA synthesised in the absence of inhibitor. Error bars are ± SD.     
 
6.2.4 Kanglemycin A is active against Mycobacterial RNAP and MDR M. 
tuberculosis 
Rifampicin has been used as a frontline treatment for over half a century against 
infections caused by M. tuberculosis. However, Rif resistant strains are becoming 
increasingly prevalent and problematic to treat (Zumla et al., 2015). Our data thus 
far suggests KglA may be effective in treating Rif resistant bacteria, in particular 
MDR-M. tuberculosis. To investigate the effectiveness of KglA against MDR- M. 
tuberculosis we entered into a collaboration with Dr Joanna Bacon of the TB 
research group at Public Health England. MIC determination data shown here 
were gathered by Dr Joanna Bacon.  
To assess activity against Rif resistant M. tuberculosis we determined MIC values 
for Rif and KglA against a clinical MDR-M. tuberculosis isolate, Beijing 
08/00483E. This particular isolate is fully resistant to Rif and is also resistant to all 
other first-line antitubercular drugs (ethambutol, isoniazid and pyrazinamide). 
Beijing 08/00483E carries the most frequently observed amino acid mutation in 
Rif resistant M. tuberculosis (βS450L, M. tuberculosis numbering; S531L, E. coli 
numbering) (Jamieson et al., 2014, Zhang et al., 2014b). In addition to the MDR-
isolate, we also assessed activity against two Rif susceptible strains, H37Rv and 




orders of magnitude less sensitive to Rif than the Rif-sensitive strains (Figure 6.5, 
A). On the contrary, KglA was active against all 3 strains in a dose-dependent 
manner, demonstrating KglA is active against MDR-M. tuberculosis. Despite this, 
KglA was less active than Rif against Rif-sensitive strains. This is apparently 
contradictory to in vitro data suggesting KglA and Rif are equally active against E. 
coli RNAP (Figure 6.1, C). It is plausible KglA and Rif act differently at M. 
tuberculosis RNAP. Subsequently, we assessed transcription inhibition by Rif and 
KglA at M. smegmatis RNAP, a commonly used experimental model for M. 
tuberculosis RNAP. The amino acid composition of the Rif-binding pocket is 
identical in both Mycobacterial RNAPs (Figure 6.5, B). The mode of transcription 
inhibition by KglA and Rif at M. smegmatis appeared very similar to inhibition of 
E. coli RNAP. At high concentrations both Rif and KglA inhibited full length 
transcripts with a concurrent accumulation of short abortive RNAs (Figure 6.5, C). 
Again, as with E.coli RNAP, synthesis of CpApUpC was observed in the 
presence of Rif but inhibited in the presence of KglA (transcription was initiated 
with CpA) (Figure 6.5, C). This is indicative KglA, when compared to Rif, retains 
its additional hindrance to translocation of 5’ non-phosphorylated nascent 
transcript at Mycobacterial RNAP. Indeed, the mode of inhibition of de novo 
transcription by KglA was also identical to that seen at E.coli RNAP (Figure 6.5, 
D). Synthesis of pppApU was strongly inhibited by KglA, yet Rif allowed synthesis 
of dinucleotide triphosphate and even permitted some synthesis of pppApUpC. 
The IC50 of KglA at M. smegmatis RNAP indicated it was around four-fold less 
active than Rif (Figure 6.5, E). It is worthy of mention, the increased sensitivity of 
Mycobacterial RNAP to rifamycins is well documented in prior literature (Zenkin 
et al., 2005b). Despite the slightly lower activity of KglA at mycobacterial RNAP 
when compared to Rif, the respective activities cannot explain the disparity in 
activity between Rif and KglA at Rif-sensitive M. tuberculosis. The most plausible 
explanation for this difference is due to decreased ability of KglA to cross the cell 
envelope.  
Discussion 
The growing prevalence of Rif resistant infections demands compounds with 
novel modes of action and novel binding interactions. This study has shown KglA 




pocket and inhibits transcription through a novel molecular mechanism. Structural 
analysis of KglA bound within T. thermophilus open promoter complexes has 
shown the additional sugar (β-O-3,4-O,O’ methylene digitoxose) and acid (2,2-
dimethylsuccinic acid) moieties at C27 and C20, respectively, establish new 
contacts within the Rif binding pocket and influence compound conformation 
within the Rif binding pocket. The slight rotation away from the binding pocket 
may allow the compound to attenuate the effect of certain resistance mutations 
(Mosaei et al., 2018). Consequently, the altered conformation and novel binding 
interactions within the Rif pocket may explain the preliminary data indicating 
activity of KglA against a suite of Rif-resistant bacterial RNAPs. Indeed, our data 
here show only a double mutation within the Rif binding pocket leads to 
resistance in vitro.  
The mode of action of KglA is different to that of Rif. During de novo transcription, 
KglA inhibits the formation of the first phosphodiester bond, whereas Rif inhibits 
the formation of the second phosphodiester bond. With our collaborators, the 
combined biochemical and structural approach we have taken here has allowed 
us to discern the basis of this mechanistic difference. The C20 2,2-
dimethylsuccinic acid moiety appears to afford an additional steric and 
electrostatic obstacle to both initiating nucleotide binding and to translocation of 
the nascent transcript. Interestingly, inhibition of first phosphodiester bond 
synthesis has been described previously for the semisynthetic rifamycin, rifabutin 
(Artsimovitch et al., 2005). However, in this instance, 5’ non-phosphorylated 
dinucleotide ApU (corresponding to +1,+2 positions) was used to initiate 
transcription from the T7A1 promoter, unlike our use here of CpA (corresponding 
to -1,+1 positions). Consequently, our results are not comparable. Nevertheless, 
our data show KglA failed to inhibit synthesis of 5’ non-phosphorylated 
trinucleotide, despite the earlier projected clash with 5’ cytidine when transcripts 
are initiated with CpA, suggesting they likely act through different mechanisms.  
KglA inhibition of first phosphodiester bond formation is likely to offer a further 
ancillary mechanism of inhibition, when compared to Rif. RNAP can continually 
synthesis 2-3 nucleotide abortive products (termed RNA priming) when bound to 
Rif (McClure and Cech, 1978, Campbell et al., 2001). However, Rif binding is 




synthesising a longer transcript, which would then prevent Rif binding if Rif were 
to transiently dissociate, is quite probable. However, inhibition of first 
phosphodiester bond formation by KglA would serve to prevent this RNA priming. 
This effect may be of particular relevance in the context of Rif-resistant RNA 
polymerases in which binding affinity will be significantly reduced, and the 
transient dissociation of antibiotic becomes more probable (Molodtsov et al., 
2017b, Campbell et al., 2001).  
Semi synthesis of the rifamycin class has generally centred on variations of the 
C3/C4 positions of the naphthoquinone moiety (Bacchi et al., 1998, Sensi, 1983). 
Synthetic modifications of the ansa-bridge have generally rendered compounds 
inactive or significantly less potent. The unique substituents of KglA described 
here reveal the significant potential of ansa-bridge modifications, particularly the 
novel binding interactions that can be utilised by substitution at the C27 position. 
Furthermore, flexible acidic substitutions at the C20 position can facilitate novel 
interactions with the initiating nucleotide. It appears, however, that these native 
modifications come at the cost of reduced penetration of the cell envelope. This is 
most likely a consequence of the polar carboxyl groups present on the C20 2,2-
dimethylsuccinic acid sidechain. Indeed, despite a highly similar potency and 
mode of action at mycobacterial RNAP, KglA has a significantly reduced potency 
against Rif-susceptible strains of M. tuberculosis when compared to Rif. 
Although, it should be noted, KglA still possesses MIC values below those of 
frontline antitubercular drugs isoniazid and pyrazinamide. Importantly, however, 
KglA remained active against the MDR-M. tuberculosis isolate, Beijing 
08/00483E, which is completely resistant to Rif. The struggle to find compounds 
active against MDR-M. tuberculosis, plus the beneficial mechanistic 
characteristics of the inhibitor we have described here, demand KglA be 
optimised for clinical usage.  
In summary, KglA is a naturally evolved solution to the question of Rif-resistant 
bacteria, in particular Rif-resistant M. tuberculosis. Our study has illustrated there 
is still great scope to effectively explore the chemical space surrounding the 
rifamycin core. In particular, novel binding interactions within the Rif pocket can 
be utilised by substitution at the C27 position. Furthermore, substitution at C20 




Namely, additional steric and electrostatic hindrance to translocating nascent 
RNA and binding of initiating nucleotide. Together, KglA offers an exciting new 























Chapter 7. Rifampin ADP-ribosyl transferases from M. 
smegmatis and M. abscessus have differing substrate 
specificities. 
7.1 Introduction 
Resistance to the front line TB drug Rifampicin (Rif) is typically conferred through 
point mutations within the rpoB gene encoding the Rif binding β-subunit of RNAP 
(Campbell et al., 2001). However, Rif is also subject to enzymatic inactivation by 
several recently described bacterial enzymes (Spanogiannopoulos et al., 2012, 
Baysarowich et al., 2008, Liu et al., 2016, Stogios et al., 2016). ADP-ribosylation 
of Rif by M. smegmatis Rifampicin ADP-ribosyl transferase (ArrMs) is believed to 
preclude Rif binding to the RNAP β subunit. ArrMs utilises an NAD+ cosubstrate to 
catalyse the ADP-ribosylation of Rif at the C23 hydroxyl group, with concurrent 
expulsion of the nicotinamide moiety from NAD+ (Morisaki et al., 2000) (Figure 
7.1, A). Rifamycin SV, and newer semi-synthetic Rif derivatives rifaxamin and 
rifabutin, are also substrates for ArrMs, suggesting the enzyme has a broad 
substrate specificity (Baysarowich et al., 2008).  However, it has recently been 
shown C25 carbamate derivatives of rifampicin exhibit greatly improved 
antimicrobial activity against M. smegmatis (Combrink et al., 2007). In vitro 
experiments with purified ArrMs indicated C25 carbamate rifamycins are resistant 
to inactivation by Arr (Combrink et al., 2007). The recently solved crystal structure 
of ArrMs in complex with Rif provides a rational explanation for this evasion of Arr 
inactivation; the supposed position of the large C25 carbamate group would 
afford a pronounced clash within the ArrMs Rif binding pocket (Baysarowich et al., 
2008). Seemingly, C25 carbamates do not bind to the enzyme and evade 
inactivation by ADP-ribosylation. It was recently discovered the genome of the 
pathogen M. abscessus may encode a Rifampicin ADP-ribosyl transferase 
(ArrMab) conferring innate high-level Rif resistance. Deletion of ArrMab increases 
sensitivity of M. abscessus to Rif by over 500-fold. Interestingly, C25 modified 
rifamycins (Figure 7.1, C) showed increased activity against WT M. abscessus, 
but also against an M. abscessus mutant lacking ArrMab, suggesting increased 




abscessus (Rominski et al., 2016). This indicates the putative ArrMab may have a 
different substrate specificity to ArrMs. 
 
Figure 7.1 Structural scheme of ADP-ribosylation by rifampicin ADP ribosyltransferases (Arr) (A) 
ADP-ribosylation of rifampicin by Mycobacterial Arr (Baysarowich et al., 2008) (B) Anticipated 
ADP-ribosylation of kanglemycin A by Arr. (C) The chemical structure of C25 carbamate 
rifampicin derivatives. 
 
The ability of C25 carbamates to avoid inactivation by ArrMs suggests other 
modifications to the ansa- chain may preclude binding to Arr. The natural product 
KglA is an ansamycin antibiotic that inhibits transcription by binding within the Rif 
binding pocket on the β-subunit of RNAP. The compound has distinctive 
substituents present on the ansa bridge; a 2,2-dimethylsuccinic acid chain at C20 
and a β-O-3,4-O,O’ methylene digitoxose moiety at C27. When bound to RNAP, 




produce a distinctivive binding conformation (Mosaei et al., 2018). Consequently, 
KglA inhibits RNAP by a unique steric occlusion mechanism and retains activity 
at Rif resistant RNAPs. Whether these unique moieties effect KglA binding to Arr 
is yet to be assessed. We speculated these large bulky substituents may prevent 
KglA binding to Arr in a manner analogous to C25 carbamate Rif derivatives 
(Figure 7.1, B). Consequently, in this study, we aimed to discern if M. abscessus 
Arr encodes a functional Rifampicin ADP-ribosyl transferase, and aimed to 
determine if KglA is a substrate for purified ArrMs and ArrMab. We also assessed 
the activity of ADP-ribosylated rifampicin and ADP-ribosylated KglA in an in vitro 
transcription assay.  
7.2 Results  
7.2.1 Characterisation of Mycobacterium smegmatis Arr (ArrMab) 
Firstly, in order to characterise ArrMs in vitro, we cloned the Arr gene from M. 
smegmatis into a pET28 expression vector, and expressed and purified the 
protein from E.coli. To assess activity of ArrMs, we utilised a tandem LC-MS 
based assay in which antibiotic substrate and NAD+ cosubstrate were incubated 
in the absence and presence of ArrMs, and then the reaction products separated 
by HPLC and resolved by tandem mass spectrometry. When Rif is incubated with 
NAD+ in the absence of ArrMs, Rif, and its oxidised form rifampicin quinone (Rifq), 
are resolved with no identifiable ADP-ribosylated product (Figure 7.2, A, B). 
However, when Rif is incubated in the presence of NAD+ and ArrMs, both Rif and 
Rif quinone are ADP-ribosylated, confirming the activity of our purified ArrMs 
(Figure 7.2, top panel). We then assessed if KglA was subject to ADP-
ribosylation by ArrMs. As seen previously with Rif, incubation of KglA with NAD+ in 
the absence of ArrMs afforded no ADP-ribosylation of the antibiotic. Interestingly, 
additional incubation with ArrMs  also failed to ADP ribosylate KglA, suggesting 
that KglA is not a substrate of ArrMs (Figure 7.2, bottom panel).  
To clarify the in vivo efficiency of antibiotic inactivation, or lack thereof, of ArrMs, 
we performed in vitro inactivation reactions with a tandem disk assay. Increasing 
concentrations of ArrMs were coincubated with NAD+ and antibiotic (1mg/ml), and 
then spotted onto paper disks which were placed onto a lawn of S. aureus 




functional inactivation of the respective antibiotic. As shown in figure Figure 7.2, 
E, the control antibiotic carbenciliin is not inactivated by ArrMs. However, as 
indicated by our LC-MS based assay, rifampicin is inactivated by ArrMs, resulting 
in decreased zones of inhibition when ArrMs concentration is increased. 
Additionally, consistent with our previous data, KglA is resistant to inactivation by 
ArrMs, as indicated by no decrease in zone of inhibition even at very high 
concentrations of ArrMs. Combined with previous data, this result reaffirms KglA is 






Figure 7.2 M. smegmatis Arr (Arrms) fails to inactivate kanglemycin A (KglA) by ADP-ribosylation.   
Representative reverse phase HPLC traces of in vitro inactivation of rifampicin (Rif) by Arrms. 
(Upper panel) Trace represents the Rif standard in which Rif is incubated with NAD+ in the 
absence of ArrMs. (Lower panel) Trace represents Rif incubated with NAD+ for 1h in the presence 
of ArrMs. Absorbance is at 220nm. (B) Positive ion mass spectrum corresponding to peaks 
indicated ‘1’, ‘2’, ’3’ and ‘4’ identified in (A). Ion adducts are as indicated. (C) Representative 
reverse phase HPLC traces of in vitro incubation of KglA (Rif) with Arrms. (Upper panel) Trace 
represents the KglA standard in which Rif is incubated with NAD+ in the absence of ArrMs. (Lower 
panel) Trace represents KglA incubated with NAD+ for 1h in the presence of ArrMs. Absorbance is 
at 256nm. (D) Positive ion mass spectrum corresponding to peaks indicated ‘1’ and ‘2’ identified 
in (C). Probable Ion adducts are as indicated. (E) Disk diffusion assay of aliquots of in vitro 
reactions (corresponding to (A) and (C)) with carbenicillin, rifampicin, or kanglemycin A incubated 
in the presence of increasing concentrations of ArrMs. Paper disks were soaked with aliquots from 
in vitro reactions and were placed on LB agar plates infused with lawn of S. aureus RM4220 
(Combrink et al., 2007). 
 
ArrMs. Note the smaller zones of inhibition seen with KglA, when compared to Rif, 
is thought to be due to poorer penetration of the compound through the cell 
envelope.  
Furthermore, our collaborators in the lab of Prof. Peter Sander at the University of 
Zurich have gathered MIC data for Rif and KglA with both WT M. smegmatis and 
ΔArrMs M. smegmatis (unpublished). Their results show ΔArrMs M. smegmatis is 
considerably more sensitive to Rif than the WT strain. However, there was 
essentially no difference in sensitivity of both WT and ΔArrMs strains to KglA, 
further corroborating KglA is not a substrate for ArrMs. 
7.2.2 Characterisation of Mycobacterium abscessus Arr (ArrMab) 
Prior genetic experiments have indicated the substrate specificity of a putative 
ArrMab may differ from that of ArrMs. Consequently, we aimed to determine the 
function and activity of ArrMab in vitro. We cloned the Arr gene from M. abscessus 
into a pET28 expression vector, and expressed and purified the protein from E. 
coli. Once more, we utilised our tandem LC-MS based assay to determine the 
activity of ArrMab. As previously, coincubation of Rif and Rif quinone with NAD+ in 
the absence of ArrMab resulted in no ADP-ribosylated products (Figure 7.3, top 
panel). However, upon coincubation of NAD+ and Rif with ArrMab we see a shift in 
retention time distinctive of ADP-ribosylation of Rif and Rif quinone. ADP-
ribosylation of Rif was confirmed through identification of masses corresponding 




apparent Arr gene present in M. abscessus encodes a functional Rifampicin 
ADP-ribosyl transferase. Next, we attempted to determine if KglA is a substrate 
for ArrMab. As previously, coincubation of KglA and NAD+ in the absence ArrMab 
fails to facilitate ADP-ribosylation of the antibiotic (Figure 7.3, bottom panel). 
However, when KglA is incubated with ArrMab and the cosubstrate NAD+ there is 
a characteristic shift in retention time of the product, analogous to that seen with 
rifampicin. The peak corresponds to a compound with the exact mass of 1523.40 
Daltons; the predicted mass of ADP-ribosyl KglA (Figure 7.3, bottom panel). This 
confirms ArrMab can inactivate KglA, and possesses a broader substrate specificity 
than its homologue ArrMs.   
To ascertain the efficacy of antibiotic inactivation by ArrMab within an in vivo 
context, as for ArrMs, we performed in vitro inactivation reactions alongside 
tandem disk assay. As previously, increasing concentrations of ArrMab were 
coincubated with NAD+ and antibiotic, and then spotted onto paper disks which 
were placed onto lawns of S. aureus RN4220. Again, apparent decreases in 
zones of inhibition were interpreted to indicate functional inactivation of the 
respective antibiotic. As suggested by our LC-MS assay, ArrMab is a functional 
Rifampicin ADP-ribosyl transferase. Rif activity is almost completely eliminated by 
both low- and high- range concentrations of ArrMab tested here (Figure 7.3, E). 
Fascinatingly, ArrMab is indeed capable of inactivating KglA; there was marked 
reduction in the zone of inhibition when KglA is incubated with ArrMab. This data 
further corroborates the functionality of ArrMab in innate resistance of M. 
abscessus to a wide range of rifamycins, and clarifies KglA is a substrate of 
ArrMab (Figure 7.3, E).  
In addition, our collaborators in the lab of Prof. Peter Sander at the University of 
Zurich have gathered MIC data for Rif and KglA with both WT M. abscessus and 
ΔArrMab M. abscessus (unpublished). Their results show ΔArrMab M. abscessus is 
considerably more sensitive to Rif than the WT strain. Furthermore, there was a 
marked increase in sensitivity of the ΔArrMab M. abscessus strain to KglA, when 






Figure 7.3 M. abscessus Arr (ArrMab) inactivates kanglemycin A (KglA) by ADP-ribosylation.   
Representative reverse phase HPLC traces of in vitro inactivation of rifampicin (Rif) by ArrMab 
(Upper panel) Trace represents the Rif standard in which Rif is incubated with NAD+ in the 
absence of ArrMab. (Lower panel) Trace represents Rif incubated with NAD+ for 1h in the 
presence of ArrMab. Absorbance is at 220nm. (B) Positive ion mass spectrum corresponding to 
peaks indicated ‘1’, ‘2’, ’3’ and ‘4’ identified in (A). Ion adducts are as indicated. (C) 
Representative reverse phase HPLC traces of in vitro inactivation of KglA (Rif) with ArrMab. (Upper 
panel) Trace represents the KglA standard in which Rif is incubated with NAD+ in the absence of 
ArrMab. (Lower panel) Trace represents KglA incubated with NAD+ for 1h in the presence of 
ArrMab. Absorbance is at 256nm. (D) Positive ion mass spectrum corresponding to peaks indicated 
‘1’ and ‘2’ identified in C. Probable Ion adducts are as indicated. (E) Disk diffusion assay of 
aliquots of in vitro reactions (corresponding to (A) and (C)) with carbenicillin, rifampicin, or 
kanglemycin A incubated in the presence of increasing concentrations of ArrMab. Paper disks were 
soaked with aliquots from in vitro reactions and were placed on LB agar plates infused with lawn 





7.2.3 Rifampicin and kanglemycin A binding affinities at ArrMab and ArrMs  
The crystal structure of ArrMs  complexed with Rif provides an explanation for how 
C25 carbamate derivatives of rifampicin evade inactivation by ADP-ribosylation 
(Baysarowich et al., 2008). If the binding mode is comparable to Rif, the C25 
substituent is expected to sterically clash with the interior of the Arr Rif binding 
pocket, preventing high affinity association to the protein. Thus far, our data show 
KglA is not a substrate for ArrMs. We had previously hypothesised the large ansa 
bridge substituents; a 2,2-dimethylsuccinic acid chain at C20 and a β-O-3,4-O,O’ 
methylene digitoxose moiety at C27, may produce a similar steric clash within the 
antibiotic binding pocket. To ascertain if the additional substituents of KglA 
preclude binding to ArrMs, we assessed binding affinities of both Rif and KglA at 
ArrMs  and ArrMab by microscale thermophoresis (MST). Apparent dissociation 
constants (Kd) were determined by titrating serial dilutions of antibiotic against 
ArrMs and ArrMab.  
As expected, Rif binds to both ArrMs  and ArrMab, although the compound binds 
with greater affinity to ArrMs, suggesting the apparent diversity in substrate 
specificity of ArrMab comes at a cost of reduced binding affinity (Figure 7.4, A). 
Conversely, as predicted, KglA binds to ArrMs with a drastically reduced affinity 
when compared to Rif, suggesting the bulky 2,2-dimethylsuccinic acid chain at 
C20 and/or β-O-3,4-O,O’ methylene digitoxose at C27 of KglA prevents high 
affinity binding of the compound (Figure 7.4, B). In contrast, KglA bound to ArrMab 
with an affinity comparable to Rif, further corroborating KglA as a substrate for 
ArrMab.  Indeed, from this data, it is apparent KglA is not a substrate for ArrMs due 
to a marked reduction in binding affinity at the enzyme. However, ArrMab 
accommodates high affinity binding of KglA, consequently facilitating inactivation 
by ADP-ribosylation. 
In an attempt to identify structural elements that may determine the respective 
substrate specificities, we overlaid the crystal structure of KglA onto the structure 
of ArrMs complexed with Rif using pair fit atomic alignment (Figure 7.4, C, D). If 
KglA adopts a similar conformation to Rif within the ArrMs binding pocket, our 
structure suggests a marked steric clash of the C27 β-O-3,4-O,O’ methylene 








Figure 7.4 Substrate specificity of M. smegmatis and M. abscessus Arr. (A) Binding affinities of 
rifampicin at labelled M. abscessus Arr and labelled M .smegmatis Arr identified by microscale 
thermophoresis. (B) Binding affinities of kanglemycin A at labelled M. abscessus Arr and labelled 
M .smegmatis Arr identified by microscale thermophoresis. For both (A) and (B), Fnorm 
(normalized fluorescence = fluorescence after thermophoresis/initial fluorescence) is plotted 
against antibiotic concentration. Error bars are ± SD. (C) Crystal structure of Rif (green stick 
model) complexed with M. smegmatis Arr (Baysarowich et al., 2008). Arr is shown as semi-
transparent surface model. (D)  Modelling of KglA (blue stick model, side chains are depicted in 
yellow) in the Rif binding pocket of M. smegmatis Arr (2HW2). Arr is shown as semi-transparent 
surface model. Projected steric clash with interior of Arr rifampicin binding pocket is indicated. (E) 
Sequence alignment of Arr M. smegmatis and M. abscessus with regions of homology indicated. 
The alpha helix structure (ArrMab α1) highlighted in (F) is indicated with a red asterisk. (F) 
Modelling of KglA (blue stick model, side chains are depicted in yellow) in the Rif binding pocket 
of M. smegmatis Arr (2HW2). Arr is shown as gray ribbon model. M. abscessus low homology 
alpha helix (ArrMab α1) is identified within the structure of M. smegmatis Arr, indicated in red 
ribbon/stick model, and projected steric clash with interior of M. smegmatis Arr rifampicin binding 
pocket is indicated.   
 
bulky substituent would clash with an alpha helix structure (residues 54-65) that 
constitutes one half of the Rif binding cleft (Figure 7.4, E, F). This alpha helix, 
termed α1, is implicated in Rif binding interactions; residue D55 makes polar 
interactions with O11 of Rif, whilst A56, W59, G60 and L63 form non-polar 
interactions with the carbon backbone of the ansa- bridge (Baysarowich et al., 
2008).  
To ascertain how this steric clash may be overcome in Mycobacterium 
abscessus, we analysed sequence homology of ArrMs  and ArrMab. Overall, the 
amino acid sequences are strikingly similar, exhibiting a 67.4% sequence 
homology (Figure 7.4, E). However, ArrMab α1 bears almost no sequence 
homology with ArrMs. This lack of homology may underlie structural differences 
that determine the broader substrate specificity exhibited by ArrMab. Furthermore, 
the variation of α1 residues involved in Rif binding may underlie the reduced 
affinity with which ArrMab binds Rif, perhaps as a consequence of reduced or 
altered binding contacts with the respective substrate. Yet, structural analysis of 
the respective Arr enzymes complexed with KglA and Rif is required in order to 






7.2.4 ADP-ribosylation renders Rifampicin inactive at RNA polymerases in 
vitro  
ADP-ribosylation of Rif by Arr enzymes occurs at the hydroxyl group at the C23 
position; an essential oxygen functionality in binding of Rif to RNAPs. Indeed, 
early SAR experimentation demonstrated any alteration of this functionality 
abolished activity of the compound (Aristoff et al., 2010, Bacchi et al., 1998).  
 
 
Figure 7.5 ADP-ribosyl rifamycins fail to inhibit RNAP and do not function as an initiating 
substrate. (A) Quantification of inhibition of in vitro transcription by rifampicin and ADP-ribosyl 
rifampicin. Transcription was performed by WT E. coli RNAP on a linear DNA template containing 
the T7A1 promoter. Reactions were initiated with 5’- non-phosphorylated dinucleotide primer CpA. 
Quantification is derived from average of [32P]-labelled run-off and terminated transcription 
products. Values were normalised to quantity of [32P] RNA synthesised in the absence of inhibitor. 
Error bars are ± SD. (B) A representative gel of in vitro abortive transcription performed by WT E. 
coli RNAP on a linear DNA template containing the T7A1 promoter. Reactions were initiated with 




Despite the assertion that ADP-ribosylation of Rif prevents binding of the inhibitor 
to RNAP, ADP-ribosyl Rif has never been analysed against RNAP in vitro. 
Consequently, we produced ADP-ribosyl Rif by incubating Rif with purified ArrMs 
and isolating the compound with a C8 solid phase extraction cartridge. We then 
analysed the effects of purified ADP-ribosyl Rif on transcription by WT E. coli 
RNAP on a linear DNA template containing the T7A1 promoter. Expectedly, ADP- 
ribosyl Rif was completely unable to inhibit transcription even at high 
concentrations, showing ADP-ribosylation renders rifampicin ineffectual by 
inactivating inhibitory activity (Figure 7.5, A).  
Interestingly, the structure of ADP ribosyl-Rif possesses an accessible 3’ hydroxyl 
group on the ribosyl moiety that may subsequently act as an initiating substrate 
for RNAP. Despite, poor binding to RNAP, we assessed if high concentrations of 
ADP-ribosylated Rif can act as an initiator of abortive transcription by WT E. coli 
RNAP on a linear DNA template containing the T7A1 promoter, and compared 
abortive synthesis to several other initiating substrates; CpA, ATP and NAD+. 
Cognate ATP and dinucleotide CpA are efficient initiating substrates of abortive 
synthesis, whereas transcription initiation by NAD+ is comparatively less efficient 
(Figure 7.5, B). However, abortive transcription initiating from ADP-ribosyl Rif was 
virtually undetectable, when compared to CpA, ATP and NAD+. The great steric 
bulk of ADP ribosyl Rif and its required orientation within the i site of RNAP would 
likely produce a series of large steric clashes with the interior of RNAP, producing 
an extremely high energy initiation complex. Indeed, when considering the high 
concentration of substrate (1mM) used in this instance, under physiological 
conditions the amount of transcription initiation from ADP- ribosyl Rif would be 
negligible. Unfortunately, lack of material prevented further reciprocal analysis of 
ADP-ribosyl KglA in vitro. However, ADP- ribosylation would likely prevent the 
compound binding to RNAP in a manner identical to Rif. Furthermore, the 
increased bulk of KglA, when compared to Rif, would further reduce the suitability 
of ADP-ribosyl KglA as an initiating substrate. Indeed, our results indicates ADP-
ribosylation of rifamycins cannot subsequently be used as initiating substrates by 






The communal existence of bacteria generates pressure to gain a competitive 
edge over neighbouring microorganisms. Consequently, bacteria have evolved a 
number of mechanisms to counter antibiotics secreted by microbes in their 
surroundings. Indeed, resistance determinants are found almost ubiquitously 
amongst bacteria (Crofts et al., 2017). The secondary metabolite precursors of 
clinical rifamycins are produced by several actinomycetes from highly competitive 
marine and terrestrial environments. Furthermore, synthetic Rif derivatives have 
been used to treat a number of clinical infections for over 60 years (Wang et al., 
2012, Kim et al., 2006). Consequently, many pathogenic and non-pathogenic 
bacteria have developed a diverse array of strategies to survive in the presence 
of rifamycins (see section 1.3.1 for further details).  
Rifamycins inhibit transcription by targeting the β-subunit on bacterial RNAP, 
consequently preventing translocation of the nascent transcript and inhibiting 
formation of the second or third phosphodiester bond (McClure and Cech, 1978). 
Resistance to rifamycins is most commonly conferred through point mutations 
within the Rif binding pocket on the β-subunit (Campbell et al., 2001). However, 
our work here has shown the growing relevance of rifamycin antibiotic 
inactivation by ADP-ribosylation in pathogenic Mycobacteria.  
ADP-ribosylation of Rif by Arr was first discovered as an intrinsic mechanism of 
resistance in Mycobacterium smegmatis. ArrMs utilises an NAD+ cosubstrate to 
catalyse the ADP-ribosylation of Rif at the C23 hydroxyl group, with concurrent 
expulsion of the nicotinamide moiety from NAD+ (Morisaki et al., 2000) (Figure 
7.1). It had been proposed ADP-ribosylation by Arr enzymes inactivates Rif by 
eliminating the C23 hydroxyl group essential for binding to RNAP. Furthermore, 
addition of the ADP-ribosyl at C23 orientates the bulky substituent toward the 
surface of the Rif binding pocket on RNAP, likely precluding binding Rif by severe 
steric clash (Campbell et al., 2001). Indeed, here we show for the first time ADP-
ribosylation of Rif completely abolishes activity of Rif at RNAP in vitro, most likely 
by precluding binding of the compound to RNAP. Furthermore, we show the 




substrate for RNAP. We believe this mechanism of covalent inactivation is likely 
to be mutual to all bacterial Arr enzymes. 
In addition to Rif, the natural product rifamycin SV, and semi-synthetic Rif 
derivatives rifaxamin and rifabutin, are also substrates for ArrMs, indicating a 
broad substrate specificity (Baysarowich et al., 2008). However, the discovery 
that bulky C25 carbamate Rif derivatives are not subject to ADP- ribosylation by 
ArrMs indicated ansamycins with large steric bulk may be able to evade the 
enzyme, seemingly by no longer associating with the Arr Rif binding pocket 
(Combrink et al., 2007, Baysarowich et al., 2008). The RNAP inhibitor KglA is a 
novel ansamycin antibiotic with unique bulky substituents present on the ansa 
bridge; a 2,2-dimethylsuccinic acid chain at C20 and a β-O-3,4-O,O’ methylene 
digitoxose moiety at C27 (Peek et al., 2018, Mosaei et al., 2018) (Figure 7.1). We 
hypothesised these unique sidechains may prohibit the antibiotic binding to ArrMs, 
and consequently evade ADP- ribosylation. Indeed, our data show KglA is not a 
substrate for ArrMs in vitro, as a consequence of reduced binding affinity at the 
enzyme. Molecular modelling of KglA bound to ArrMs indicated a large steric clash 
with the interior of the binding pocket, offering a plausible explanation for the 
inability of the compound to associate with ArrMs. Considering KglA also retains 
activity against RifR RNAPs and RifR bacteria (Peek et al., 2018, Mosaei et al., 
2018), the antibiotic may be a promising lead compound with which to target 
some pathogens possessing Arr enzymes.  
However, recently, a putative Arr encoding gene was identified in the highly 
pathogenic Mycobacterium abscessus, one of the most extensively drug-resistant 
strains of rapidly growing non-tuberculous mycobacteria (NTM) (Rominski et al., 
2016). M. abscessus is responsible for a wide range of infectious manifestations, 
including debilitating infections of the skin and respiratory system. A principal 
challenge in treating infections caused by M. abscessus is the bacteria’s 
extraordinary level of innate resistance to a plethora of clinical antibiotics (Luthra 
et al., 2018). Indeed, deletion of putative ArrMab increases M. abscessus 
sensitivity to Rif almost 500 fold. Yet, C25 modified rifamycins, which evaded 
activity at ArrMs, showed equal activity against both WT M. abscessus, and an M. 
abscessus mutant lacking ArrMab, suggesting the putative ArrMab may have a 




wished to ascertain if, i) The M. abscessus genome encodes a viable Arr 
enzyme, and ii) if so, is the unique ansamycin KglA a substrate for purified ArrMab 
in vitro. Indeed, our data show the M. abscessus genome encodes an active Arr 
responsible for innate resistance to Rif. Like ArrMs, we show ArrMab utilises an 
NAD+ cosubstrate to catalyse the ADP- ribosylation of Rif, presumably at the C23 
hydroxyl group, as is the case for Rif (Baysarowich et al., 2008). However, unlike 
ArrMs, the bulky ansamycin KglA remains a substrate of ArrMab, and is 
consequently subject to covalent inactivation by ADP-ribosylation. This indicates 
ArrMab possesses a divergent substrate specificity to ArrMs, and can seemingly 
accommodate a broader range of ansamycins with bulky ansa-bridge 
substituents. To examine exactly how ArrMab can accommodate the binding of 
larger rifamycin substrates, we performed sequence alignment analysis to identify 
divergence in the amino acid sequence of the Rif binding pocket of ArrMab and 
ArrMs. Indeed, our analysis shows a large portion of the interior of the Rif binding 
pocket of ArrMab and ArrMs lack sequence homology. In particular, an alpha helix, 
termed α1, implicated in several binding interactions with the Rif ansa-bridge, 
possesses almost no sequence homology between ArrMs and ArrMab. We propose 
the differing amino acid constitutions of the interior binding pocket likely underlie 
structural differences facilitating different substrate specificities. However, direct 
structural analysis of ArrMab complexed with KglA is required to ascertain the 
exact structural basis of ansamycin substrate binding. Furthermore, structural 
analysis of how different Arr enzymes bind varying substrates is essential for the 
rational design of novel antibiotics which can evade Arr. Indeed, understanding of 
how ADP- ribosylation mechanisms vary amongst different bacteria is essential if 
this abundant resistance mechanism is to be nullified.   
Exactly how M. abscessus Arr and M. smegmatis Arr have diverged to 
accommodate a different range of ansamycin substrates has not yet been 
investigated. Nevertheless, competition amongst environmental bacteria places 
strong evolutionary pressure on production of variant antibiotics capable of 
avoiding common resistance mechanisms, while synchronously pressurising the 
development of resistance mechanisms with which to evade these novel variants. 
Indeed, bulky ansamycin compounds, such as KglA, are produced by 




abscessus (Peek et al., 2018, Honda et al., 2018). Consequently, it is tempting to 
speculate KglA represents an evolved solution to both spontaneous and innate 
resistance mechanisms of bacterial competitors (Peek et al., 2018, Mosaei et al., 
2018). Subsequently, producers of KglA placed a selective advantage upon 
competitors capable of surviving in their presence, leading to the development of 
more diverse Arr enzymes capable of inactivating novel, more complex 
rifamycins. Indeed, there is now strong genomic evidence that most innate 
resistance mechanisms seen in clinical pathogens are of environmental origin 
(Peterson and Kaur, 2018). Consequently, many pathogenic bacteria may 
already possess a reservoir of resistance determinants to nullify as of yet 
undiscovered antibiotic variants. Therefore, a comprehensive understanding of 
resistance mechanisms is essential if we are to capitalise upon future antibiotic 
discoveries and facilitate the rational development of efficacious antibiotics with 


















8. Concluding Remarks 
Transcription, the first stage of gene expression, is performed by the multi-
subunit RNA polymerase (RNAP). The indispensable nature of transcription and 
sequence divergence from eukaryotic counterparts make bacterial RNAP an 
excellent target for antibiotics. However, very few clinical antibiotics target RNAP. 
The growing prevalence of antibiotic resistance amongst pathogenic bacteria 
demands the identification of novel antibacterial compounds acting through novel 
molecular mechanisms. Here, we conducted four distinct projects in which we 
investigated the molecular mechanisms of several previously uncharacterised 
transcription inhibitors. 
Most clinical antibiotics are derived from the natural products of actinomycete 
bacteria. Our industrial collaborators DemurisTM previously compiled a library of 
actinomycete bacteria that activate an RNAP reporter strain and therefore may 
produce novel inhibitors of bacterial transcription. Consequently, we aimed to 
identify and characterise novel inhibitors of bacterial transcription produced by 
strains from this particular strain library. 
Firstly - our industrial collaborators DemurisTM previously compiled a library of 
actinomycete bacteria that activate the yvgS RNAP reporter strain and therefore 
may produce novel inhibitors of bacterial transcription. Subsequently, we aimed 
to identify and characterise novel inhibitors of bacterial transcription produced by 
strains from this particular strain library. We utilised In vitro transcription assays 
combined with mass spectroscopic analysis to identify DEM40380 as a producer 
of Antibiotic A39079S-1, a broad spectrum ansamycin antibiotic with a previously 
undefined mechanism of action (Boeck, 1985). Here, we have presented data 
suggesting the compound inhibits transcription through a steric occlusion 
mechanism typical of rifamycins, likely by targeting the Rif binding pocket on 
RNAP. The compound possesses the distinctive naphthelenic, 17-mer ansa 
chain structure characteristic of rifamycin antibiotics. However, the activity of 
antibiotic A39079S-1 sheds new light on the structure-activity relationship of 
rifamycins. The compound structure indicates a methoxy group at C27, common 
to most rifamycins, can seemingly be cleaved to a hydroxyl without abolishing 




A39079S-1 suggests this substituent is not required for the correct conformation 
of essential oxygen functionalities at C1, C8, C21 and C23. This observation may 
point to a site on the ansa- bridge where small substituents can be introduced 
successfully to rifamycins.  
Secondly - the recently discovered antibiotic ureidothiophene (Urd) was identified 
within a commercial screen of synthetic compounds in which inhibition of S. 
aureus RNAP was analysed. Here, we have shown the inhibitor targets 
regulatory sub-region 1.2 of the sigma subunit to prevent melting of the -10 
promoter element. The compound consequently prevents formation of the 
transcription competent open promoter complex. Urd inhibition is dependent upon 
the integrity of σR1.2, suggesting the compound may directly, or perhaps 
indirectly (allosterically), interact with this particular σ factor sub-region. σR1.2 
has previously been shown to play a vital role in formation of stable open 
complexes (Wilson and Dombroski, 1997, Baldwin and Dombroski, 2001, Zenkin 
et al., 2007). Specifically, it is proposed to allosterically regulate recognition of the 
-10 promoter element by σR2.3. By interacting with σR1.2, we believe Urd 
interferes with this regulatory signal between σR1.2 and σR2.3, preventing the 
formation of the open promoter complex. 
Thirdly - a prior screening program conducted by our industrial collaboraters 
DemurisTM had identified the rifamycin type natural product kanglemycin A (KglA) 
as an inhibitor of rifampicin resistant RNAPs. Here, we show the unique ansa-
bridge substituents of the compound act to form new binding contacts with 
RNAP. We also present data showing KglA inhibits transcription through a unique 
steric occlusion mechanism, distinct from that of Rif. During de novo transcription, 
KglA inhibits the formation of the first phosphodiester bond, whereas Rif inhibits 
the formation of the second phosphodiester bond. With our collaborators, the 
combined biochemical and structural approach has allowed us to discern the 
basis of this mechanistic difference. The C20 2,2-dimethylsuccinic acid moiety 
appears to afford an additional steric and electrostatic obstacle to both initiating 
nucleotide binding and to translocation of the nascent transcript. Furthermore, we 
have shown KglA also inhibits mycobacterial RNAPs, and consequently retains 




Finally - we investigated ADP- ribosylation as a mechanism of KglA inactivation 
by Mycobacterium smegmatis and Mycobacterium abscessus rifampicin ADP-
ribosyltransferase (Arr) enzymes. We show KglA is not a substrate of the 
rifampicin inactivating Arr purified from Mycobacterium smegmatis, but remains a 
substrate of Arr purified from the extensively drug resistant pathogen 
Mycobacterium abscessus. We determined dissociation constants for KglA at 
both Arr enzymes and discovered KglA is unable to bind to ArrMs, yet is able to 
bind to ArrMab. Molecular modelling of KglA bound to ArrMs indicated a large steric 
clash with the interior of the binding pocket, offering an explanation for the 
inability of the compound to associate with the enzyme. To identify the basis for 
the differing substrate specificities between Arr enzymes, we performed 
sequence alignment analysis to identify divergence in the amino acid sequence 
of the Rif binding pocket of ArrMab and ArrMs. Our analysis indicates a large portion 
of the interior of the Rif binding pocket of ArrMab and ArrMs lack sequence 
homology. Specifically, an alpha helix, termed α1, implicated in several binding 
interactions with the Rif ansa-bridge, possesses almost no sequence homology 
between ArrMs and ArrMab. We suggest the differing amino acid constitutions of the 
interior binding pocket likely underlie structural differences facilitating different 
substrate specificities. Additionally, we have shown ADP-ribosylation of Rif 
completely abolishes activity of Rif at RNAP in vitro, most likely by precluding 
binding of the compound to RNAP. Also, we have also shown the ADP-ribosyl 
moiety present on ADP-ribosyl Rif cannot function as an initiating substrate for 
RNAP. 
By investigating these unique mechanistic processes, we have advanced our 
understanding of how transcription targeting antibiotics function at RNAP. 
Furthermore, we have furthered our understanding of the mechanisms utilised by 
pathogenic bacteria to facilitate resistance to transcription targeting antibiotics. 













T7A1-F 5’-GGTCGACTCTAGAGGATCGCT-3’  
T7A1-R 5’-Bio-CGACGTTGTAAAACGACGGCCAGTG-3’ 
lacUV5-F 5’-CTCACTCATTAGGCACCCCAGGC-3’ 




galP1-R 5’- CTCATAATTCGCTCCATTAGGCTTATG-3’ 
βR143A-F 5’-TGTTATCAACGGTACTGAGGCTGTTATCGTTTCCCAGCTG-3’   
βR143A-R 5’-CAGCTGGGAAACGATAACAGCCTCAGTACCGTTGATAACA-3’   
βS531L-F 5’-CGCACAAACGTCGTATCTTGGCACTCGGCCC-3’   
βS531L-R 5’-GGGCCGAGTGCCAAGATACGACGTTTGTGCG-3’  
σ70E104Q-F 5’GTACGCATGTACATGCGTCAAATGGGC-3’ 
σ70E104Q-R 5’-CAACGGTGCCCATTTGACGCATGTACATGCGTAC-3’ 
ArrMs-F-NdeI 5’-TAAGCAAAGCTTGTCAGTCATAGATGA-3’   
ArrMs-R-Hind III 5’-TAAGCAAAGCTTATCCTCACCAACCTC-3’ 
ArrMab-F-NdeI 5’-TAAGCACATATGATGGCGAATCCGCC-3’ 
ArrMab-R-Hind III 5’-TAAGCACATATGATGACGATGCCCAA-3’ 
 




















pTZ19-T7A1 Kanamycin PT7A1 (Kashlev et al., 
1996) 
pTZ19- galP1 Kanamycin PgalP1 (Minakhin and 
Severinov, 
2003) 
pT7blue-T7A2 Ampicillin PT7A2 (Yuzenkova et 
al., 2011) 









pACYCDuet-1_Ec_rpoZ Kanamycin PT7–rpoZ (Murakami, 
2013) 
pET28a-σ70  Kanamycin PT7-rpoD:Nterm:His6 (Zenkin et al., 
2007) 
pET28a-σ70-E104Q  Kanamycin PT7-
rpoDE104Q:Nterm:His6 
This work 
pET28a-ArrMs Kanamycin PT7-M. smegmatis 
Arr:Nterm:His6 
This work 








Figure S3. List of strains used in this work   
Species/Strain Genotype Reference 
Bacillus subtilus  
(yvgS) 
B. subtilis 168 
amyE::PhelD-lacZcat 
reporter strain 
(Hutter et al., 2004b) 







































phoA glnV44 Φ80 
Δ(lacZ)M15 gyrA96 








fhuA2 lacZ::T7 gene1 
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